Mechanistic constraints on the formation of virion morphotypes in Vaccinia virus. by Holley, Joe
1  
  
 
  
MECHANISTIC CONSTRAINTS ON THE     
FORMATION OF VIRION MORPHOTYPES IN   
VACCINIA VIRUS.  
  
JOE HOLLEY  
  
A thesis submitted for the degree of Doctor of Philosophy 
of the University of Surrey  
  
  
Faculty of Health and Medical Sciences  
University of Surrey   
Guildford   
  
Supervisors:  
Dr Carlos Maluquer de Motes  
Dr David Ulaeto  
  
Co-supervisor:   
Professor Gill Elliott  
2  
  
Statement of Originality   
  
I certify that:  
• The work presented in this thesis was conducted at the University 
of Surrey in the laboratory of Dr Carlos Maluquer de Motes. This 
thesis is comprised of my original work towards the degree of 
Doctor of philosophy.  
• To the best of my knowledge, this thesis does not contain material 
previously published by any other person except where due 
acknowledgment has been made in the text.  
  
  
  
  
Joe Holley  
  
  
  
  
  
 
  
  
3  
  
Acknowledgments  
When I started this process, I could not believe that this time would eventually come. It is hard 
for me to comprehend just how transformative this process has been and how much I am 
indebted to the wonderful people who have made this a reality. Nevertheless, I hope I can 
adequately convey my appreciation in these paragraphs.   
This PhD would never had got off the ground if it were not for the fantastic supervision of  Dr. 
Carlos Maluquer de Motes. I thank you for the constant support and guidance you gave 
throughout, and especially during the times when I struggled. From the day I first started in the 
lab, to cell-gate and beyond, your guidance and patience was always there. Even if you may 
have wanted to murder me. I honestly could not have asked for a better supervisor. I have 
developed so much, both as a scientist and as a person because of meeting you.   
I am also incredibly grateful for the guidance of Dr David Ulaeto. Your encouragement, 
optimism and shirts have been an inspiration to me. I am incredibly thankful for the 
opportunities you have given me. It has been a privilege to have worked for you.    
I would also like to thank my Co-supervisor Professor Gill Elliott and past and present members 
of the Elliott lab; Dr Juliet Jones, Dr Tiffany Russell, Dr Kathleen Pheasant and  Dr Katja Ebert 
Keel for helping me through the daily struggles of lab life. I am truly grateful for your support, 
both emotional and scientific, in addition to your tolerance of my incessant (and often) inane 
questions.   
My lab experience would not have been as good as it was if were not for the support of and 
companionship of past and present members of the Maluquer de motes lab: Iliana Georgana, 
Pao Ribo and Marta Itarte. I also thank the past and present members of the 01AW00 office for 
tolerating my outbursts of frustration, joy and the “organized chaos” of my desk.  
I thank my family Mum, Dad, Andrew and Peter for your constant support. I also thank my 
girlfriend Ginny Deimantaviciute for maintaining my sanity during the past two years. I give 
thanks to my friends, particularly Dr Max Roberts and Edmund Kempin for reminding me that 
life exists outside of the laboratory.  
   
4  
  
Abstract  
Vaccinia virus (VACV) morphogenesis is controlled by a temporal cascade enacted by 
intermediate and late promoter sequences, in conjunction with virally encoded transcription 
factors. VACV morphogenesis culminates with the formation of two structurally and 
functionally distinct virion morphotypes from a single mature virus (MV) progenitor; the 
intracellular mature virus (IMV) and extracellular enveloped virus (EEV). IMV are typified by 
their single membrane and the presence of the A26 protein, which is expressed at 10 hours post 
infection. EEVs are characterized by their double membrane and suite of virally encoded 
proteins, the most crucial of which is the F13 protein expressed at 4 hpi.   
Previous investigations have implicated the temporal expression of A26 protein as a regulatory 
switch, negatively regulating the formation of EEV during late times of infection. However, 
reverse genetic approaches have refuted this claim. Despite this, these studies do not consider 
the temporal organization of key IMV and EEV proteins, in addition to their potential to 
regulate one another.   
The aim of this study was to investigate the concept of altering the temporal regulation of both 
A26 and F13 to generate novel phenotypes, exploring the mechanism underpinning IMV vs 
EEV balance. Recombinant viruses were generated with F13L and A26L alleles expressed 
under the control of either F13L or A26L promoter sequences. When A26L was introduced 
under the intermediate F13L promoter sequence a significant plaque size reduction was 
observed. In addition, a further deduction was observed when F13 expression was delayed 
under the late A26 promoter. Temporally advanced A26 expression significantly altered its rate 
of association with the key MV membrane protein A27, which is required for EEV formation. 
When A26 was expressed under the intermediate F13L promoter, incorporation of A26 on 
virions was significantly enhanced when compared to A26 expressed under its native promoter 
sequence. This was correlated with a small reduction in EEV formation.   
The data presented in this thesis reveals the A26 protein as a potential negative regulator of 
EEV formation. The temporal segregation of A26 from the EEV morphogenesis proteins; F13 
and A27 underpins the transition from EEV to IMV production. In addition, this thesis 
introduces the concept of altering temporal regulation to explore the constraints of the poxviral 
genome and its ability to acquire variation. These findings will assist in the refinement of 
sequencing algorithms used to characterise novel pathogen populations.  
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1 Introduction  
1.1 The family Poxviridae: A general overview  
Viruses are obligate intracellular parasites that infect all members of the eukaryota and 
prokaryota. As such viruses are incredibly diverse in their general physical structures and their 
DNA or RNA genome replication strategies. Despite the near infinite diversity of viruses, all 
are unified by their ability to generate mRNA that is translated by host ribosomes. This is the 
basis of the Baltimore classification system proposed by David Baltimore and encompasses 
seven classes of mRNA transcription mechanisms employed by viruses (Baltimore, 1971).  
  
Poxviruses belong to the Poxviridae family and are classified under group I of the Baltimore 
system. Poxviruses are unique in contrast to fellow group I members such as the Herpesviridae, 
Adenoviridae and Papovaviridae as the poxvirus replication cycle is purely cytoplasmic. 
Unlike fellow group I members, the Poxviridae do not exploit the host-cell DNA replication 
machinery, and they rather encode an entire suite of polymerases, transcription factors, 
ribonucleotide reductases and other accessory proteins to establish infection of susceptible cells 
independently of the nuclear machinery. In addition to encoding its own replication machinery 
poxviruses encode an arsenal of immunomodulatory proteins to evade and subvert host 
defences. As such poxviral genomes range from 120-360 kilobase (kb) pairs in size, encoding 
over 220 open reading frames (ORFs).   
  
Despite the considerable size variation across different poxvirus strains, the general architecture 
of the poxvirus genome is highly conserved and has been studied in detail. The main 
distinguishing feature of the VACV genome are the inverted terminal repeats (ITRs). These 
ITRs are comprised of identical A/T rich sequences and are located at either side of the genome 
(Geshelin and Berns, 1974, Baroudy et al., 1982). The ITRs within VACV are 104 bp in length 
and are incompletely base paired. The bulk of ITR sequence consists of tandem repeats (Wittek 
and Moss, 1980). The functional significance of the ITRs is that they are required for 
concatemer resolution during genome replication (DeLange and McFadden, 1987). Between 
these ITRs VACV expresses a set of highly conserved genes dedicated to DNA replication, 
transcription and virion assembly. These essential genes are located toward the centre of the 
genome, whereas non-essential genes such as those required for host interaction and virulence 
18  
  
are clustered towards the termini of the genome (Figure 1-1)  (Smith et al., 2013). VACV and 
poxvirus genomes are intron-less and contain little noncoding DNA, which is distributed as 
small intergenic sequences.  
  
  
    
Figure 1-1. VACV genome organisation   
A schematic of HindIII fragments of the VACV genome, genes dedicated to immune evasion are 
underscored in red, the central conserved region containing genes required for DNA replication and 
morphogenesis are underscored in green adapted from (Hruby, 1990) 
 
The first VACV strain to be sequenced in full was strain Copenhagen, identifying 198 major 
and 68 minor coding regions (Goebel et al., 1990). To designate and classify these genes, a 
nomenclature was derived from HindIII digestion of Copenhagen viral genomic DNA. The 
individual HindIII fragments were labelled using alphabetic characters; genes within the 
fragments were numbered according to their position relative to the left end of the fragment. 
For example, the A26L gene is the 26th gene from the left end of Hind III fragment A. The 
direction of transcription is designated by either L (Left) or R (right) relative to the orientation 
of the genome. The Copenhagen nomenclature is applied to most other poxviruses, including 
the most commonly used laboratory strain WR. Whilst the Copenhagen nomenclature does not 
always apply to WR. When possible WR genes are designated according to their Cop 
homologue to facilitate identification.  
  
Aside from the unique genome structure and composition of poxviruses, family members share 
an unusual characteristic in that poxviral infection results in the production of two infectious 
forms with unique, distinguishable characteristics. The virions produced during infection are 
the single membrane intracellular mature virus (IMV) and the extracellular enveloped virion 
(EEV). Each virion form is both morphologically and biochemically distinct and fulfil specific 
roles within the infectious cycle.   
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The IMV are characterised by a single membrane and are the abundant progeny within poxvirus 
infection. The composition of the IMV membrane includes a large proportion of proteins 
dedicated to virus entry, in addition within some poxvirus strains IMV proteins enhance virion 
stability. As such the role of IMV within the poxvirus infection cycle is to facilitate host-to-
host transmission and promote persistence and stability within the environment. In contrast, the 
EEV are typified by an additional membrane derived from the trans-golgi network or the 
endosomes of infected cells (Schmelz et al., 1994) The additional membrane present on EEV 
facilitates cell-to-cell transmission and secures a persistent and productive infection within the 
host (Smith et al., 2002). The Poxviridae family encompasses a diverse collection of genera, 
with extensive host-range, virulence, clinical and historical significance. There are more than 
100 poxvirus genomes sequenced and their analyses have revealed that poxviral proteins are 
more closely related to eukaryotic proteins than viral or bacterial proteins (Lefkowitz et al., 
2006). Poxviruses can be split into two subfamilies: the Chordopoxvirinae and the 
Entomopoxvirinae. The host range of the former is the vertebrates; in contrast to the latter 
which has an insect host range. The Chordopoxvirinae subfamily is comprised of nine defined 
genera: Avipoxvirus, Cervidopoxvirus, Leporipoxvirus, Capripoxvirus, Molluscipoxvirus, 
OPXV, Parapoxvirus, Suipoxvirus and Yatapoxvirus (Table 1-1).  
Subfamily  Genus  Prototypical members  
Chordopoxvirinae  Avipoxvirus  Fowlpox virus  
Cervidopoxvirus  Deerpox virus  
Capripoxvirus    Sheeppox virus   
Leporipoxvirus  Myxoma virus  
Molluscipoxvirus  Molluscum contagiosum  
OPXV  Vaccinia virus (VACV), Variola virus  
(VARV)  
Parapoxvirus,  Orf virus   
Suipoxvirus  Swinepox virus  
Yatapoxvirus  Yaba monkey tumor virus  
  
Table 1-1. Family Poxviridae; subfamily Chordopoxviridae  
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The most significant and most studied genus in the poxvirus is the OPXV or OPXVs, which 
includes Variola virus (VARV), the aetiological agent of smallpox and one of the deadliest 
pathogens in human history. The prototypical member of this genus and the best studied 
poxvirus is Vaccinia virus (VACV), which was used as a live attenuated vaccine for the 
smallpox eradication program of the late 1970s (Fenner, 1982). The origin of VACV is 
unknown and has no known natural host (Baxby, 1981). However, VACV has a broad host 
tropism and can infect multiple species including humans. VACV is endemic to cattle in brazil 
and routinely causes outbreaks potentially affecting man. Other OPXV members include 
Cowpox virus (CPXV), the virus originally used by Edward Jenner to vaccinate against 
smallpox, and Ectromelia virus (ECTV), the causative agent of mousepox and an excellent 
model for virus-host interactions due to their host range being restricted to mice (Esteban and 
Buller, 2005). In the absence of VARV, the most medically significant OPXV is monkeypox 
virus (MPXV), an emerging zoonosis endemic to central Africa particularly in the Democratic 
Republic of Congo (DRC) (Rimoin et al., 2010). MPXV outbreaks have also occurred in 
several other west and central African nations including, Nigeria, Sierra Leone, Sudan and the 
Central African Republic (CAR) (Formenty et al., 2010, Berthet et al., 2011).   
  
Interest in poxviruses is multi-faceted. After the eradication of smallpox poxviral research has 
intensified to better understand and characterise the unique ability of poxviruses to antagonize 
innate and adaptive immunity. In addition, poxviruses are the basis of numerous polyvalent 
vaccine candidates owing to the substantial flexibility of the poxvirus genome.  
VACV can accommodate over 25 kbp of exogenous DNA (Smith and Moss, 1983).  
Poxviruses are also being employed as oncolytic agents, with several candidate therapies in 
stage II clinical trial (Russell et al., 2012). The remarkable ability of poxviruses to evade the 
host immune system is of significant scientific interest. A large proportion of ORFs within 
OPXV are dedicated to immune evasion and as such are ideal candidates to study host-pathogen 
interactions.   
  
Despite the successful eradication of smallpox, samples of live agent still exist and are held by 
the Centre for Disease control (CDC) in the United States and the State centre of virology and 
biotechnology (VECTOR) in the Russian Federation. As such the existence of VARV stocks 
poses a risk of accidental or intentional release as an act of biological warfare (Henderson et 
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al., 1999). Due to recent developments in synthetic biology, the chemical synthesis of poxvirus 
genomes is now possible (Noyce et al., 2018). The possibility that the VARV genome could be 
re-synthesized from sequence data available within the public domain for use in an act of 
bioterrorism is of significant concern (Organization, 2017). Due to the cessation of the 
smallpox vaccination program, a large proportion of the population is naive to OPXV infection 
and is vulnerable. Despite the availability and general safety profile of the smallpox vaccine 
stockpiles, in the event of a smallpox release mass vaccination is unsuitable for 
immunocompromised individuals. These issues are compounded by the limited availability of 
smallpox antiviral therapies. A recent advancement on this front has been the current 
development of the VARV antiviral ST-246® (Mucker et al., 2013), which targets the essential 
EEV morphogenesis protein F13L (Duraffour et al., 2015).   
  
1.2 Medical relevance of OPXV  
1.2.1 VARV  
The OPXV of most clinical and historical relevance to human health was VARV. VARV is 
highly infectious and lethal disease. Unlike other OPXVs VARV is human-specific and had no 
known natural reservoir. VARV can be classified into two subtypes according to the severity 
of the disease that it inflicts: VARV major was associated with outbreaks with high case fatality 
rates (30%), whereas VARV minor was a milder form of the disease with associated case 
fatality of <1% (Esposito et al., 2006). Variola major infection was characterized by papular 
lesions with a centrifugal distribution, clustering on the torso and trunk and radiating out 
towards the extremities. Variola major has a variety of other clinical presentations (Table 1-3) 
(Rao and Organization, 1972).   
Clinical presentation   Characteristics   
Ordinary  Papular skin lesions:  
Confulent- Confluent distribution of lesions on face and extremities in a 
centrifugal distribution.  
  
Semiconfluent- Confluent distribution of lesions on face. With localized lesions 
on extremities.   
 
Discrete- sporadic distribution of lesions with areas of healthy skin.  
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Modified  Like ordinary. Presents with an accelerated clinical course  
Flat   Characterized by flat lesions with a centrifugal distribution, with high case 
fatality rate.  
Haemorrhagic   lethal with 100% case fatality, characterized by haemorrhages of the skin and 
mucous membranes. Presents with or without lesion formation  
  
Table 1-2. Clinical presentations of VARV major skin lesions.  
  
The pathogenesis of smallpox proceeds from an initial percutaneous exposure or by inhalation 
of aerosolized virus leading to infection of the respiratory mucosa. After infection the virus 
migrates to the regional lymph nodes, where the patient develops an asymptomatic viremia at 
3-4 days post infection (dpi), coinciding with viral replication within the bone marrow, spleen 
and lymph nodes (Breman and Henderson, 2002). After 8 dpi a secondary viremia develops, 
resulting in fever. The characteristic rash associated with smallpox is caused by migration of 
the virus via infected leukocytes to the underlying blood vessels of the dermis. The virus then 
propagates within the dermal layer, infecting neighbouring cells. Lesions then appear in the 
epidermis where swelling leads to rupture of cellular membranes causing the vesicular lesions. 
After the incubation period of 12-14 days, symptoms include fever, headache, backache and 
severe malaise. Formation of the maculopapular rash is concentrated on the face and oral 
mucosa before spreading to the trunk and legs in a characteristic centrifugal distribution. The 
rash progresses from vesicular to pustular, the contents of the pustules gradually dry and crust 
over leading to scarring of large areas of affected skin. The main cause of death from variola 
infection is due to toxaemia from immunocomplexes generated by the immune system in 
response to Variola infection (Henderson et al., 1999). Therapeutic interventions for smallpox 
infection are limited, the antiviral ST-246 is an effective medical intervention validated in non-
human primate models (Mucker et al., 2013).   
  
1.2.2 Monkeypox virus  
In the absence of VARV, the most clinically relevant OPXV has become MPXV, which causes 
smallpox-like disease in humans that includes fever and the characteristic rash of VARV 
infections. MPXV is a zoonotic infection endemic to West and Central Africa, with recent 
outbreaks occurring in Nigeria and Sierra Leone (Yinka-Ogunleye et al., 2018). The incidence 
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of the disease has increased 20-fold since smallpox vaccination campaigns halted in the DRC. 
The case fatality rate (CFR) of MPXV ranges between 1 – 11 %. CFRs as high as 15 % are 
observed in unvaccinated children (Rimoin et al., 2010). The natural reservoir of and host of 
MPXV is unknown, but the virus has been isolated from west and central African rodents and 
non-human primate species (Khodakevich et al., 1986, Radonic et al., 2014). Transmission of 
MPXV occurs primarily via contact with infected animals via hunting or the preparation of 
bush-meat. Human-to-human transmission occurs via respiratory droplets or percutaneously 
from contact with pustular lesions. The disease course and pathogenesis of MPXV is like that 
of VARV, but with reduced severity. However, fulminant and systemic  
MPXV infection can occur, resulting in viremia and elevated levels of proinflammatory 
cytokines (Nagata et al., 2014). MPXV infection is also associated with other sequelae such as 
corneal scarring resulting in blindness and secondary bacterial infections.   
  
1.2.3 VACV  
VACV is the prototype OPXV and is the most studied. VACV infection is generally 
characterized as a low-grade or asymptomatic. Infection with VACV affords protection from 
otherwise lethal VARV infection. This property was exploited during the smallpox eradication 
program. There are several VACV strains that were exploited for vaccination such as Dryvax, 
Wyeth and Lister. Recent research has indicated that most of these were in fact a mixture of 
multiple strains (Osborne et al., 2007, Garcel et al., 2007). Infection with VACV is usually 
mild and self-limiting. However, ocular infections can lead to corneal scarring and blindness. 
In addition, shed virus from vaccinated individuals can rarely result in adverse dermatological 
conditions such as eczema vaccinatum in patients with atopic dermatitis (Copeman and 
Wallace, 1964). Other sequelae of direct infection include progressive vaccinia in 
immunocompromised individuals, a condition characterised by a continual expansion of the 
initial vaccination lesion into the tissues leading to necrosis and bacterial superinfection (Neff 
et al., 1967).   
  
1.2.4 Cowpox virus  
Cowpox virus (CPXV) is an emerging zoonotic infection as such it infects a broad range of 
hosts including rodents, cats, cattle and humans. The secession of the smallpox vaccination has 
increased the number of susceptible individuals, as a result several outbreaks have occurred 
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(Vogel et al., 2012).   CPXV infection in humans is characterized by localized pustular lesions 
on the hands that are usually self-limiting (Baxby et al., 1994). However fatal infections can 
occur in immunocompromised patients (Eis-Hubinger et al., 1990).   
  
1.3 Poxviruses as vaccine vectors  
1.3.1 VACV  
Poxviruses have formed the basis of vaccinology and have been exploited throughout history 
to promote immunity to pathogens. Obvious examples include Edward Jenner’s seminal use of 
CPXV as a vaccine against smallpox (Jenner, 1798). The significant antigenic similarity 
between CPXV and VARV was later demonstrated (Downie et al., 1950) and paved the way 
for similar studies with VACV and its use of VACV for the eventual eradication of smallpox 
in 1980 (Fenner et al., 1987). VACV is an attractive candidate for the development of vaccine 
vectors due to its unique characteristics. VACV infection elicits robust antibody and T-cell 
mediated responses, resulting in lifelong immunity. The substantial capacity of the VACV 
genome to accommodate over 25 kbp of exogenous DNA permits insertion of multiple foreign 
antigens in addition to co-stimulatory molecules such as cytokines and chemokines to enhance 
immune responses. The first example of recombinant VACV generated via molecular cloning 
was the insertion of the Hepatitis B surface antigen (HBs) into the thymidine kinase (Tk) loci 
under a synthetic early promoter sequence (Smith et al., 1983). These initial experiments 
resulted in a live recombinant VACV vaccine that produced HBs specific antibodies in non-
human primates (Moss et al., 1984). Other examples of recombinant VACV include the 
incorporation of the rabies glycoprotein cDNA into the Copenhagen strain of VACV (COP) 
(Kieny et al., 1984). In addition to the genomic flexibility of VACV, its physical and genomic 
stability, the lack of oncogenicity and the absence of an animal reservoir for the virus have 
facilitated its success. Despite the potential of replication competent VACV based vaccine 
vectors, there are number of limitations that prevented widespread use. The safety profile of 
live VACV vectors is undesirable, VACV based vectors cannot used in immunocompromised 
individuals due to the occurrence of side effects such as progressive vaccinia. In addition, 
transmission of replication-competent VACV is not limited to the vaccinee, and incidences of 
horizontal transmission of VACV are well documented (Young et al., 2011).   
  
25  
  
These concerns urged for the need of replication deficient VACV vectors. A notable example 
of those is modified Vaccinia Ankara (MVA), generated after 572 serial passages in chick 
embryo fibroblasts (CEF), a process that led to the loss of 15 % of the genome (Mayr and 
Munz, 1964, Meyer et al., 1991). MVA is defective in viral morphogenesis in most mammalian 
cells as it lacks expression of post-replicative genes, which include a number of crucial EEV 
proteins including F13L (Blasco and Moss, 1991), A27L (Dallo et al., 1987) and B5R 
(Martinez-Pomares et al., 1993). Consequently, MVA is unable to produce infectious progeny 
in human cells, although expression of early and some intermediate genes proceeds  
(Sutter and Moss, 1992). Despite the abortive infection in mammalian cells, recombinant MVA 
expressing influenza hemagglutinin (HA) produced substantial antibody titers and cytotoxic T-
lymphocyte (CTL) responses. The protective effect of recombinant MVA expressing influenza 
hemagglutinin (HA) rivalled that of VACV WR when immunised mice were challenged with 
influenza virus (Sutter et al., 1994). However, one perceived drawback of MVA based vectors 
is that when used in isolation do not provided sufficient immunogenicity in-vivo. As a 
consequence, MVA is mostly used in heterologous boost regimes where initial priming is 
followed up with MVA expressing the same antigen. Currently there are numerous PI/II/III 
clinical trials utilizing MVA in this regimen for infectious agents such as HIV, M. Tuberculosis 
(Scriba et al., 2010) and plasmodium falciparum (Sheehy et al., 2012) as well as, more recently, 
members of the Filoviridae Ebola and Marburg viruses (Milligan et al., 2016).  
  
Another example of a replication deficient VACV is strain is NYVAC which was derived from 
VACV Copenhagen with 18 ORF deletions. Of the deleted ORFs two are critical for nucleotide 
metabolism; the thymidine kinase gene (J2R) and ribonucleotide reductase (I4L). In addition, 
NYVAC is deficient for the VACV encoded hemagglutinin (A56R), the IMV morphogenesis 
protein A26L and over 12 ORFs encoding immunomodulatory genes (Tartaglia et al., 1992). 
NYVAC based vectors have demonstrated good antibody and lymphocyte proliferation 
responses (Kazanji et al., 2001). In contrast to MVA, the underlying mechanism underpinning 
NYVACs replicative deficiency is that translation of late genes is blocked by phosphorylation 
of alpha subunit of the eukaryotic translation initiation factor 2 (eIF-2α) (Najera et al., 2006).  
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1.3.2. Avian poxviruses  
Poxviral vaccine vectors are not limited to VACV. Some of the most promising viral vectors 
in use are derived from the Avipoxvirus (APV) genus. APV are one of the largest and most 
diverse group of viruses, infecting birds and poultry. Members of this genus are of agricultural 
and veterinary significance. There are 10 recognised members of the APV infecting over 200 
avian species (Lefkowitz et al., 2017). APV are also the largest of the Poxviridae with genomes 
ranging between 260-365 kbp in size. The protypical member of the APV is the Fowlpox virus 
(FWPV) (Afonso et al., 2000). APV are attractive vaccine vector candidates for several reasons. 
Replication is restricted to avian hosts and causes abortive infection in mammalian cells (Taylor 
et al., 1988) limiting the potential of horizontal transmission of the vaccine to other individuals. 
In addition to the large genome size allowing incorporation of several antigens. Another benefit 
of these vectors is that anti-sera generated from OPXV. OPXV infection does not protect 
against APV infection, meaning that an APV vector is effective even if an individual has 
received a vaccination against smallpox. Vaccine vectors based on FWPV and Canarypox virus 
(CPV) are already in use in veterinary medicine against rabies, West Nile fever, and avian 
influenza (Taylor et al., 1995, Siger et al., 2004, Bublot et al., 2006). APV-based vectors are 
also in development for human use. The most attractive candidate is the attenuated strain 
ALVAC, derived from CPV, which for reasons not completely understood is a hundred times 
more efficient in generating protective immunity than their FWPV counterparts (Taylor et al., 
1991). Consequently, ALVAC-based vectors have been utilized in several clinical trials against 
AIDS and malaria. The most promising and advanced ALVAC candidate was vCP1521 in 
combination with two booster doses of the Gp120 subunit vaccine AIDSVAX, with an efficacy 
of 31.2 % (Rerks-Ngarm et al., 2009).  
  
1.4 Poxviruses as oncolytic agents  
Besides vaccine vectors poxviruses have emerged as efficient oncolytic agents. Poxvirus 
tropism is suited to cancer cells as poxviral replication utilizes epidermal growth factor 
EGFR/RAS signaling to facilitate replication (Yang et al., 2005b), this is underscored by the 
fact that VACV encodes its own EGF homologue Vaccina virus growth factor (VGF) for this 
purpose (Buller et al., 1988). In cancer cells EGFR and EGF are often upregulated (Sporn and 
Roberts, 1985). Poxviruses are also suited to infect cancer cells as they do not rely on receptor 
mediated entry into target cells, entry is facilitated through either direct membrane fusion or 
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endocytic entry (Moss, 2006). The ability of poxviruses to spread and disseminate within the 
host is also an advantage. The EEV form acts to effectively stealth virions by enclosing IMV 
in a host derived membrane (Schmelz et al., 1994, Tooze et al., 1993), few virion proteins are 
exposed on the EEV membrane and are resistant to complement by the incorporation of host 
complement control proteins: cluster of differentiation (CD) markers CD46, CD55 and CD59 
(Vanderplasschen et al., 1998). These characteristics allow oncolytic poxviruses to be 
administered intravenously and to be delivered to metastatic tumours  
(Breitbach et al., 2011). Lastly, these beneficial characteristics are combined with the 
amenability of the poxvirus genome to be modified using traditional recombinant and modern 
synthetic DNA technologies to incorporate a wide array of tumour antigens and immune-
stimulatory molecules (Noyce et al., 2018).   
  
Oncolytic poxviruses are predominantly based on replication competent VACV, as attenuated 
vaccine strains such as MVA and NYVAC are unable to replicate in mammalian cells. These 
include recombinant Wyeth, Copenhagen and Western Reserve (WR) VACV strains 
(Mastrangelo et al., 1999, Foloppe et al., 2008, Ricordel et al., 2018). Recombinant VACV 
Wyeth strains expressing granulocyte macrophage simulating factor (GM-CSF) has been used 
for incurable cutaneous melanoma, in his case the virus was administered directly to tumours. 
The cytopathic effect of the virus was sufficient to de-bulk much of the melanomas treated, in 
addition expression of GM-CSF successfully recruited macrophages and CD-4+ and CD-8+ T-
lymphocytes to the sites of administration (Mastrangelo et al., 1999).   
  
Oncolytic poxviruses based on the WR strain include vvDD, a virus deficient in the viral 
thymidine kinase (J2R) and encoded growth factor (VGF). As a result it is unable to replicate 
in healthy cells but demonstrates selective replication in cancer cells where there is excess 
cellular TK (Hengstschlager et al., 1994). vvDD exhibited enhanced cytopathic effect in mouse 
xenographs when compared to a TK deficient Wythe strain (Thorne et al., 2007).   
  
Oncolytic poxvirus candidates are not restricted to recombinant VACV strains. Myxoma virus 
(MYXV) the causative agent of myxomatosis in rabbits (de Beaurepaire Aragão, 1927) has 
demonstrated significant oncolytic potential. MYXV specifically infects rabbits and produces 
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an abortive infection in other mammalian cells. However, MYXV can infect and effectively 
replicate in cancer cell lines and was shown to be effective in eliminating glioma xenographs 
in immunodeficient mice (Lun et al., 2005, Sypula et al., 2004)). Additionally, MYXV has 
been applied to traditional cancer therapy strategies such as autologous stem cell 
transplantation to treat multiple myeloma (Bartee et al., 2012).   
  
1.5 Immune response to infection  
Due to its importance as a vaccine vector and oncolytic virus, VACV is the model virus to 
understand the immune response against poxvirus infection. The host immune response to 
VACV is substantial, activating both innate and cell mediated immune systems leading to virus 
clearance. The initial barrier that all viruses must overcome in-order to establish infection is 
the innate immune system; comprising neutrophils, macrophages, dendritic cells (DC), Natural 
killer (NK) cells, complement proteins and inflammatory cytokines including interferon (IFN). 
After activation of the innate immune system to limit the initial infection and to signal the 
adaptive immune system, a wider, more extensive response is enacted via the cell-mediated 
and humoral immune responses. This response allows the specific clearance of pathogen 
infection and the generation of immunological memory. Both cytotoxic T lymphocytes (CTLs) 
and B lymphocytes are critical to mount an effective response against VACV.  
  
1.5.1 Innate immune sensing of VACV   
For an immune response to be generated VACV must first be sensed by pattern-recognition 
receptors (PRR). A combination of studies carried out on both human and murine macrophages 
and DC have concluded that the innate immune response to VACV is cooperatively activated 
by Toll-like receptors (TLR), cytoplasmic DNA and RNA sensors, and inflammasomes 
(Unterholzner et al., 2010, Georgana et al., 2018, Delaloye et al., 2009, Dai et al., 2014). Total 
or partial deletion of these components led to an increase in the production of inflammatory 
cytokines. An overview of how these pathways operate is presented.  
  
TLR signalling is mediated by interaction of poxvirus derived ligands on either the cell surface 
(TLR-2 and TLR-4) or cellular compartments (TLR-9 and TLR-3).TLR-2 recognized a variety 
of  pathogen associated molecular patterns (PAMPS) from bacteria, fungi and viruses, whereas 
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TLR4 recognizes Lipopolysaccharide (LPS) (Akira et al., 2006) Binding of ligand such as LPS 
to TLR4, leads to recruitment of myeloid differentiation primary response protein (MyD88) to 
the cell surface by toll/interleukin-1 receptor domain contacting adaptor protein (TIRAP). 
Following MyD88 recruitment, signaling can occur directly or via the adaptor protein TIR 
domain containing adaptor inducing interferon (TRIF). In the MyD88 dependent pathway, 
TRIF complexes with the Interleukin 1 receptor associated kinase (IRAK-1), IRAK-1 is then 
phosphorylated an additional kinase IRAK-4 (Keating et al., 2007). The initial phosphorylation 
of IRAK-1 leads to autophosphorylation and dissociation from MyD88. IRAK-1 then 
associates with the E3 ubiquitin (Ub) ligase TNF receptor associated factor 6 (TRAF-6), which 
in conjunction with Ub conjugating enzymes autopolyubiquitylates IRAK1 (Emmerich et al., 
2013). Recognition of these Ub chains by the mitogen activated protein kinase TAK-1 leads to 
the activation of both the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB) and MAPK pathways. The NF-κB pathway is regulated by the inhibitor of κB (IκB) kinase 
(IKK) complex, consisting of three subunits: IKK-α, IKK-β and IKK-γ. TAK-1 interfaces with 
IKKβ and phosphorylates it, this in turn results in Phosphorylation and activation of IKK-β by 
TAK-1 allows the phosophorylation of IκBα leading to its degradation by the E3 ligase β-TrCP 
(Yaron et al., 1998, Alkalay et al., 1995). Once IκBα has been degraded the p65/p50 
heterodimer translocates to the nucleus to initiate transcription of inflammatory response genes.  
  
The TRIF dependent mechanism is more direct and leads to the expression of interferon 
response genes via translocation of the transcription factors Activated protein 1 (AP1), NFκB 
and interferon regulatory factor 3 (IRF-3). TRIF interfaces with TRAF-3 leading to 
phosphorylation and activation of the TAK1/TAB complex is via the kinase RIP-1, initiating a 
signaling cascade via mitogen activated protein kinase (MAPK) leading to the phosphorylation 
and subsequent translocation of AP1s to the nucleus (Kawai and Akira, 2008). Alternatively, 
TRAF-3 mediates the phosphorylation and translocation of IRF3 via interfacing with IKK 
kinase proteins IKKi and TBK1. In this instance TRIF oligomerizes and then associates with 
TRAF-3, this association recruits scaffold proteins TANK, NAP1, SINTBAD and TBK1 
forming a signaling complex (Ostuni et al., 2010). This signaling complex then ubiquitinylated, 
leading to the phosphorylation of IRF-3, which dimerizes and is translocated into the nucleus 
to initiate production of type I interferon (Kawai and Akira, 2008, Tseng et al., 2010).with 
Interaction In VACV infection the MyD88 dependent and independent pathways of TLR-2 are 
activated. Production of proinflammatory cytokines; Interleukin-1 (IL-1), IL-6, IL-12 was 
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mediated by the MyD88 dependant pathway and INF-B by the independent pathway. In 
addition, the maturation of splenic dendritic cells (DCs) was shown to be dependent on TLR-2 
pathway activation in-vivo, leading to proliferation of CTLs (Zhu et al., 2007).  The specific 
poxvirus derived ligands that stimulate TLR-2 are unknown.  
  
Poxviruses are also sensed by TLR-3 and TLR-9 within the endosome. These TLRs detect 
nucleic acids; double stranded RNA (TLR-3) and unmethylated CpG-DNA. Activation of 
TLR-9 and signaling via MyD88 is critical for generating antiviral cytokines such as INF-α by 
DC cells. TLR-9 was shown to be critical for recognition of ECTV and systemic release of 
antiviral cytokines in mice (Samuelsson et al., 2008).   
  
1.5.2 Cytosolic RNA sensing   
Due to the cytosolic lifestyle of poxviruses detection of nucleic acids within the cytoplasm of 
infected cells is essential for the activation of antiviral innate immunity. Cytosolic nucleic acid 
sensors act as the primary detection system in non-immune cells, as TLR largely segregated to 
immune cells such as dendritic cells (Takeda et al., 2003). Two sensors have been described 
that detect viral RNAs; melanoma differentiation-associated protein 5 (MDA5) and retinoic 
acid inducible gene-I (RIG-I) (Yoneyama et al., 2004, Andrejeva et al., 2004). Both RIG-I and 
MDA5 share similar structures and modes of activation. Structurally they consist of two cystine 
aspartic acid protease (caspase) recruitment domains known as 2CARD, a death domain 
helicase (DExH) and a regulatory domain (RD). RIG-I interacts with 5’ triphosphate motif of 
RNAs, closing around the RNA in an ATP dependent reaction (Hornung et al., 2006). 
Hydrolysis of ATP induces a conformational change exposing the 2CARDs, these CARD 
domains then interact and with the downstream adaptor molecule MAVS positioned on the 
mitochondrial membrane. Oligomerization of the CARDs of activated RIG-I initiates the 
nucleation of MAVS on the mitochondrial membrane, assembling large filamentous structures 
on the surface of the mitochondria. These MAVS filaments are potent activators of INF-α/β, as 
they are ubiquitinylated by E3 ligases TRAF-2, TRAF-5 and TRAF-6 to activate IKK and 
TBK1, leading to NF-κB and IRF3 mediated signalling (Hou et al., 2011, Jiang et al., 2012, 
Zeng et al., 2010).   
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1.5.1.3 Cytosolic DNA sensing  
Cytoplasmic sensing of viral DNA has emerged as critical for the activation of antiviral 
immunity and signaling leading to IFN production. DNA sensing in the cytosol is mediated by 
the DNA binding and nucleotidyl-transferase protein, cyclic GMP-AMP synthase (cGAS) (Sun 
et al., 2013). Association of cGAS with dsDNA triggers the production of cyclic AMP/GMP 
dinucleotide (cGAMP), a second messenger molecule which interfaces with the stimulator of 
interferon response genes (STING) on the ER (Ishikawa and Barber, 2008). Interaction of 
cGAMP triggers STING dimerization and phosphorylation (Ishikawa and Barber, 2008, Liu et 
al., 2015a).  Besides cGAS other molecules have been reported as cytosolic DNA sensors. 
These include interferon-inducible myeloid differentiation transcriptional activator 16 (IFI16) 
, DNA-PK or the DEAD-box helicase 41 (DDX41) that act independently from STING.  
  
1.5.1.4 Inflammasomes  
The inflammatory cascade is also initiated within the cytoplasm by the formation of 
inflammasomes. Inflammasome formation is dependent upon the interaction of cytoplasmic 
NOD like receptors (NLR) which are divided according to the presence of a pyrine domain 
(NLRP) and a caspase domain (NLRC).  NLR activation is dependent upon recruitment and 
oligomerisation of the adaptor protein ASC (Latz et al., 2013). The ASC protein contains an 
CARD domain which recruits the inactive procaspase-1, triggering self-cleavage and activation 
of caspase-1 and subsequent cleavage of pro-IL-1β and pro-IL-18 to their mature forms 
(Thornberry et al., 1992, Gu et al., 1997).   
  
1.5.3 IFN, cytokines and chemokines  
IFNs are cytokines that induce a potent antiviral state that inhibits viral growth and replication, 
as such they are an attractive target of VACV immune evasion genes. This is underscored by 
the fact that between 30-50 % of VACV genomes are dedicated to immune evasion, encoding 
proteins that effectively disable the induction of antiviral immune signaling in response to 
proinflammatory cytokines. In mammals 3 types of IFNs have been described; type I IFN 
including IFN-alpha and IFN-beta; type II INFs including IFN gamma; and the type III IFN 
lambda. Type I IFN are produced by most cell types in direct response to infection following 
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the coordinated activation of NF-kB, IRFs and MAPK signaling pathways and trigger the 
production of IFN stimulated genes (ISG) via the Janus tyrosine kinase (JAK) – signal 
transducer and activator of transcription (STAT) pathway.   
  
Besides IFN other cytokines are critical in the immune response such as TNFα, IL-1 and IL18. 
TNFα is a pleotropic cytokine which is particularly important for the regulation of the pro-
inflammatory cascade and macrophage activation (Parameswaran and Patial, 2010). Binding 
of TNFα to TNF receptors 1 and 2 (TNFR1 and TNFR2) initiates signalling via TRADD and 
TRAF to initiate proinflammatory responses. TNFR1 activation mediates apoptosis, whereas 
TNFR2 activation leads to the induction of the NFκB and the MAPKKK pathway, instigating 
the further release of inflammatory mediators, and promoting immune cell proliferation 
(Tartaglia and Goeddel, 1992).  IL-1 is a proinflammatory cytokine with a diverse array of 
functions. Binding of IL-1 to the IL-1 receptor (IL-1Rα) leads to the induction cycoloxgenase 
type 2 (COX2) and inducible nitric oxide synthase (iNOS) leading to vasodilation. IL-1 is also 
a potent simulator of Th2, Th17 and B-lymphocyte function (Dinarello, 2009).  IL-18 is a 
member of the IL-1 cytokine family and is expressed by antigen-presenting cells and a handful 
of non-hemopoeitic cells. It is first expressed as a precursor known as ProIL-18 that undergoes 
caspase-1 cleavage to its active form which binds the IL-18 receptor (IL-18R). The IL-18R is 
structurally similar to the TLR superfamily, as such signaling is mediated via the adaptor 
protein MyD88 leading to the induction NFκB and MAPKKK pathways (Biet et al., 2002).     
  
Finally, the ability of immune cells to migrate is dictated by the release of chemotactic 
cytokines, the chemokines. Upon release from infected cells chemokines are bound by hostcell 
glycosaminoglycans. The deposited chemokines then bind to chemokine receptors on 
leukocytes triggering signaling cascades, resulting in the migration of these cells towards the 
site of infection in a concentration dependent manner. There are two chemokine families 
designated as CXC or CC. The CXC chemokine family is named as such due to an intervening 
amino acid residue between the first two cystines of the protein. CXCs also contain a receptor 
binding site in the N-terminus of the protein which is required for receptor binding and 
neutrophil chemotaxis (Graves and Jiang, 1995). The CC chemokine family is defined by the 
presence of two cystine residues at the beginning of the protein and play a role in the stimulation 
of neutrophils, leukocytes and T-leukocytes 2(Graves and Jiang, 1995). The expression of most 
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chemokines is controlled by inflammatory transcription factors, such as NF-kB and IRFs upon 
detection of foreign organisms.   
  
1.5.4 NK cells  
Within the innate immune response NK cells play an essential role. NK cells are large granular 
leukocytes that counter viral infection by detecting an altered self-phenotype on the surface of 
infected cells. This “altered self” phenotype is dependent upon expression of MHC-1 in 
conjunction with activating/inhibitory receptors and stress induced ligands. These activating 
and inhibitory receptors include C-type lechtin and immunoglobulin like receptor families. The 
predominant inhibitory receptor of NK cells is NKG2A, which binds the HLAE subunit of 
MHC-I conferring tolerance. Conversely activating receptors such as NKG2D and natural 
cytotoxicity receptors (NCR); kkp46,80 and 30 stimulate NK mediated cytolysis (Phillips et 
al., 2013, Vivier and Ugolini, 2010). Upon binding to activating/inhibitory ligands on affected 
cells, a signaling cascade is initiated by Immuno-receptor tyrosine-based inhibiting /activating 
motifs (ITIM and ITAM). The activation of NK cells is dependent on the phosphorylation of 
ITAM triggered by interaction with activating ligands. ITAM phosphorylation recruits the scr 
homology 2 domain kinase (Syk), the subsequent signaling cascade leads to the expression of 
INF-γ and triggers the delivery of cytotoxic granules to the affected cell (Vivier et al., 2004).  
  
The innate immune response to VACV infection is significantly enhanced by NK cells, 
enhanced recruitment of NK cells is observed at the site of VACV infection (Jacobs et al., 2006, 
Natuk and Welsh, 1987). VACV infection has also been shown to significantly alter the 
expression of key activating and inhibitory ligands on the surface of infected cells. For 
example, during VACV infection MHC-1 expression is down-regulated (Kirwan et al., 2006). 
In addition, the NKG2A receptor is sensitive to the down-regulation of HLA-E on the surface 
of VACV infected cells (Brooks et al., 2006). Infection has also been shown to alter the 
distribution of C-type lectins on the cell surface, leading to NK mediated cytolysis (Williams 
et al., 2012). Infection with VACV infection also alters the profile of NK cell receptor (NCR) 
ligands on the cell surface (Chisholm and Reyburn, 2006). The modification of activating and 
inhibitory host cell ligands increases the susceptibility of VACV infected cells to NK cell lysis. 
Despite these changes VACV is still able to modulate NK cell activity by direct and indirect 
mechanisms. The poxvirus hemagglutinin protein A56 binds NCRs; NKp30 and NKp46, 
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inhibiting NKp30 activation whilst enhancing NKp46 activation (Jarahian et al., 2011). 
Presumably the activating/inhibitory effect of A56 is tailored to maintaining NK cells in an 
inactive state when responding to cells presenting an abnormal combination of NK ligands 
specific to VACV infection. VACV indirectly controls NK cells by inhibiting INFα/β and 
proinflammatory cytokines IL-12, IL-16 and IL-18 which are essential of enhanced NK-cell 
activity.  
1.5.5 Complement   
Complement proteins are an essential component of the innate immune system, as such they 
are critical for the clearance of VACV infections. The complement cascade initiated by the 
classical, lectin and intrinsic cascades assists in the opsonization of virion particles. In addition, 
complement proteins are required for the formation of the membrane attack complex (MAC), 
resulting in the lysis of infected cells. The complement cascades are mechanistically complex, 
employing an array of regulatory and effector proteins (Noris and Remuzzi, 2013). However, 
each cascade converges on the production of the major precursor proteins C3 and C5. C3 is 
cleaved by C3b convertase forming the active effectors C3a and C3b. C3a has potent 
inflammatory activity and stimulates chemotaxis of leukocytes via the interaction of C3a with 
the C3a receptor (Walport, 2001). The production of C3b is required for the assembly for C5 
convertase, which generates the effector C5 molecules C5a and C5b. In addition, C3b mediates 
the opsonization of pathogens and infected cells via the interaction of its thioester bond (Noris 
and Remuzzi, 2013). The C5 effector molecule C5a promotes inflammation, whereas C5b in 
conjunction with other complement proteins leads to the formation of the MAC. The MAC 
complex permeabilizes membranes of both viruses and infected host cells (Bayly-Jones et al., 
2017)  
  
1.5.6 Cell mediated and humoral immunity to VACV infection  
Cell mediated immunity is essential for clearance of OPXV infections. The importance of the 
adaptive response is underscored by the increased susceptibility of immunocompromised 
individuals to poxvirus infection (Neff et al., 1967, Redfield et al., 1987). The main effectors 
of the adaptive response, CD4+ and CD8+ T-lymphocytes play a crucial role in curtailing  
VACV infection. Mouse studies have revealed that CD8+, CD4+ lymphocytes and 
macrophages are indispensable in curtailing infection. The absence of either was shown to 
severely reduce the antiviral activity of MHC-1 restricted T-lymphocytes, resulting in 
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incomplete clearance of the infection. When macrophages were depleted a 100% mortality rate 
was observed amount of the mice tested (Karupiah et al., 1996).   
  
Whilst the cell mediated response is critical during primary infection, the humoral immune 
system is essential in protecting against reinfection. After recovery from initial infection, long 
lived CD4+ lymphocytes, B-memory and plasma cells persist for decades after infection (Crotty 
et al., 2003). Protection against VACV infection is broad but most significant is the production 
of neutralizing antibodies (Abs). It has long been established that IgG derived from VACV 
infection is an effective method of prophylaxis (Kempe et al., 1961). Analysis of protective 
Abs generated from poxvirus infection indicate that the predominant correlates of protection 
consist largely of MV proteins; A27, H3, D8, A28, A13 and A17 (Davies et al., 2005). In 
contrast, Abs generated against EEV proteins are limited to A33 and B5 (Bell et al., 2004). Abs 
generated from VACV infection have been shown to be cross protective across several 
pathogenic OPXV including MPXV, CPXV and VARV (Gilchuk et al., 2016). Antibodies 
generated from VACV infection also bolster the activity of CD8+ T-lymphocytes via ADCC 
(Perrin et al., 1977).  
 
 
 
1.6 VACV genome replication and gene expression  
1.6.1 Genome replication   
Poxvirus DNA replication occurs within the cytoplasm of infected cells, independently of the 
host nuclear replicative machinery. To accomplish this VACV encodes a suite of proteins 
required for DNA replication in the cytoplasm including precursor metabolism, replication and 
DNA processing.   
 
Protein  Mass (kDa)  Cop nomenclature   
DNA replication  
DNA polymerase  
  
117   
  
E9L  
36  
  
Helicase-primase  90  D5R  
Uracil DNA glycosylase  25  D4R  
Processivity factor  49  A20R  
Protein kinase  35  B1R  
DNA binding protein  30  I3L  
DNA ligase  63  A50R  
DNA processing  
Holiday junction resolvase  
  
21  
  
A22R  
Topoisomerase  37  H6R  
DNA packaging  
ATPase  
  
34  
  
A32R  
Telomere-binding protein 1  36  I1L  
Table 1-3. VACV encoded replicative enzymes 
 
  
VACV genome replication occurs at 2 hours post infection and is characterized by the 
establishment of what appear to be punctate nuclei within the cell cytoplasm, known as viral 
factories. Production of new progeny occurs as soon as 8 h post infection (Salzman, 1960). For 
replication to occur efficiently, essential replicative proteins are packaged as mRNA and 
translated upon a release of viral DNA into the cytoplasm. The poxvirus polymerase E9L bears 
homology to eukaryotic polymerases and synthesizes DNA 3’-5’ with proofreading activity 
(Wang et al., 1989, Challberg and Englund, 1979).  
  
Replication of VACV DNA occurs via self-priming, with the rolling hairpin strand 
displacement mechanism being the one generally accepted and is outlined in Figure 1-2 
(Tattersall and Ward, 1976). The genome is nicked near the hairpin termini, generating a free 
3’ end where nucleotides can be added, extending towards the hairpin loop. As the ITR regions 
have complementarity, extension at the 3’ end loops back around forming the first hairpin of 
the newly synthesized genome. Extension of deoxynucleotides continues towards the other end 
of the genome, this process generates a concatemer of two genomes juxtaposed at the terminal 
hairpin termini (Moyer and Graves, 1981). This is the most basic representation of VACV 
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genome replication, as the IRT regions permit the formation of cruciform DNA structures of 
up to four genomes (Garcia et al., 2006). These concatemers are resolved into singular genomes 
via the hairpin terminal loops by the VACV encoded holiday junction resolvase A22 (DeLange 
and McFadden, 1987, Garcia et al., 2000).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. A schematic of the strand displacement model of VACV genome replication.  (1) The 
genome is nicked near the hairpin termini. (2) Deoxynucleotides extend towards the 3’ end of the 
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genome. (3) The complementarity of the ITR with incomplete base pairing leads to a re-circularisation 
of the Hairpin termini as nucleotides continue to extend toward the 5’ end of the genome. (4) Continual 
extension towards the 5’ end generates a concatemer of two genomes. (5) The genome concatemer is 
resolved via holiday junction resolvase, generating two independent genomes. Figure adapted from 
(Moss, 2013) 
1.6.2 VACV promoters and gene transcription  
The mechanism of poxvirus transcription is highly conserved across all poxviruses and is 
controlled by the individual expression of genes within specific temporal classes, coordinating 
genome replication, host immune evasion and viral assembly. All classes of genes are 
transcribed by a viral RNA polymerase. Approximately 118 ORFs in VACV are expressed 
early and are required for genome replication, immunomodulation and transcription of 
intermediate genes (Yang et al., 2010). Genes within the intermediate and late temporal class 
encode proteins required for morphogenesis. Proteins and mRNAs required for DNA 
replication are also expressed late and are packaged into progeny virions for the next replicative 
cycle. Intermediate and late genes are expressed after DNA synthesis and account for 93 ORF 
within VACV (Yang et al., 2010). Within this group of post-replicative genes 53 are in 
intermediate class and 38 are expressed late, with 2 genes that were detected but were unable 
to be resolved via western blot (Yang et al., 2010, Yang et al., 2011).  
  
Expression of early, intermediate and late genes is controlled by a temporal cascade, where 
early genes express transcription factors for intermediate genes. Intermediate gene products 
then encode transcription factors for late genes. Finally, these late genes produce transcription 
factors required for early genes, which are then packaged into virions for the next replication 
cycle (Yang et al., 2013). This processive transcriptional cascade is made possible as VACV 
encodes RNA polymerases and transcription factors unique to each temporal gene class, 
accompanied by a well-defined set of early, intermediate and late promoters.   
  
Replication of VACV within the cytoplasm is dependent on the production of translatable 
mRNAs encoding early proteins. This must be achieved independently of the host cell nuclear 
transcription machinery, therefore VACV encodes its own DNA dependent RNA polymerase 
known as RPO. The RPO is a complex multiprotein assembly of 9 individual components; J6R, 
A24R, H4R, A29R, E4L, J4R, A5R, D7R, G5.5R (Broyles, 2003a). Recognition of early, 
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intermediate and late genes is reliant on a specific set of promoter sequences and virally 
encoded transcription initiation factors (VTFs) outlined in Figure 1-3.  
  
  
Figure 1-3. Consensus promoter sequences and transcription initiation complexes of VACV. A 
Consensus sequences of early, intermediate and late promoter sequences, black arrows indicate 
transcription initiation sites. Numbers following letters indicates the number of repeated bases, “N” 
represents any nucleotide. B Model of corresponding transcription initiation complexes for early, 
intermediate and late promoters, mechanisms with viral proteins shaded blue and host derived nuclear 
proteins in shaded yellow. Mechanisms of the proteins are explained further in the text. Figure adapted 
from (Broyles, 2003b).  
  
Transcription of early mRNA occurs within the viral core and is driven by the assembly of the 
RPO and early transcription factor (VETF), a heterodimeric complex of proteins A7 and D6 
that spans either side of transcription initiation site (Broyles et al., 1988, Broyles and Fesler, 
1990, Gershon and Moss, 1990). These binding sites are present in the -12 to -29 and +7 to +10 
regions identified within early promoter sequences (Davison and Moss, 1989b,  
Broyles et al., 1991). Upon binding to these sites, VETF recruits the multi-subunit RPO and 
VETF is displaced in an ATP dependent reaction allowing transcription to begin (Li and 
Broyles, 1993). All VACV mRNA possess a 5’ m7Gppp cap which is synthesized by the 
heterodimeric capping enzyme D1/D12 (Niles et al., 1989, Morgan et al., 1984). Newly 
synthesized early mRNA is delivered into the cytoplasm through pores on the surface of the 
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virion core, to be translated by host ribosomes (Kates and McAuslan, 1967, Munyon et al., 
1967).   
  
  
Intermediate transcription proceeds after DNA replication, the gene products required for the 
synthesis of intermediate mRNAs are derived from early genes. Among these gene products 
are the subunits of the vaccinia intermediate transcription factor (VITF). The VITF consists of 
a multimeric complex of virally encoded proteins (E4, A8, A23) and host derived transcription 
factors VITF-2 and Ying/Yang1 (YY1) (Rosales et al., 1994a, Sanz and Moss, 1999, Rosales 
et al., 1994b). In addition to unique transcription factors, intermediate genes require a separate 
RNA polymerase lacking the H4 sub-unit (Wright and Coroneos, 1995). In this way 
intermediate gene expression is segregated by an RNA polymerase of different structure, as the 
presence of H4 confers specificity of the RPO complex to early promoter sequences (Deng and 
Shuman, 1994, Ahn et al., 1994). Assembly of the VITF complex occurs at intermediate 
promoter sequences, which can be characterized by an upstream A/T rich element and 
TAAATG motif where transcription initiates Figure 1-3 .  
  
Several cellular proteins have been implicated in the localization of transcription factors to 
intermediate promoters. These include the TATA binding protein (TBP) that has been shown 
co-localize with viral replication complexes. TBP preferentially binds A-T rich sequences, like 
those that are present upstream of the initiation element of intermediate promoters (Knutson et 
al., 2006). The nuclear protein YY1 has also been implicated in binding to Intermediate 
promoter regions (Broyles et al., 1999). This is because some intermediate promoters contain 
an additional GG at the 3’ end of the TAAT motif that has been shown to negatively regulate 
intermediate transcripts (Knutson et al., 2009). It has been hypothesised that this negative 
regulation is a mechanism to further delay, and thus temporally segregate, intermediate genes.   
  
Transcription of coding mRNA does not immediately follow binding of the RNA polymerase 
to the initiation site. The RNA polymerase slips on the complementary TTT of the TAAATG 
initiation motif, this slippage generates a 5’ polyA tract ranging from 3 to 53 residues in length 
(Bertholet et al., 1987, Schwer and Stunnenberg, 1988). PolyA formation has also been 
observed on early transcripts via a similar mechanism (Ink and Pickup, 1990). The significance 
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of the polyA tract was only recently discovered, as almost all of the 5’ UTR of intermediate 
and late mRNAs consists of polyA tract. The presence poly(A) tract was shown to enhance the 
translation of mRNAs within infected cells. Moreover, the authors determined that a 5’ poly(A) 
tract of 12 residues was optimal and conferred the biggest translational advantage (Dhungel et 
al., 2017). The typical poly(A) length of post-replicative viral mRNAs is between 8 – 12 
residues (Yang et al., 2012). These data imply that poxviruses have evolved to finely-tune the 
5’ polyA length to maximize the translation of viral mRNAs over the host (Dhungel et al., 
2017). Termination of intermediate transcripts is dependent upon the interaction of 
transcription elongation (G2 and J3R) and release factors (A18) (Xiang et al., 1998, Black and 
Condit, 1996, Latner et al., 2000).   
 
Transcription of the late class of genes is the final stage of the transcriptional cascade and is 
dependent upon intermediate gene products. These include the late transcription factor (VLTF) 
subunits; A1, A2 and G8 as well as a newly synthesized RNA polymerase lacking the H4 
subunit (Wright and Coroneos, 1995, Hooda-Dhingra et al., 1989). The function of the VLTF 
components is unknown. However, the G8 and A1 proteins have been shown to interact 
(McCraith et al., 2000). As with intermediate transcription, host genes are also implicated in 
the transcription of late genes including TBP, YY1 and the nuclear riboproteins: B1, A2 and 
RBM3 (Wright et al., 2001, Knutson et al., 2006, Knutson et al., 2009). These transcription 
factors bind to specific elements within the canonical late promoter sequence; the A/T rich 
upstream element and the initiation motif TAAAT (Davison and Moss, 1989a). Moreover, 
structural elements of the intermediate promoter can give rise to a dual intermediate late activity 
and has been hypothesised to be a mechanism to fine-tune expression levels and provide 
overlap where constant expression of a viral protein is required. These structural elements 
include a T at the +4 positions of the TAAA initiation sequence TAAAT+4, in addition late 
activity is enhanced by a T rich spacer between -12 and -8 nucleotide positions of the promoter 
sequence.  
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1.7.3 VACV RNA translation  
Translation of VACV mRNA is dependent on the host-translation machinery. Despite the 
significant size the capacity of the VACV genome, is its insufficient to accommodate the full 
set of 83 proteins and regulatory subunits required for host translation. The process of 
translation during poxvirus infection is like that of the host cell. To fully utilize the host 
translational machinery, poxviruses exploit the unique structure of their mRNAs, modulation 
of host translational machinery and prevent stress induced suppression of translation. VACV 
mRNA share the same general structure of host mRNAs; a 5’ m7 cap, polyA leader, coding 
mRNA and 3’ polyA tail. Initiation of viral mRNA translation begins with the recruitment of 
elongation factor 4 (eIF4E) to the 5’ m7Gppp cap. Upon recruitment to the cap eIF4G interacts 
with eIF3 which effectively bridges the eIF4E/eIF4G cap complex with the 40s ribosomal 
subunit. The combination of eIF4G and eIF3 load the 40s ribosome onto the polyA leader, 
where it begins to scan along the 5’UTR for the translation initiation codon AUG which is 
facilitated by eIF2. Recognition of the initiation codon by the 40s/eIF2 complex recruits the 
60s ribosomal subunit forming the functional 80s ribosome, beginning translation of mRNA 
and generating a linear polypeptide chain. Translation is halted once the 80s subunit runs into 
the stop codon, typically UAA.   
  
The unique 5’ polyA leader of early, intermediate and late poxvirus mRNA affords a 
translational advantage over host mRNAs (Dhungel et al., 2017). Typically, long stretches of 
A residues within the 5’ UTR are counterproductive for translation initiation as the ribosome 
tends to slide bidirectionally on long stretches of adenosine residues (Koutmou et al., 2015). 
However, the presence of the PolyA leader leading directly to the AUG initiating codon has 
been shown to be advantageous. The translation of these mRNAs is not fully dependent on the 
formation of the eIF4E cap binding complex, as such translation may proceed in a cap 
independent manner (Shirokikh and Spirin, 2008, Dhungel et al., 2017). To enhance translation 
of mRNA with polyA leaders, poxviruses have been shown to actively remodel components of 
the translational machinery. The VACV kinase B1 phosphorylates the variable loop region of 
a scaffold protein of the 40s ribosomal subunit, the receptor for activated C kinase 1 (RACK1) 
required for signaling and regulation of translation (Sengupta et al., 2004, Rabl et al., 2011, Jha 
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et al., 2017, Lin et al., 1992). Typically, in mammalian cells this loop is uncharged; however, 
in plants the loop is negatively charged. Phosphorylation by B1 converts the loop to a plant-
like state. This modified loop slows the rate of initiation by the 40s subunit, compensating for 
the slippage of the RNA polymerase on intermediate and late transcripts (Jha et al., 2017).  
  
An additional mechanism that poxviruses employ to control host ribosomes is the expression 
of two mRNA de-capping enzymes D9 and D10 (Parrish and Moss, 2007, Parrish and Moss, 
2006), which leads to degradation of host and viral mRNA. The recent discovery that the polyA 
leaders may play a role to enhance translation of viral mRNA, coupled with modification of 
40s ribosomal components to promote cap-independent translation, indicate a collective 
strategy to prioritize viral translation over the host.   
  
These mechanisms of ribosomal control act independently to the virus efforts to subvert host 
mediated sequestration of translation machinery. In the antiviral response, dsRNA molecules 
are detected by the cytoplasmic RNA sensor PKR leading to translational shutoff within the 
host cell. As a counter to this VACV encode an inhibitor of PKR, the K3 protein, which acts 
as a substrate for eIF2α phosphorylation (Davies et al., 1993, Davies et al., 1992). Preferential 
phosphorylation of K3 prevents eIF2α mediated host translational shutoff (Davies et al., 1992).   
  
1.7 Post translational modifications of VACV proteins  
During infection VACV proteins undergo a plethora of post translational modifications 
(PTMs), in order to alter and regulate the function of proteins within replicative and 
morphogenesis cycles. Analysis of VACV proteins has revealed a number of PTMs of 
significance, including proteolytic cleavage, glycosylation, phosphorylation and acylation. The 
substantial number of proteins expressed during a typical VACV infection make it difficult to 
include a comprehensive list of individual PTMs. Therefore, only examples of PTMs essential 
for replication and morphogenesis will be discussed.   
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1.7.1 Proteolytic cleavage  
Proteolytic cleavage plays a role at multiple points during protein synthesis. For example, 
following synthesis of the poly-peptide chain the initiating methionine or leader sequences 
required for membrane translocation are cleaved. In addition, precursor proteins can undergo 
cleavage generating the active form of the protein. There are multiple examples of viral proteins 
that undergo-cleavage during morphogenesis, particularly in the maturation of immature virion 
(IV) to the mature virion (MV). To this aim VACV encodes several proteases that are essential 
for viral morphogenesis including proteins I7 and G1 (AnsarahSobrinho and Moss, 2004, 
Whitehead and Hruby, 1994b). The targets of these proteases include components of the virion 
core, proteins A10, A3 and L4 (Katz and Moss, 1970, Moss and Rosenblum, 1973, Weir and 
Moss, 1985), that are cleaved at a conserved Ala-Gly-X motif (Whitehead and Hruby, 1994a). 
A particularly important example of a proteolytically cleaved morphogenesis protein is A17, 
an integral component of the IMV membrane, which anchors a subset of IMV surface proteins 
involved in virus entry and intracellular locomotion and wrapping (Wang et al., 2014, Howard 
et al., 2008, Sanderson et al., 2000). A17 contains an Ala-Gly-X cleavage site and is cleaved 
by the virally encoded protease I7 at the N and C terminus (Ansarah-Sobrinho and Moss, 2004).   
  
1.7.2 Glycosylation  
Glycosylation is the process of covalently adding carbohydrates to proteins with often profound 
effects on the final conformation and stability of proteins. Typically, secreted and membrane 
associated proteins are glycosylated. The sugars added during glycosylation can be N-linked 
through amino or hydroxyl groups of asparagine and/or serine residues, or Olinked to any serine 
or threonine. Glycosylation takes place within the Golgi, using host glycotransferases. There 
are numerous examples of glycosylated proteins in VACV, for instance most of the proteins 
required for EEV morphogenesis are glycoproteins. Significant examples include A56, the viral 
hemagglutinin, where 75 % of the protein is N-glycosylated and the remaining 25 % is O-
linked (Shida and Dales, 1981, Shida and biology, 1986). Other examples of glycosylated EEV 
proteins include proteins B5 and A34 (Engelstad et al., 1992, Duncan and Smith, 1992), which 
are essential membrane components required for wrapping, infectivity and release of EEV 
(Wolffe et al., 1993, Takahashi-Nishimaki et al., 1991, Blasco et al., 1993). B5 and A34 directly 
interact, and the presence of B5 directly affects the glycosylation of A34 (Breiman and Smith, 
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2010). When glycosylation was inhibited, A34 was shown to accumulate within the ER 
(Breiman and Smith, 2010).   
  
1.7.3 Phosphorylation   
Phosphorylation is an ATP dependent reaction to transfer phosphate groups to the hydroxyl 
groups of serine, threonine, tyrosine, histidine and lysine amino acid residues. The effect of 
phosphorylation upon target proteins effectively modulates enzymatic function and can 
influence protein-protein interactions. Protein phosphorylation is ubiquitous in eukaryotic 
systems and is integral for the functioning of signaling cascades involved in innate immunity, 
cell growth and differentiation. Within the context of VACV infection phosphorylation plays 
an integral role, such as in the remodelling of IMV proteins by the virally encoded 
serine/threonine protein kinase F10 (Lin and Broyles, 1994). Expression of F10 is essential for 
viral replication as ΔF10 viruses cannot be constructed. Temperature sensitive mutants have, 
however, revealed that morphogenesis is blocked in tsF10 viruses (Traktman et al., 1995). 
Specifically F10 phosphorylates the integral components of IMV membranes A14 and A17 
(Betakova et al., 1999). In addition, F10 associates with A30, a component of the viral assembly 
complex required for the phosphorylation and subsequent processing of the IMV membrane 
protein A17 (Szajner et al., 2004b). The role of these proteins within morphogenesis facilitates 
the wrapping of virion cores with membrane crescents forming immature virions (IV).  
  
In addition to the F10 kinase, VACV encodes a second serine/threonine kinase known as B1 
(Lin et al., 1992). In contrast to F10, the importance of B1 lies in regulating viral DNA 
replication, intermediate/late gene expression and translation. B1 phosphorylates the H5 
protein which is a component of the VLTF complex and is required for translation elongation 
(Beaud et al., 1995). Additionally, B1 has been implicated in the modulation of RACK1 to 
enhance translation of poly-adenylated viral mRNA as explained previously (Jha et al., 2017). 
In terms of genome replication protein B1 is required to phosphorylate barrier to 
autointegration factor (BAF). BAF is host-encoded DNA binding protein present within the 
nucleus and cytoplasm. The function of BAF is to bind exogenous DNA, preventing viral DNA 
replication. To counter this cellular inhibitory mechanism, B1 phosphorylation of BAF 
abrogates its ability to bind viral DNA (Wiebe and Traktman, 2007).  
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1.7.4 Acylation   
Acylation is a form of PTM where fatty acids are attached to amino groups of polypeptide 
chains. Fatty acids such as myristic and palmitic acids are covalently linked via a thioester bond 
to cystine/threonine residues. Due to the hydrophobic nature of acyl groups, fatty acid linkage 
usually occurs within the internal surfaces of proteins. As such, acylated proteins are typically 
localized to membranes. As with the other forms of PTM explained above, acylation is 
important for VACV morphogenesis, particularly to the function of EEV proteins. Amongst 
these, F13 is an acylated and palmitoylated protein essential for the wrapping of IMV with 
membranes derived from the trans-Golgi network forming EEV (Hiller and Weber, 1985, 
Grosenbach et al., 1997). The palmitoylation of F13 occurs at cysteines at positions  
185 and 186 (Grosenbach et al., 1997), targeting it to the Golgi membranes, effectively 
anchoring the protein to the surface of the EEV membrane (Grosenbach et al., 1997, Husain 
and Moss, 2001, Schmutz et al., 1995).  
  
1.8 VACV lifecycle  
The VACV replication cycle is unique as it occurs exclusively within the cytoplasm. For this 
to be accomplished, VACV must exploit many viral and host derived proteins required for 
entry, cytoplasmic localisation, DNA replication, morphogenesis and eventual egress of 
progeny virions. The significant body of knowledge pertaining to the poxvirus life cycle was 
derived from the study of VACV. The cytoplasmic lifecycle of VACV is complex but can be 
broken down into a series of steps; namely cell attachment and entry; dissolution of the virion 
core, and subsequent release of viral DNA and lateral bodies; establishment of viral factories, 
followed by crescent membrane formation; formation of immure virions and MV maturation, 
leading to EEV formation; culminating in the egress of infectious virus particles. This process 
is summarised in Figure 1-4.  
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Figure 1-4 An overview of the poxvirus lifecycle.   
The poxviral lifecycle is initiated by attachment and entry and release of the virion core into the 
cytoplasm, initiating transcription of early mRNAs, intermediate transcription factors, DNA and RNA 
polymerases. DNA replication and virion assembly occur within the viral factory and is driven by a 
cascade of intermediate and late gene expression, ultimately leading to the formation of the immature 
virion (IV). This is shortly followed by a maturation step, producing the first infectious progeny the 
mature virion (MV). As MVs exit the viral factory they are trafficked via the host cell cytoskeleton to 
the trans-golgi network where they wrapped forming intracellular enveloped virions (IEV). IEV are 
then trafficked to the cell periphery via host-microtubule transport where they exit the cell, where they 
are released into the extracellular environment as extracellular enveloped virions (EEV) or retained on 
the cell surface as cell associated enveloped virus (CEV). CEV can be propelled from the cell surface 
via the polymerization of actin tails.   
  
1.9.1 Attachment and Entry.  
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Attachment of IMV or EEV to host cells occurs through different mechanisms. Attachment of 
IMV is dependent upon binding to host cell glycosaminoglycans (GAG) on the surface of host 
cells. To achieve this, four viral proteins with GAG binding activity are incorporated onto the 
IMV membrane; H3, D8, A27 and A27. Proteins A27 and D8 have been identified to bind 
heparin sulphate (Hsiao et al., 1998, Hsiao et al., 1999), whereas H3 and A26 have been 
identified to bind chondroitin sulphate and laminin, respectively (Lin et al., 2000, Chiu et al., 
2007). The specific mechanism of EEV attachment is not fully understood. More recently, the 
F13 protein which is critical for wrapping of EV has been implicated in enhancing infectivity 
and entry into cells (Bryk et al., 2018). In the absence of F13, EEV membranes were more 
resistant to polyanionic membrane dissolution and as such were shown to have delayed entry 
kinetics (Law et al., 2006). Implying that the presence of F13 on the EEV membrane sensitizes 
it to acid induced membrane dissolution within endosomes (Bryk et al., 2018).   
  
Following attachment to cells by binding to host cell GAGs, virions are brought into the cell 
by micropinocytosis (Mercer and Helenius, 2008). Contact of virions with the host cell 
membrane instigates a substantial rearrangement of the host cytoskeleton, causing blebbing of 
the plasma membrane (Mercer and Helenius, 2008). Membrane blebbing in response to IMV 
binding has been associated with activity of epidermal growth factor receptors, protein kinase 
C (PKC) and p21 activated kinase (PAK1) (Mercer et al., 2010). The constituent components 
of the IMV membrane have also been implicated in entry (Ichihashi and Oie, 1983). IMV 
membranes are comprised of 36% phosphatidylserine (PS) (Zwartouw, 1964), a marker of 
apoptotic bodies that are phagocytosed by professional macrophages and other non-immune 
cells. As such VACV exploits apoptotic mimicry to enhance entry via micropinocytosis 
(Mercer et al., 2010, Mercer and Helenius, 2008).   
  
Once IMV or EEV have been internalised they fuse out of the endosome to deliver the viral 
core into the cytoplasm for replication to proceed. For IMV this process is regulated by a 
9protein complex known as the entry fusion complex (EFC) that is located on the surface of 
the IMV membrane and consists of proteins A28, G3, G9, H2, J5, L5, A16 and O3. Efforts to 
determine the structure and function of the EFC have shown that the majority of proteins 
interact amongst themselves (Wolfe and Moss, 2011). The exact mechanism regulating the 
function of the EFC is unknown. However, it is known to be regulated by a dimeric protein 
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complex associated with the IMV membranes A26 and A25. The A26 protein plays a key role 
within VACV entry and assists in attachment to host cell laminin (Chiu et al., 2007). A26 is a 
57.5 kda protein which is exclusive to IMV (Ulaeto et al., 1996) and is associated with the EFC 
components A16 and G9 (Chang et al., 2012). The function of A26 within the context of the 
EFC is to negatively regulate its fusion activity with the endosomal membrane at neutral pH. 
In this way A26 acts as an acid sensitive fusion suppressor, preventing the premature fusion of 
the EFC with the plasma membrane (Chang et al., 2012). During endosome maturation 
hydrogen ion concentration increases, leading to the dissociation of A26 from the EFC. As the 
inhibition of A26 is removed, the EFC can then fuse to the endosomal membrane, delivering 
the virion core into the cytoplasm, and allowing morphogenesis to commence (Figure 1-5A).   
  
  
 
  
Figure 1-5. A diagrammatic representation of VACV entry mechanisms.  
(A) IMV entry facilitated by PAK1 activation and micropinocytosis. Acid dependent dissociation of 
A26 from the EFC mediates IMV membrane fusion to the endosome and core release into the cytoplasm. 
(B) EEV entry via micropinocytosis and acid induced dissolution of the EEV membrane, leading to 
IMV membrane fusion with endosomal membranes. (C) Ligand induced membrane  fusion. 
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Entry of EEV occurs through an alternate mechanism due to the presence of the EV membrane, 
which prevents a direct contact between the inner IMV membrane and the endosomal 
membrane. Therefore, upon internalisation, the outer EEV membrane is first disrupted by the 
acidification of mature endosomes, after which the EFC complex on the IMV membrane can 
contact the endosomal membrane (Figure 1-5B).  The exact properties of the EEV membrane 
that make it susceptible to acid-induced dissolution are unknown. However, the F13 protein 
has been suggested to enhance membrane sensitivity to elevated pH (Bryk et al., 2018). EEVs 
are also capable of non-fusogenic entry to host cells at neutral pH. Interaction of ligands with 
EEV membrane proteins B5 and A34 triggered disruption of the EEV membrane, allowing the 
IMV membrane to fuse directly with the plasma membrane Figure 1-5C.  
  
1.8.2 Dissolution of the virion core and viral factory formation  
Once the viral core has been delivered into the cytoplasm it begins to dissociate. The virion 
core is composed of supercoiled DNA and approximately 47 proteins essential for viral 
replication that were synthesised and packaged during late infection of the previous cell. These 
proteins include all virally encoded DNA replication enzymes outlined above  (Table 1.3), in 
addition to the early transcription factor VETF. Once inside the cytoplasm early genes are 
transcribed and the mRNA is extruded into the cytoplasm via pores in the core surface. 
Following transcription of early genes, the activated core begins to dissociate releasing the 
lateral bodies (LB) into the cytoplasm. LBs are large proteinaceous complexes packaged within 
the virion and flank the core. The exact composition of the LBs is uncertain; however, they 
have been shown to contain proteins F17, G4, VH1. The F17 protein is the most abundant, 
accounting for 69% of the lateral body and its function is dependent on proteasomal 
degradation (Schmidt et al., 2013). Activation and dissociation of the virion core leads to the 
release of viral genome into the cytoplasm and is coupled with early gene expression. Shortly 
after genome release, DNA replication proceeds within membrane bound cytoplasmic 
occlusions known as viral factories (Kajioka et al., 1964). These electron dense structures are 
known to be the site of viral replication, virion assembly and transcription of post-replicative 
genes (Moss, 1990, Katsafanas and Moss, 2007).  This process is depicted in Figure 1-6.  
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Figure 1-6. Sequence of viral core dissociation and genome release.   
Transcription of early genes occurs within the virus core immediately after delivery into the cytoplasm. 
mRNAs are extruded through pores in the core surface for translation by host ribosomes. Dissociation 
of the viral core leads to the release of intermediate transcription factors, lateral bodies and the viral 
genome. DNA replication is imitated within virus factories.   
  
1.8.3 Virion morphogenesis: Membrane crescents and immature virion formation  
Following DNA replication within viral factories, the coordinated transcriptional cascade leads 
to the expression of post-replicative genes required for morphogenesis. The first discernible 
structure associated with virion formation is the membrane crescents which are derived from 
the host ER and are the first precursor of the Immature virion (IV) membrane. Membranes are 
trafficked from the host ER by incorporation of the early L2 membrane protein (Maruri-Avidal 
et al., 2011a, Maruri-Avidal et al., 2011b). Following transport of ER membranes to viral 
factories these are augmented by the virion structural protein D13, forming crescent structures. 
Membrane crescents are multi-layered with a smooth trilaminar lipoprotein layer supported by 
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a curved honeycomb like mesh of D13 trimers (Szajner et al., 2005, Heuser, 2005). D13 has no 
transmembrane domain, thus it can only act as a mechanical skeleton to support the 
membranous crescents. To bridge the proteinaceous scaffold to the membrane, D13 associates 
with the membrane via the N-terminus of the A17 transmembrane protein (Bisht et al., 2009). 
The A17 protein is complexed with A14 on viral membranes and both undergo a range of post 
translational modifications at the N and C termini which are critical for crescent formation and 
IV maturation to MV (Krijnse-Locker et al., 1996). As IV morphogenesis proceeds membrane 
crescents are extended, curving into a spherical structure enclosing the so-called viroplasm, a 
dense collection of proteins that are to be incorporated into the MV. The ends of the crescent 
are capped by the A11 protein to prevent the membrane from sealing, allowing genomic DNA 
to be packaged. The process of DNA replication occurs independently from IMV 
morphogenesis. Newly synthesised genomes are trafficked into spherical IVs. How the 
genomes are trafficked to the site of IV morphogenesis and packaged is not understood.   
  
After packaging of the genome, maturation of IV to MV occurs. This is a complex process that 
is dependent on a set of seven highly conserved proteins; A30, A15, D2, D3, J1, and F10 and 
G7, known as the seven-protein complex (7PC) (Szajner et al., 2004a), as well as other viral 
proteins. Each member of the 7PC is required for normal IMV morphogenesis, since the 
deletion of any of these genes gives rise to defective virions.   
  
A30 is a 9 kDa protein and is present within the core of MVs. Its function within MV 
morphogenesis is to co-localize membrane crescents with the viroplasm, as deletion mutants 
generate “empty” IV particles lacking viroplasm (Szajner et al., 2004a). Deletion of the 10 kDa 
A15 protein also led to a similar phenotype (Szajner et al., 2004a).  
  
Protein G7 is a 42 kDa and has multiple functions within the MV morphogenesis pathway. It 
has been implicated in both the trafficking of crescents within the viral factory and their 
subsequent association with the viroplasm (Mercer and Traktman, 2005). G7 undergoes 
proteolytic cleavage at two Ala-Gly-X sites by the G1 protease, in addition to phosphorylation 
by F10 (Whitehead and Hruby, 1994a, Mercer and Traktman, 2005). These PTM appear to be 
required for IV to IMV maturation.  
53  
  
  
The J1 protein exists as an oligomeric complex and is packaged within progeny virions. It is 
also required for the stabilisation of the 7PC (Chiu et al., 2005). Deletion of J1 leads to aberrant 
“empty” IV indicating a potential role for J1 in the packaging of viral DNA (Chiu and Chang, 
2002). In the absence of J1 the proteolytic processing of core IMV proteins A10 and A3 iss 
also impaired, suggesting that J1 has a role within the maturation of IV (Chiu and Chang, 2002).   
  
The proteins D2 and D3 have molecular masses of 16.9 and 27 kDa respectively, and like the 
other members of the 7PC are essential for IV formation (Dyster and Niles, 1991, Szajner et 
al., 2004a). The virally encoded 50 kDa kinase F10 has importance within IV morphogenesis. 
F10 is associated with membranes and phosphorylates numerous substrates including the 
members of the 7PC;  A30 and G7 as well as the structural proteins A17, A14, A3, A4 (Szajner 
et al., 2004b, Betakova et al., 1999)   
  
In addition to the 7PC, several other proteins have been implicated in the maturation of IV to 
MV including the virally encoded proteases I7 and G1 (Moss and Rosenblum, 1973) and the 
phosphotase F17 (Hiller and Weber, 1982, Kao and Bauer, 1987). Upon formation of spherical 
IV containing nucleoid, several proteolytic events must occur that result in the formation of the 
characteristic brick shaped MV. Firstly, the D13 scaffold must be removed and the internal 
core proteins must undergo remodelling. These events occur sequentially. Removal of the D13 
scaffold is dependent on the proteolysis of the N terminus of the A17 membrane protein by I7 
(Unger et al., 2013, Ansarah-Sobrinho and Moss, 2004). In addition to cleaving A17, I7 also 
facilitates the cleavage of virion core precursor proteins to their active forms; A10, A3 and L4 
via the Ala-Gly-X motif (Byrd et al., 2002). After removal of the D13 scaffold the membrane 
begins to collapse down in conjunction with the proteolytic activity of G1. The activity of both 
I7 and G1 is dependent on F17. If F17 is removed, internal core precursors do not undergo 
cleavage and result in abnormal membrane arrangement of IVs (Zhang and Moss, 1991). F17 
has also been implicated in the condensation and association of lateral bodies with the virion 
core (Schmidt et al., 2013), this process is summarised in Figure 1-7.   
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Figure 1-7. An illustration of the IMV morphogenesis pathway.  
 ER membranes are trafficked to the viral replication factories by incorporated L2 proteins. Once inside 
the factory membrane crescents are formed by the association of D13 structural lattices with integral 
membrane proteins A17 and A14. As membrane curvature increases, association with viroplasm is 
mediated by members of the 7PC: D2, D3, A30, J2, and A15. The curved membrane is capped with the 
A11 to prevent premature closure of the membrane before packaging of the DNA nucleoid forming 
INVs. Maturation of INVs to IMVs is dependent on the post-translational modification of structural 
proteins by F10, I7, G1, and F17 and removal of D13 scaffold. Fully matured IMVs are trafficked from 
the viral factory. Figure adapted from (Liu et al., 2014).  
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1.8.4 Formation of IMV and IEV, EEV and CEV 
Typically, the first MVs that are produced are subjected to further processing where acquire an 
additional membrane becoming intracellular enveloped virions (IEV). The progression of MV 
to IEV is largely dependent on additional membrane modification steps prior to egress from 
the viral factory. These modifications include the addition of the 14 kDa membrane associated 
protein A27 (Dallo et al., 1987), which is a necessary step required for the wrapping of MVs 
to form IEV (Rodriguez and Smith, 1990). A27 is expressed at intermediate times during 
infection and exists as a 42 kDa trimeric complex of three alpha helical subunits of monomeric 
A27 and is associated with A17 on the IMV membrane (Wang et al., 2014, Howard et al., 
2008). Aside from its function in VACV entry (explained above), A27 is required for 
microtubular transport to the trans-golgi network (TGN) (Sanderson et al., 2000), although it 
was later shown that microtubular transport could occur through an A27-independent 
mechanism (Ward et al., 2005, Rodriguez and Smith, 1990). The general pathway for 
production of the virion forms is depicted in Figure 1-8. 
 
Figure 1-8: A schematic of the virion progeny produced by VACV infection. 
Newly synthesized MV characterized by the presence of A27 trimers (yellow) are trafficked via 
microtubules to the trans-golgi network where wrapping occurs generating IEV, characterised by the 
presence of F13 (blue). IEV are trafficked to the cell periphery where they fuse to the cell membrane 
and exit the cell. Virions are retained on the cell surface as CEV or released as EEV. Expression of A26 
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(red) coincides with the accumulation of IMV which cannot be wrapped and thus remain in the cell until 
lysis.  
After a subset of MV harbouring the A27 protein have been trafficked to the TGN to be 
wrapped, the remaining MV are further modified by the addition of the 57.5 kDa fusion 
suppressor A26. Expression of A26 occurs during late infection at approximately 12 hours post 
infection and associates with A27 via a disulphide bond (Howard et al., 2008, Ulaeto et al., 
1996). Expression of A26 correlates with a decrease in EEV production and an accumulation 
of IMV during late infection. This observation led to the hypothesis that the expression of A26 
negatively regulates EEV during infection. The theory was strengthened by the observation 
that A26 is absent on EEVs. Despite the apparent regulatory role of A26, ΔA26 viruses do not 
exhibit enhanced EEV release (Howard et al., 2008).   
 
 
Within the VACV replicative cycle the terminal virion progeny is the A26+ve IMV, which 
accumulate within the cell until lysis. The proposed function of the IMV is to propagate 
infection to naïve hosts, owing to the durability of the IMV from environmental stresses. In the 
majority of Orthopox strains IMV are discreet particles, however in some OPXV strains such 
as Cowpox, Raccoon pox, and Ectromelia virus IMVs are included within spherical 
proteinaceous structures within the cytoplasm known as A-type inclusion bodies (ATI). The 
function of the ATI is to occlude IMV into large spherical structures, further enhancing the 
stability of IMV. The determining factor for ATI formation is the presence of the ATI protein, 
A25. The A25 protein is 160 kDa in size and polymerizes to form the large spherical structures 
within the cytoplasm, A25 contains hydrophobic repeats at the C-termini which are required 
for self-association (Funahashi S, Sato T, Shida H. 1988, Patel DD et.al 1986). Recruitment of 
the IMV to the ATI is facilitated by the interaction of A25 to the key IMV surface protein A26 
(Pickup, DJ. 2002). The A25 protein tethers IMV via a non-covalent interaction with the N-
terminus of A26 bound on the surface of the IMV, the association of A25 to A26 and thus 
recruitment of IMV to the ATI body is dependent upon the assembly of the multiprotein 
complex of IMV proteins A17, A27 and A26 a schematic of the interactions of these membrane 
proteins is outlined (Figure 1-9) (Howard, AR. 2010). The exact mechanism for A26 mediated 
association to the ATI is unknown, although it has been proposed that the presence of A26 
upon IMV accelerates the rate of migration via the microtubule network to distant ATI bodies 
(Howard, AR. 2012).  
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Figure 1-9: A schematic of IMV interaction with ATI  
Trimeric A27 associates with A17 on the surface of the IMV, A26 associates to the C-terminal CC 
motif of A27 via a disulphide linkage. The bound A26 acts as a bridge to associate with the ATI 
which consists of oligomerized A25. The N terminal domain of A26 interacts with A25 via a non-
covalent bond.  
 
The A25 orf is only expressed to appreciable levels at approximately 24 hours post infection, 
the promoter sequence contains the canonical late element (TAAATG) (Funahashi S, Sato T, 
Shida H. 1988). As such late expression kinetic of A25 coincides with its binding partner on 
the surface of IMV A26 which shares the same late promoter element and has a limited 
accumulation at 24h post infection (Ulaeto et.al, 1996).  As such towards the late times of 
infection, newly generated A26+ve IMV are sequestered into ATI bodies.  
 
In addition to its function in sequestering IMV within ATI bodies, A25 has been shown to be 
an acid sensitive fusion regulator (Chang et.al. 2012). Interestingly the A25 protein is truncated 
and inactive in VACV, MPXV, VARV and HPXV, therefore these viruses are unable to 
produce ATI bodies. The capacity for ATI formation can be reconstituted as, In the case of 
VACV WR complementation of a A25 derived from CPXV was sufficient to restore ATI 
formation. The absence of a full length A25 protein in OPXVS with clinical significance to 
humans has been postulated as an adaption to enhance spread and dissemination via aerosol 
(Kastenmyer R.J. 2014). 
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1.8.5 Enveloped virion formation  
EEVs are essential for dissemination within the host organism. The transition of MV into their 
extracellular milieu gives rise 3 different types of virions that are essentially distinguished by 
their enveloped status; the intracellular enveloped virion (IEV), the cell-associated enveloped 
virion (CEV) and the extracellular enveloped virion (EEV). IEV are MV that become further 
wrapped by a double layer of membrane that has been reported to derive from the cellular 
endosomes (Tooze et al., 1993) or the TGN (Hiller and Weber, 1985) although the latter is 
more generally accepted. IEV travel towards the cell surface via microtubules and fuse with 
the plasma membrane exposing a double-membraned particle. These particles are either 
released into the cytoplasm as EEV or retained on the cell surface as CEV. Release of EEV is 
enhanced by the formation of actin filaments (Frischknecht et al., 1999). Re-infection of the 
infected cell (also known as super-infection) is prevented by the A56/K2 complex (Doceul et 
al., 2010b, Brum et al., 2003). An outline of the EEV morphogenesis pathway is shown in 
Figure 1-10.   
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Figure 1-10. A schematic of the EV morphogenesis pathway.   
Following release from the viral factory MVs are trafficked to the trans-golgi network via microtubule 
transport where they are wrapped with golgi derived membrane studded with EEV proteins and become 
IEV. IEVs exploit microtubule motility to translocate to the cell periphery where they fuse to the host 
cell membrane. IEV can be released into the cytoplasm as EEV or retained on the cell surface as CEV.   
  
The functional and biological significance of the EEV is attributed to the viral proteins that are 
associated with the second cellular membrane. This membrane contains a suite of nine virally 
encoded proteins; A34, A36, A56, A33, B5, E2, K2, F13, and F12. Wrapping of IMV with host 
derived cellular membranes enables egress of virion progeny into the extracellular 
environment. In addition, the membrane coat acts as a shield, preventing recognition of viral 
proteins on the inner virion core by the immune system. Membrane wrapping provides 
enhanced protection from complement activity, preventing membrane attack complex (MAC) 
formation. This protection is provided by the incorporation of cellular membrane proteins; 
clusters of differentiation (CD46, CD55, CD59, CD71, CD81) and MHC I antigen 
(Vanderplasschen et al., 1998).  
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1.8.6 EEV membrane proteins   
F13L is a 42 kDa protein and is the most abundant protein present on EEVs (Hirt et al., 1986). 
F13 is expressed at intermediate time points during the poxvirus replication cycle and is 
localised to the outer and inner membrane of IEV (Husain et al., 2003). This change in 
membrane distribution is mediated by the palmitoylation of cysteine residues 185 and 186. 
Palmitoylation increases hydrophobicity of the protein allowing its insertion into the EEV outer 
membrane (Hiller et al., 1981, Schmutz et al., 1995) .   
Functionally F13 is required for the recruitment of membrane derived from the TGN or early 
endosomes. This is facilitated by both its membrane topology, as well as its biochemical 
activity as a broad-specificity phospholipase (Baek et al., 1997). F13 bears homology to the 
phospholipase D (PLD) superfamily, as such it contains a HxKxxxxD motif within the 
Cterminal region of the protein (Ponting and Kerr, 1996, Koonin, 1996). The phospholipase 
activity of F13 appears to be critical to its function in virion wrapping as mutations within the 
HKD motif result in a severe reduction in EEV formation (Roper and Moss, 1999). In addition, 
F13 contains a highly conserved “L-domain” motif (YxxL) which is essential for wrapping of 
MVs and release of EEV (Honeychurch et al., 2007). F13 interacts with proteins from the late 
endosomal biogenesis pathway: Rab9 and TIP47 via a conserved diaromatic YW motif at 
residues 253 and 254 (Chen et al., 2009).   
 
F13 is critical for EEV formation, deletion mutants are severely inhibited in vitro leading to a 
10-fold decrease in EEV production (Blasco and Moss, 1991). The significance of the F13 
protein is underscored by the fact that it is the target of the only currently available ant-viral 
therapeutic for OPXV infection, ST-246 (Yang et al., 2005a, Mucker et al., 2013, Duraffour et 
al., 2015). The exact mechanism of inhibition by ST-246 is unknown, however its interaction 
appears to be sufficient to block the interaction between F13 and Rab9 (Chen et al., 2009). In 
addition to its function within EEV morphogenesis, F13 has been implicated in facilitating acid 
sensitive dissolution of the EEV membrane upon entry as described above (Bryk et al., 2018).   
  
Besides F13 other VACV proteins are essential for the different steps leading to EEV 
formation. Proteins A36 and F12 are found exclusively on the outer membrane of the IEV. F12 
is important for trafficking IEVs via microtubules to the cell surface. A36 also exploits the cell 
cytoskeleton to enhance release and cell to cell spread of CEV (Blasco and Moss, 1992). 
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Phosphorylation of tyrosine residues 112 and 132 on A36 leads to activation of cellular 
pathways leading to actin polymerization beneath the CEV, a mechanism known to propel the 
virus away from the infected cell facilitating spread and preventing superinfection (Doceul et 
al., 2010a). This mechanism also requires protein B5 which is associated with the EEV 
membrane. B5 is a 42 kDa highly glycosylated protein that interacts with A36 via its 
transmembrane domain (Perdiguero and Blasco, 2006). It has also been shown to be required 
for the disruption of the EEV membranous envelope allowing the virion to bind to GAGS 
(Roberts et al., 2009). B5 is also known to be an important target for neutralizing antibodies 
(Putz et al., 2006).   
  
Like A33, the A34 protein has a significant effect on the release of CEVs from the infected cell 
surface. A34 is a C-type lectin-like transmembrane glycoprotein found on the exterior of EEV 
and CEV. A34 has a significant effect on EEV production and partly dictates the infectivity of 
progeny EEV. Deletion of A34 within VACV WR results in a 25-fold increase in EEV 
formation however the EEVs produced were found to have significantly decreased infectivity 
(McIntosh and Smith, 1996). Typically, the EEV accounts for approximately 1 % of the 
infectious progeny of VACV WR, however within the International health department-J (IHD-
J) strain of VACV EEVs account for 30 % of the total infectious progeny (Payne, 1979). 
Subsequently, plaques produced by IHD-J have a characteristic “comet” tails when compared 
to WR. This difference between the two strains is attributed to a single point mutation K151E 
within A34 (Blasco et al., 1993). Incorporation of the single point mutation into WR was 
sufficient to convey the comet forming phenotype (Blasco et al., 1993). As the mutation is 
positioned within the carbohydrate recognition domain of A34, it has been theorised that A34 
may also play a role in cell attachment (Blasco et al., 1993).  
  
Finally, protein A56 is an 85 kDa protein that is distributed on the EEV outer membrane and 
on the membrane of infected cells. It was one of the first poxvirus proteins to be characterized 
due to its apparent hemagglutination activity (Dehaven et al., 2011). A56 undergoes extensive 
glycosylation, thought to be the reason why antibody binding and neutralization of EEVs is 
poor (Pulford et al., 2004). A56 forms a complex with protein K2 and prevent fusion of 
accumulating IMVs with infected cells during late infection as well as super-infection (Brum 
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et al., 2003) . This inhibition occurs via interaction with proteins G9 and A16 that are essential 
for virus entry and fusion and are situated on IMV membrane. 
 
1.8.7 EV and IMV morphogenesis: A regulated process?  
The proteins of interest to this study are F13 and A26. These are essential for VACV 
morphogenesis and are expressed at specific time-points with distinctive roles in the VACV 
morphogenesis cycle. F13L is a phospholipase which is essential for the wrapping of IMVs to 
form EEVs which account for 1% of viral progeny. Despite their limited number EEVs are 
highly efficient in mediating intracellular spread within the host, therefore EEV formation is 
prioritized in the VACV infectious cycle. This is reflected by the temporal expression kinetic 
where F13 is expressed 4-6 hpi, reaching maximal expression at 9-12 hpi (Ulaeto et al., 1996). 
In this way F13 expression correlates with IEV formation (Payne and Kristensson, 1985). A26 
is required for adherence to host cellular laminin and functions as fusion regulator of IMV EFC, 
therefore enhances infectivity of IMV virions. IMVs account for the bulk of VACV progeny, 
accounting for 99% of infectious virions. IMVs lack an additional membrane and therefore are 
not as effective as EVs in cell to cell spread as they are more susceptible to complement and 
antibody mediated inactivation. However, IMVs are more physically robust which enhances 
host to host spread. In contrast to F13 which is expressed at 4-6 hpi, A26 is expressed later at 
10 hpi reaching maximal expression after 18 hpi (Fig. 1-9) (Ulaeto et al., 1996). A26 expression 
triggers an apparent shutoff of EVs formation, the reason for which is unknown. Both A26 and 
F13 are classified as late genes according to the canonical consensus sequence but are 
expressed at discrete time points with contrasting function.  
  
Ultimately VACV morphogenesis is coordinated by a transcriptional cascade of intermediate 
and late promoters. Understanding the association between key morphogenesis proteins and 
their roles within EV and IMV morphogenesis is critical to understanding the regulatory 
mechanisms underpinning virion production. F13 is present only in EV membranes, as such 
expression correlates with EV production (Ulaeto et al., 1996). Conversely A26 is an essential 
component of IMV membranes and its expression correlates with IMV production. These two 
proteins are temporally isolated from one another, as they are introduced at different points of 
the morphogenesis pathway at specific times resulting in a shift in virion production. Despite 
the importance of understanding the temporal association between morphogenesis proteins, the 
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collective body of knowledge about the topic has been derived from the study of deletion 
mutants. These studies have the capacity to ascribe specific roles to viral genes but cannot 
determine their relationship with other genes. When this approach is applied to the regulation 
of EV and IMV formation deletion of F13 impairs EEV formation, severely attenuating plaque 
size and viral replication kinetics (Blasco and Moss, 1991). Conversely, deletion of A26 did 
not affect plaque size, confirming that this is entirely dependent on EEV formation (Howard et 
al., 2008, Ulaeto et al., 1996). Assuming the role of A26 as a negative regulator of EEV 
formation, one could have expected an increase in EEV production. However, it is not clear 
whether this also depends on other cellular factors or resources (i.e. availability of membranes). 
No matter what factors regulate EEV production it seems clear that classical deletion mutants 
cannot provide any insight into the complex signaling that governs the EEV/IMV balance.  
 
 
 
  
  
1.9 Aims  
This thesis aims to exploit the unique expression kinetic profile of key EV and IMV proteins 
F13 and A26 to dissect the potential regulatory mechanisms underpinning the switch from EV 
to IMV production. We speculated that inducing early expression of A26 and delaying 
expression of F13 could induce a bias towards IMV by delaying EEV or advancing IMV 
formation. As A26 is thought to negatively regulate membrane wrapping and EV formation. 
This phenotype would be expected to be deleterious, generating significantly less IEV, CEV 
and EEV, and as such limiting the virus’ capability of cell-to-cell spread. In addition to altering 
the course of virion morphogenesis, rearrangement of promoter sequences and its subsequent 
effect on phenotype will determine the constraints to which the VACV genome can be 
manipulated. This aspect is of increasing importance given the recent advancements in 
synthetic biology, in particular the chemical synthesis of horsepox virus (Noyce et al., 2018). 
Therefore, an understanding of how the regulatory sequences within the intergenic regions of 
poxviruses can be manipulated will assist in the construction of sequence analysis algorithms 
for novel viruses and other emerging pathogen populations.   
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The aim of this project is therefore to explore the hypothesis that the architecture of the VACV 
genome could be manipulated to introduce phenotypical change. This will be explored by 
manipulating two viral morphogenesis proteins that are crucial to the formation of IMV and 
EEV in the VACV cycle: F13L and A26L. To achieve this, the transcriptional regulation of 
these two genes will be altered by swapping of their promoter sequences to generate a panel of 
recombinant viruses via transient dominant selection. To facilitate the selection of promoter 
swapped viruses and the detailed characterization of the resulting phenotype, F13 and A26 will 
be C and N-terminally tagged with 3XFLAG and V5 epitope tags. The inclusion of epitope 
tags will allow the characterization of their altered expression kinetics and interactions with 
other morphogenesis proteins. Therefore, the aims of this thesis are:   
  
  
  
1. Generate a suite of recombinant viruses where the promoter sequences of F13L 
and A26L are swapped. 
 
 
    
2. Characterize these promoters swapped viruses to determine:  
  
a. The significance of late F13 expression kinetics on the 
release of EEV.    
   
b. To determine the effect of intermediate A26 expression on  
  
the formation of EEV.   
  
  
  
c. Investigate the temporal association between A27 and  
 
intermediate A26 expression as a potential mechanism for  
 EEV negative regulation.  
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2  Materials and Methods  
  
2.1 Materials:  
2.1.1 Solvents   
Reagent Description 
DMSO  
Dimethyl sulfoxide (Sigma Aldrich Aldrich)  
EtOH  
Fischer Scientific  
MeOH  
Methanol (Honeywell research)  
Ultrapure miliQ water  
Type 1 purified water   
Nuclease free water  
Nuclease free water (Invitrogen)  
Deionized water  
Water purified using type 3 system (reverse osmosis)   
Table 2-1. A table of solvents used in this thesis   
 
2.1.2 Buffers  
Reagent Description 
Cell lysis buffer  
50 mM Tris-HCL (pH 7.5), 150 mM NaCL, 1% Triton 
X100 (v/v) in ultrapure MiliQ water.  
10x PBS 
1.37M NaCL, 2.7mM KCl, 8 mM Na HPO, 2 mM 
KHPO in ultrapure MiliQ water. Adjusted to pH 7.4 
with 1M sodium hydroxide solution.  
1x PBS  
10x PBS soluition diluted as required in ultrapure 
MiliQ water.  
1X Tris-Borate EDTA buffer  
(TBE)  
89 mM Trizema base, 20mM acetic acid and 1mM 
EDTA (pH 8.0) in ultrapure miliQ water. 
Table 2-2. A table of buffers used in this thesis   
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2.1.3 Reagents for Bacterial culture  
  
Reagent Description 
0.1M PIPES (pH 6.5)  0.1M PIPES in ultrapure MiliQ water.  
1M Kac solution  1M Kac in ultra-pure MiliQ water.  
1M MnCl2   1M in Ultra-pure MiliQ water.  
1M RbCL  1M RbCl in Ultra-pure MiliQ water.  
50% Glycerol solution   50% (w/v) Glycerol (Sigma) in ultra-pure MiliQ water.  
Carbenicillin solution  1mg/mL Carbenicillin (Sigma Aldrich) in ultrapure miliQ 
water, filter sterilized before use.  
HB101 E.coli    Thermo-Fisher scientific  
Lysogeny broth (LB)   10 g/L tryptone, 5 g/L Yeast extract, 5 g/L sodium chloride  in 
deionized water.   
Transformation Buffer 1  
(TFB1)  
30 mM Kac, 100mM RbCl, 10mM CaCl2, 50mM MnCL2,  
15% Glycerol in ultrapure MiliQ water.   
Transformation Buffer 2  
(TFB2)  
10mM PIPES, 75mM CaCL, 10mM RbCL and 15% Glycerol 
in ultrapure MiliQ water.  
Table 2-3. A table of the bacterological reagents used in this thesis  
2.1.4 Cell culture reagents 
Reagent Description 
DMEM (10% FBS Dulbecco’s Modified Eagle Medium (DMEM; High glucose 
with phenol red. Suplemented with 5% FBS (v/v) and 1% 
Penicillin/streptomycin glutamine solution (v/v)  
Foetal bovine serum (FBS) 
 
FBS (seralab).  
 
Penicillin streptomycin 
Glutamine  
 
PSG (Thermofisher scientific) 
Trypsin 0.05% Trypsisn EDTA (Invitrogen) 
Table 2-4: A table of the cell culture reagents used in this thesis 
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2.1.5 Reagents for Virology  
 
Reagent Description 
Agarose, Low gelling temperature  Agarose, Low gelling temperature (Sigma Aldrich)  
CMC 3%  
3% (w/v)  Carboxymethyl cellulose (CMC) (VWR 
Chemicals) in MiliQ water.  
Crystal Violet solution (5%)  
5% Crystal violet solution (v/v) (Sigma Aldrich) 
with 15% EtOH (v/v) in Ultrapure MiliQ water.  
DMEM 2.5%  
Dulbecco’s Modified essential medium 
supplemented with 2.5% FBS (v/v) and 1% 
Pen/strep (v/v).  
EcoGPT selective 2.5% DMEM  
Dulbeccos Modified essential medium  
supplemented with 2.5% FBS (v/v), 1% Pen/strep,  
250 µg/mL MPA, 15 µg/mL Hypoxanthine and  
0.25 mg/mL Xanthine.  
Hypoxanthine  
10 mg/mL Hypoxanthine in 0.1M Sodium  
Hydroxide solution.  (Sigma Aldrich)  
Sucrose solution 36%  
36% sucrose (w/v) in 10 mM Tris (pH 9.0) 
sterilized via autoclaving.  
  
    Table 2-5. A table of reagents used for virology   
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Reagent  Description  
L-glutamine 200 mM   L-glutamine 200 mM (Invitrogen)  
MEM 10x  10x Minimal essential medium with Earle’s salts  
(Invitrogen)  
MEM 2x  10X Minimal essential Eagle Medium (MEM) 2% 
(v/v) was supplemented with 1% Pen/strep (v/v), 
5.9mM L-glutamate, 100mM Sodium bicarbonate 
solution and 5% FBS (v/v). Filter sterilized using 
Merek-Millipore Stericup sterile vacuum filtration 
system.   
MEM/CMC  1.5% CMC (v/v) with 1xMEM.  
Mycophenolic Acid (MPA)  
10 mg/mL Mycophenolic acid in 0.1M Sodium  
Hydroxide solution.  (Sigma Aldrich)  
Optimem Reduced serum media  ThermoFisher Scientific  
Proteinase K  
Proteinase K from Tritirachium album (≥800 u/mL)  
(Sigma Aldrich)  
Sodium bicarbonate  Sodium bicarbonate (7.5% aqueous solution)  
(Thermo-Fisher scientific)  
Swelling buffer  10 mM Tris (pH 9.0) filter sterilized before use.  
TransIT-LT1 transfection reagent  Thermo-Fisher Scientific  
Xanthine  
10 mg/mL Xanthine in 0.1M Sodium Hydroxide 
solution. (Sigma Aldrich)  
 Table 2-5 cont. A table of the reagents used for virology   
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2.1.6 Antibodies   
Anti- Species Source 
A27  Mouse  Dr. David Ulaeto (DSTL)  
C6  Rabbit  
Professor Geoffrey Smith  
(University of Cambridge)  
D8  Rabbit  Dr. David Ulaeto (DSTL)  
F13  Rabbit  Dr. David Ulaeto (DSTL)  
FLAG  Mouse  Sigma Aldrich  
FLAG  Rabbit  Sigma Aldrich  
Secondary anti-mouse IgG-800  Mouse  Licor Biosciences  
Secondary anti-mouse IgG-800  Mouse  Licor Biosciences  
Secondary anti-Rabbit IgG-680  Rabbit  Licor Biosciences  
V5  Mouse  Sigma Aldrich  
α-Tubulin  Mouse  Abcam  
  
     Table 2-6. A table of the antibodies used in this thesis  
  
2.1.7 Plasmids  
Plasmid 
Designation  Description  Source  
pUC-13-ecoGPT  
pUC13 based transfer vector containing the xanthine- 
guanine phosphoribosyltransferase (Ecogpt) gene derived 
from Escherichia coli fused with Green fluorescent 
protein (GFP) driven by the p7.5 promoter of vaccinia  
virus (WR).  
Maluquer de  
Motes Lab  
pSJH- 
F13mcherry  
pUC13 based transfer vector encoding the F13L left flank 
and coding sequence (40,834 - 42,325) within VACV  
WR. mCherry is fused at the C-terminus of F13L and is 
flanked with the right homology arm of the F13L loci ( 
40,455-40,831).  
Dr David  
Carpentier  
(University of  
Cambridge)  
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PJH010  
A pUC13 based transfer vector encoding the F13L left 
flank and coding sequence (40,834 - 42,325) within  
VACV WR. MCherry-FLAG is fused at the C-terminus of  
Joe Holley  
 F13L and is flanked with the right homology arm of the 
F13L loci (40,455-40,831).  
 
PJH011  
A pUC13 based transfer vector encoding the F13L left 
flank and coding sequence (40,834 - 42,325) within  
VACV WR. F13L is under the control of the A26 
promoter sequence which was introduced in-lieu of the  
F13L promoter sequence. MCherry-FLAG is fused at the  
C-terminus of F13L via a 3x alanine linker and is flanked 
with the right homology arm of the F13L loci 
(40,45540,831).  
Joe Holley  
PJH014  
A pUC13 based transfer vector encoding the F13L left 
flank, the native F13L promoter sequence and coding  
region (40,834 - 42,325). A 3xFLAG tag at is fused to the  
C-terminus via a 3x alanine linker and is flanked with the 
right homology arm of F13L (40,455-40,831)  
Joe Holley  
  
Table 2-7 Details of the plasmids used in this study   
  
  
Plasmid Designation Description Source 
PJH015  
A pUC13 based transfer vector encoding the F13L 
left flank, the heterologous A26L promoter 
sequence (139,961-139,981) and F13L coding 
region (40,834-41,949) excluding the terminal 
STOP codon. A 3xFLAG tag is fused to the 
Cterminus via a 3x alanine linker and is flanked 
with the right homology arm of F13L (40,455-
40,831)  
Joe Holley  
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PJH016  
A pUC13 based transfer vector encoding the A26L 
left flank including the A26 promoter sequence 
(139,961-140,312). A 3XFLAG tag is immediately 
downstream of the A26 promoter sequence and is 
fused to the N-terminus of A26L via a 3X alanine 
linker. Flanked by a 345 bp region of the A26L 
coding region (139,607-139,960).  
Joe Holley  
PJH017  
A pUC13 based transfer vector encoding the A26L 
left flank (139,982-140,312) and  F13L promoter 
sequence (41,949-41,966). A 3XFLAG tag is 
immediately downstream of the F13L promoter 
sequence and is fused to the N-terminus of A26L 
via a 3X alanine linker. Flanked by a 345 bp region 
of the A26L coding region (139,607-139,960).  
Joe Holley  
A26-F  
A synthesized DNA fragment encoding the  A26L 
left flank including the A26 promoter sequence 
(139,961-140,312). A 3XFLAG tag is immediately 
downstream of the A26 promoter sequence and is 
fused to the N-terminus of A26L via a 3X alanine 
linker. Flanked by a 345 bp region of the A26L 
coding region (139,607-139,960).  
Geneart  
  
Table 2-7 cont. Details of the plasmids used in this study  
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Plasmid Designation Description Source 
(pF13)A26-F  
A synthesized DNA fragment encoding the A26L 
left flank (139,982-140,312)  and F13L promoter 
sequence (41,949-41,966). A 3XFLAG tag is 
immediately downstream of the F13L promoter 
sequence and is fused to the N-terminus of A26L 
via a 3X alanine linker and is flanked by a 345 bp 
region of the A26L coding region 
(139,607139,960).  
  Geneart  
PJH018  
A pUC13 based transfer vector encoding the F13L 
left flank, the native F13L promoter sequence and  
coding region excluding the terminal stop codon  
(40,834 - 42,325). A V5 tag is fused to the C- 
Joe Holley  
 terminus of F13L via a 3x alanine linker and is  
flanked by a 276 bp sequence homologous to the 
right flank of F13L (40,555-40,830).  
 
PJH019  
A pUC13 based transfer vector encoding the F13L 
left flank (41,967-42,325), the heterologous A26L 
promoter sequence (139,961-139,981) and F13L  
coding region excluding the terminal STOP codon  
(40,834-41,949). A V5 tag is fused to the Cterminus 
of F13L via a 3x alanine linker and is  
flanked by a 276 bp sequence homologous to the 
right flank of F13L (40,555-40,830).  
Joe Holley  
  
Table 2-7 cont. Details of the plasmids used in this study  
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2.1.8 Cell lines  
Cell line  Source  Origin  Culture requirement’s  
BSC-1  Kidney  
Primate  
 (Nonhuman)  
DMEM supplemented with 10%  
FBS (v/v) and 1% penicillin  
Streptomycin (v/v)  
BSC-40  Kidney  
Primate  
 (Nonhuman)  
DMEM supplemented with 10%  
FBS (v/v) and 1% penicillin  
Streptomycin (v/v)  
HEK-293T  
Embryonic 
kidney  
Human  
DMEM supplemented with 10%  
FBS (v/v) and 1% penicillin  
Streptomycin (v/v)  
RK-13  Kidney  Rabbit  
DMEM supplemented with 10%  
FBS (v/v) and 1% penicillin  
Streptomycin (v/v)  
  
    Table 2-8. A table of the cell lines used in this thesis.    
  
  
2.1.8 Oligonucleotides  
Name  Sequence  
JH082  
TCCCAATAGGTGTTCCGGAG  
JH083  
AAAAAATGAGTTATATAAATGTGGCCATTTGCATCGG  
JH086  
ATATAACTCATTTTTTCTTATACATCCTGTTCTATCAACGATTCTAGAAT  
ATC  
JH090  
GGATCCCGTATTGGACATGCTTATGTACGTAG  
JH091  
GCGGCCGCCTTGTACAGCTCGTCCATGC  
JH095  
GCGTCTAGACATAGGAATTGGAGGCGATG  
JH096  
AATGCGGCCGCAGACTACAAA  
JH097  
AATGCGGCCGCCCCAATTTTTAACGATTTACTGTGGC  
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JH100  
CATAGGAATTGGAGGCGATG  
JH101  
CAATGGATACGGATATAGAAATAGACG  
JH102  
GACCGTGTAATATTTGCTTACATGCA         
JH103  
GCAGAAGTTGGACCCAATAATACTAGATCC A26    
M13F  
CGCCAGGGTTTTCCCAGTCACGAC     
M13R  
CAGGAAACAGCTATGAC              
SEQ  2  
GGTGGTCTTGACCTCAGCG   
SEQ 1  
 GGTGGTCTTGACCTCAGCG     
SEQ 3  
GGCCAGCGGGGGATAA      
SEQ 4  
AAGTCGACATCACAACCTAACTCA    
V5-TAG 1  
GGCCGCAGGGAAGCCCATCCGCAACCCCCTGCTGGGCCTGGA  
CAGCACGTAACCGC  
  
V5-TAG 2  
GGTTAGGTGCTGTCCAGGCCCAGCAGGGGGTTGGGGATGGGCTT 
GCCTG  
Table 2-9. A table of the oligonucleotides used in this study   
 
2.2    Viruses  
The viruses generated in this thesis are listed in (Table 2-10) and described in detail in chapters 
3, 4 and 5. vΔF13 was kindly provided by Professor Bernard Moss (National institutes of 
health, USA).   
  
Virus  Description  Source  
VACV WR  Wild-type VACV WR  
Professor  
Geoffrey Smith   
University of  
Cambridge  
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vΔF13  
VACV WR with the F13L loci replaced with 
multiple copies of the gpt sequence 
expressed under the p7.5 promoter sequence. 
(Blasco and Moss, 1991).  
Professor  
Bernard Moss  
NIH  
  
vF13mCF  
 VACV WR encoding a C-terminal 
F13mCherry fusion expressed under the 
native F13L promoter sequence.  Joe Holley  
V(pA26)F13mCF  
VACV WR encoding a C-terminal 
F13mCherry fusion expressed under the 
A26L promoter sequence.   Joe Holley  
vAP-1  
An escape mutant derived from  
V(pA26)F13mCF, with a truncated 
F13mcherry fusion  expressed under the 
A26L promoter sequence.   
Joe Holley  
vF13-F  
 VACV WR encoding a C-terminal F13 
3xFLAG sequence fusion expressed under 
the F13L promoter sequence.  
Joe Holley  
V(pA26)F13-F  
VACV WR encoding a C-terminal F13 
3xFLAG sequence fusion expressed under 
the A26L promoter sequence.  Joe Holley  
  
             Table 2-10. Details of the viruses used in this thesis.  
  
Virus  Description  Source  
vF13-F/A26-F  
vF13-F with an N-terminal A26  3xFLAG 
fusion expressed under the A26L promoter 
sequence.   
Joe Holley  
vF13-F/(pF13)A26-F  
vF13-F with an N-terminal A26  3xFLAG 
fusion expressed under the F13L  promoter 
sequence.  Joe Holley  
vR6  
Derived from vF13-F/(pF13)A26-F rescued with 
an N-terminal A26 3xFLAG fusion  
expressed under the A26L promoter  
Joe Holley  
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vF13-V5  
VACV WR encoding a C-terminal F13-V5 
fusion expressed under the F13L promoter 
sequence.  Joe Holley  
v(pA26)F13-V5  
VACV WR encoding a C-terminal F13-V5 
fusion expressed under the A26L promoter 
sequence.  
Joe Holley  
vF13-V5/A26-F  
VACV WR encoding a C-terminal F13-V5 
fusion expressed under the F13L promoter 
sequence and an N-terminal A26-FLAG fusion 
expressed under the A26L promoter.  
Joe Holley  
v(pA26)F13-V5/A26-F  
VACV WR encoding a C-terminal F13-V5 
fusion expressed under the A26L promoter 
sequence and an N-terminal A26-FLAG fusion 
expressed under the A26L promoter.  
Joe Holley  
vF13-V5/(pF13)A26-F  
VACV WR encoding a C-terminal F13-V5 
fusion expressed under the F13L promoter 
sequence and an N-terminal A26-FLAG fusion 
expressed under the F13L promoter.  
Joe Holley  
v(pA26)F13- 
V5/(pF13)A26-F  
VACV WR encoding a C-terminal F13-V5 
fusion expressed under the A26L promoter 
sequence and an N-terminal A26-FLAG fusion 
expressed under the F13L promoter.  
Joe Holley  
             Table 2-10 cont. Details of the viruses used in this thesis.  
2.3     Molecular Cloning  
Polymerase Chain reaction:  
Polymerase chain reaction was employed for the purposes of molecular cloning, screening of 
recombinant viruses, sequencing and amplification from plasmid/viral genomic DNA. PCRs 
were performed using a verity thermocycler (Applied biosystems) in 20-50 µL reaction 
volumes. For the purposes of amplifying DNA for the construction of plasmids platinum Taq 
HIFI polymerase (Promega) was used. For all other applications Q5 High-Fidelity DNA 
polymerase (New England Biolabs) was used. Template DNA was derived from plasmid DNA 
or purified viral genomic DNA. The required volumes and reaction conditions used for 
platinum Taq HIFI polymerase (Table 2-11 and Table 2-12) and Q5 polymerase (Table 2-13 
and Table 2-14) are tabulated below.    
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Platinum Taq Hifi Polymerase Reaction volumes    
Reagent  Volume   
10x Buffer HiFi   5 µL  
10mM dNTPs   1 µL  
10μM Forward Primer   1 µL  
10μM Reverse Primer   1 µL  
50mM MgSO4   2 µL  
Taq HiFi DNA Polymerase  0.2 µL  
DNA  20-50ng (1 µL)  
Nuclease free water  To 25 µL  
  
                       Table 2-11. A table of Platinum Taq Hifi Polymerase reaction volumes   
 
  
2.3.1 Platinum Taq Hifi Polymerase Thermocycler program  
Stage  Temperature  Time  
Initial denaturation  95°C  4 minutes  
35 cycles  
95°C  
55°C - 65°C  
68°C  
30 seconds  
30 seconds  
1 minute / kb  
Extension  68°C  5 minutes  
Hold  4°C  ∞  
                    
                      Table 2-12. A table of Platinum Taq Hifi Polymerase reaction conditions.  
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2.3.2 Q5 Hi-Fidelity Polymerase Reaction volumes    
Reagent  Volume   
5X Q5 reaction buffer   5 µL  
10 mM dNTPs   1 µL  
10 μM Forward Primer   1 µL  
10 μM Reverse Primer   1 µL  
50 mM MgSO4  2 µL  
Q5 High-Fidelity polymerase  0.2 µL  
DNA  20-50ng (1 µL)  
Nuclease free water  To 25 µL  
                        
                        Table 2-13. A table of Q5 Hi-Fidelity Polymerase reaction volumes   
  
2.3.3 Q5 Hi-Fidelity Polymerase Thermocycler program  
Stage  Temperature  Time  
Initial denaturation  98°C  30 seconds  
35 cycles  
98°C  
55°C - 72°C  
72°C  
30 seconds  
30 seconds  
1 minute / kb  
Extension  72°C  5 minutes  
Hold  4°C  ∞  
                      Table 2-14. A table of Q5 Hi-Fidelity Polymerase reaction conditions.   
2.3.4 PCR purification  
Following PCR amplification reaction products were purified for downstream cloning and 
sequencing applications using a Monarch PCR & DNA cleanup kit (New England Biolabs) 
according to the manufacturer’s instructions. Occasionally PCR amplicons were resolved via  
DNA gel electrophoresis to isolate DNA of correct size. In this case DNA was stained using 
SYBER safe DNA dye (Invitrogen), and the required bands excised and extracted using a 
Monarch DNA Gel extraction kit according to the manufacturer instructions.  
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DNA gel electrophoresis:  
Linearized plasmid vectors, restriction digestion products and PCR amplicons were resolved 
via DNA gel electrophoresis. Electrophoretic grade agarose (Sigma Aldrich) was weighed 
according to the desired w/v % of the final gel (0.8-2%). Agarose was then mixed 1X TBE 
buffer and heated in a microwave to dissolve. SYBER safe DNA dye (Invitrogen) was added 
at a concentration of 1:10,000. Desired volume of sample was mixed with an appropriate 
volume of 6X loading dye. Samples were loaded against 2 log DNA ladder (New England 
biolabs). Samples were electrophorized in Geneflow Fast Mini Sub tanks at 80V-100V. 
Migrated DNA fragments were visualized using Biorad Gel Doc EZ system.  
DNA fragments for restriction digestion or ligation were excised from agarose gels and 
extracted using a QIAquick Gel extraction kit (Qiagen) according to manufactures instructions.   
  
2.3.5 Restriction endonuclease Digestion  
Restriction digestion was employed for the purposes of molecular cloning and recombinant 
virus screening. Isolated plasmid DNA, PCR amplicons, or viral genomic DNA were subjected 
to restriction digestion with a variety of restriction endonucleases from Promega or New 
England biolabs according to the manufacturer’s instructions and incubated at the 
recommended temperature for 1-2 hours.    
  
2.3.6 Dephosphorylation of DNA  
Dephosphorylation was employed to remove 5’ phosphate groups from linearized plasmid to 
prevent re-circularization of plasmid DNA during ligation and to better improve ligation 
efficiency. One unit (1 µL) of TSAP was added to compatible restriction digestion reaction 
mixes including Promega restriction enzyme and reaction buffers and incubated at the 
manufacturers recommended temperature of 37˚c for 15 minutes. To better facilitate 
downstream applications, TSAP was deactivated by heating to 74˚c for 15 minutes.  
  
2.3.7 Ligation  
Ligation was employed for the insertion of DNA fragments with compatible overhangs after 
restriction digestion into linearized plasmid DNA.  Linearized plasmid vector was 
dephosphorylated using TSAP (Promega) according to the manufacturers instruction. Before 
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ligation, linearized plasmid DNA and insert DNA was quantitated and diluted accordingly and 
50ng of linearized vector was mixed with insert DNA at a molar ratio of 2:1 insert to vector.  
One unit (1 µL) of T4 DNA ligase and 1 µL 10X T4 ligase buffer was added to insert/vector 
DNA mixes and topped up to a volume of 10 µL with nuclease free water. Ligation reactions 
were incubated at room temperature for 3 hours before transforming chemically competent 
bacteria via heat shock (See section 2.3.8).  
  
Ligation of annealed oligonucleotides.  
When required annealed oligonucleotide inserts were ligated into linearized plasmid vectors. 
In this instance complementary oligonucleotides (Table 2-15) encoding the V5 epitope tag and 
overhangs complementary with plasmid vectors linearized with NotI and SacII restriction 
endonucleases were annealed.   
Designation  Sequence  Plasmids  
V5-TAG 1  5’GGCCGCAGGGAAGCCCATCCGCAACCCCCTGCTGGGCCTGG 
 ACAGCACGTAACCGC’3  PJH018  
V5-TAG 2  5’GGTTAGGTGCTGTCCAGGCCCAGCAGGGGGTTGGGGATGGG PJH019  
CTTGCCTGC’3  
Table 2-15. A table of complementary V5 oligonucleotide sequences used in the construction of relevant 
plasmids.   
The required transfer vector was linearized with NotI and SacII and dephosphorylated (refer to 
section 2.2.5 and section 2.2.6). V5 oligonucleotides were resuspended at a concentration of 
100 µM/mL in nuclease free water. Oligonucleotides were denatured at 100°C for 2 minutes 
and snap cooled on ice. 21.7 µL of each oligonucleotide was then added to a 0.2 mL tube with 
8 µL of 100mM Tris-HCL (pH 7.5). The annealing reaction was performed in a thermocycler, 
samples were incubated at 70°C for 30 minutes. Tubes were then incubated at room temperature 
for 30 minutes, followed by a 20-minute incubation on ice.   
  
Annealed oligonucleotides were phosphorylated to facilitate ligation with linearized insert. 54.4 
µL oligonucleotide mixture was mixed with of one unit (1 µL) of T4 polynucleotide kinase, 7 
µL of T4 polynucleotide buffer and 0.5 µL of 1mM ATP. The reaction mixture was topped up 
to 70 µL with nuclease free water. The mixture was incubated at 37°C for 45 minutes, followed 
by a 65°C incubation to inactivate T4 polynucleotide kinase. The annealed phosphorylated 
oligonucleotides ligated to linearized and dephosphorylated vector (Refer to section 2.2.6).   
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2.3.8 Heat shock transformation of chemically competent E.coli  
Chemically competent One Shot® TOP10 (Life technologies) were thawed on ice for 40 
minutes before use. 5 µL Ligated DNA or 0.5 µL purified plasmid DNA was added to sterile 
Eppendorf tubes pre-chilled on ice. 20 µL of Top 10 competent E.coli (Invitrogen) was added 
to the DNA mixes and incubated on ice for 30 minutes. To perform the heat shock, the 
bacteria/DNA mixes were transferred to a 42˚c heating block for exactly 45 seconds. After the 
incubation the bacteria were immediately placed back on ice for two minutes. 25 µL of the 
transformed bacteria were plated onto LB-agar plates containing 100µg/mL Carbenicillin and 
incubated for 16 hours. Positive transformants were expanded and screened by restriction 
digestion (see 2.2.4) and DNA gel electrophoresis.  
2.4 Plasmid construction  
2.4.1 PJH010  
A plasmid containing F13L fused to mCherry was originally obtained from Dr David Carpentier 
(University of Cambridge). pSJH-F13mCherry lacked important features that were important for this 
work: (i) the transfer vector lacked EGFP making selection of intermediate virus more difficult, and the 
C-terminal F13mCherry fusion lacked a FLAG tag. To resolve this issue the upstream F13 flanking 
region, the F13L gene and mCherry was amplified from the pSJH-F13mCherry vector via PCR. Primer 
pair JH090 and JH091 amplify the left homology arm, F13L ORF and mCherry sequence. The stop 
codon of mCherry was omitted so that the 3xFLAG epitope could be inserted in-frame of the mCherry 
sequence (Figure 2-1).  To allow the amplified cassette to be cloned into the pUC13-EGFP.ecoGPT 
transfer vector, JH090 and JH091 included BamHI and NotI restriction sites.  
  
 
 
Figure 2-1. A diagrammatic representation of pSJH-F13mcherry.  
To enable compatibility with existing pUC-13-EGFP.ecoGPT transfer vector PSJH-F13mcherry is to 
be PCR amplified with primers JH090 and Jh091. Primers contain 5’ restriction sites denoted by dashed 
lines. The resulting amplicon will be compatible with pUC-13-EGFP.ecoGPT based transfer vectors.  
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The resulting 2.2 kb PCR fragment containing LF-F13mCherry was digested with BamHI and 
NotI. The digested product was resolved via gel electrophoresis. To generate an F13mCherry-
3xFLAG fusion, a synthetic DNA fragment was synthesised by GeneArt (Life technologies). 
The fragment, hereby referred to as 3xFLAG-F13R, contained three copies of the FLAG 
epitope followed by a STOP codon and 250 bp of the F13L right homology arm, all flanked by 
NotI and XbaI restriction sites. The NotI and XbaI restriction sites allowed the fragment to be 
inserted into a previously constructed pUC13 based transfer vector with complementary 
restriction sites (plasmid PJH012).  
  
Plasmid PJH012 and the GeneArt plasmid containing the 3xFLAG-F13R fragment were 
digested with NotI and XbaI, and the reaction products were resolved via gel electrophoresis 
(Figure 2-2A). Digestion of PJH012 releases a 1.2 kb DNA insert fragment from the linearized 
4 kb vector fragment, whereas digestion of the Gene Art plasmid with NotI/XbaI liberated the 
366 bp 3xFLAG-F13R insert fragment (Figure 2-2B). The linearized PJH012 vector and the 
3xFLAG-F13R insert were annealed by ligation. Following transformation of chemically 
competent bacteria plasmid DNA was amplified and extracted using the NEB miniprep kit, 
thereby generating plasmid pUC13-3xFLAG-F13R.  
  
  
Figure 2-2. Insertion of 3XFLAG-RF into pUC-13-Ecogpt transfer vector.   
(A) Restrictions digest of PJH012 with notI/XbaI. Reaction products resolved via gel electrophoresis.  
The linearized 4kb vector band was excised and gel extracted. (B) Restriction digest of 3XFLAG- 
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F13R geneart construct with NotI/XbaI. The 366 bp insert fragment was excised and gel extracted  
  
To introduce the LF-F13mCherry allele generated previously replacing the left homology arm 
of the parental transfer vector, the previously constructed vector pUC133XFLAG-F13R was 
digested with NotI and BamHI. Restriction digestion yielded a fragment of 1.8 kb in size, 
consistent with the release of the 300bp left homology arm and the A26L coding region present 
in this vector.  
 
Figure 2-3. Restriction digest of PJH010 clones (C1-C3) with NotI and BamHI.   
Reaction products were resolved via gel electrophoreses. Digestion yielded a 2.2 kb band consistent 
with LF-F13mCherry PCR product.  
  
The linearized pUC13-3XFLAG-F13R vector was excised and gel extracted. The vector 
fragment was then ligated with the NotI/BamHI-digested LF-F13mCherry product obtained 
and purified previously, thus generating pUC13-F13mCherry-3xFLAG hereby designated as 
plasmid PJH010. The ligation reaction product was used to transform chemically competent 
E.coli. PJH010 plasmid DNA was extracted using the NEB miniprep kit. A restriction digest 
screen using NotI and BamHI was performed on all colonies selected to verify insertion of the 
2.2 kb LF-F13mCh cassette (Figure 2-3). Successful construction of PJH010 was also verified 
by sequencing (Data not shown).  
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2.4.2 PJH011 
Primers were designed to amplify two fragments: F1, which included the left homology region 
of F13L up to its natural promoter, and F2, which encompassed the coding region of F13L up 
to the BspEI restriction site. F1 was 388 bp in size and was amplified using the primer pair 
JH090 and JH086 (Figure 2-4A).  Primer JH090 amplified from the BamHI site within the 
PJH010 transfer vector and primer JH086 amplified 53 bp upstream of the F13L start codon 
omitting the F13L promoter. JH086 included a 5’ extending sequence containing the A26L 
promoter sequence.  
   
 
Figure 2-4. Cloning of the A26 promoter into PJH010.   
(A) PCR amplification products F1(388), F2 (639 bp), resolved via agarose gel electrophoresis. (B) 
Restriction digest of overlap extension fusion product F3 and PJ010 plasmid digested with BamHI and 
BspEI.  
Amplification of fragment F2 was performed using primer pair JH083 and JH082. Primer 
JH083 amplified from the F13L start codon and contained the A26 promoter sequence as a 3’ 
extension which is complementary to that of JH0086. Primer JH083 amplified from the BspEI 
site that exists 639 bp downstream of the F13L start codon. Amplification using primers JH083 
and JH082 produced a 639 bp fragment (Figure 2-4A).   
  
Products F1 and F2 were then fused via extension overlap PCR generating a 1 kb insert 
designated F3 which was subsequently digested with BamHI and BspEI. Fragment F3 was then 
ligated into PJH010 digested with BamHI and BspEI (Figure 2-4B). The resulting ligation 
product was used to transform chemically competent E.coli. Successful transformants were 
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expanded in LB media overnight and the DNA was extracted using the NEB monarch plasmid 
miniprep kit according to manufacturer’s instructions. Extracted PJH011 plasmid DNA was 
submitted for Sanger sequencing and the presence of the A26L promoter was verified from 
analysis of the sequence chromatogram (Figure 2-5).   
 
 
 
  
 
 
Figure 2-5. Sequence chromatogram of PJH011.  
Annotated sequence chromatogram of the F13L loci within PJH011. The upstream F14L coding region 
is underscored in red, including terminal stop codon (X) terminates before the inserted A26 promoter 
(boxed in green). The position of the ATG initiation codon (▼) and the downstream F13L coding 
sequence is underscored in black.  
 
 
Amplification of 3XFLAG-F13L-RF was performed with primer pair JH096 and JH095. The 
3XFLAG-F13L-RF amplicon and transfer vector PJH012 were digested with NotI and XbaI, 
the resulting fragments were resolved via gel electrophoresis (Figure 2-6).   
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Figure 2-6. Subcloning 3xFLAG-F13LRF into PJH012.   
(A) Restriction digest of PJH012 and 3xFLAG-F13-RF fragments. Digestion of pUC-13 based transfer 
vector PJH012 yielded a 1.2kb insert fragment, PCR amplified F13RF-FLAG resolved at 400 bp.  
  
3xFLAG-F13-RF and digested PJH012 vector fragments were extracted and ligated producing 
intermediate plasmid designated. In order to introduce the F13L open reading frames into 
PJH012-RF-F13FLAG, LF-F13 and LF-(pA26)F13 fragments were amplified from PJH010 
and PJH011 respectively.   
2.4.3  PJH014 and PJH015 
PCR amplification of LF-F13L and LF-(pA26)F13 was performed using template DNA from 
PJH010 (LF-F13L) or PJH011 (LF-(pA26)F13) transfer vectors. Reaction products and  
PJH012-RF-F13-FLAG were digested with NotI and BamHI (Figure 2-7). The digested 1.4kb 
fragments of LF-F13 and LF-(pA26)F13 were excised and gel extracted. Digestion of PJH012-
RF-F13-FLAG with BamHI and NotI yielded a 1.8 kb band consistent with release of the A27 
left flank and the A26 coding sequence. The 5kb ecoGPT vector fragment was excised and 
extracted and used for ligation with either LF-F13L or  LF-(pA26)F13, yielding pF13-F and 
p(pA26)F13-F transfer vectors.  
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Figure 2-7. Sub cloning of LF-F13 and LF-(pA26)F13 into PJH012-RF-F13-FLAG.   
Electrophoresis of PJH012 RF-F13-FLAG, LF-F13 and LF-(pA26)F13 digested with NotI and  
BamHI. Restriction digest of PJH012 RF-F13-FLAG released a fragment consistent with A26-
CFPFLAG-RF (1.6 kb). PCR amplified LF-F13 and LF-(pA26)F13 digested with NotI/BamHI resolved 
at 1.4kb.   
 
2.4.4 PJH016 and PJH017 
Two modified A26 alleles were synthesised and purchased from GeneArt and designated A26-
F and (pF13)A26-F (Figure 2-8A). A26-F encoded the 350 bp upstream flank of the A26 ORF 
including the A26L late promoter downstream of 3xFLAG epitope tag  
 
The 3xFLAG tag was fused in-frame with the A26 ORF using a 3x alanine linker incorporating 
a NotI restriction site. The (pF13)A26 fragment was identical to the A26-F with the exception 
that contained the 21 bp F13 promoter (including ATG initiation codon) in lieu of the A26  
promoter. The F13 promoter sequence contains a natural HpaI restriction site which was 
exploited to screen plaque purified viruses. Both A26-F and (pF13)A26-F fragments were 
flanked by BamHI and XbaI restriction sites to facilitate sub cloning into the pUC13-
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EcoGPT/eGFP transfer vector and create plasmids PJH016 and PJH017 respectively (Figure 
2-8B).    
 
Figure 2-8. Restriction digestion of A26-F and (pF13)A26-F plasmids.  
(A) Schematic representation of N-terminal FLAG-tagged A26 fragments A26-F and (pA26)A26-
F. (B). Restriction digestion of A26-F and (pF13)A26-F plasmids with BamHI and XbaI, yielding 
a 805 bp fragment which was subsequently sub-cloned into pUC13-EcoGPT transfer vector  
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2.4.5 PJH018 and PJH019 
Parental virus vΔF13 was rescued with plasmids encoding F13 C-terminally tagged with V5 expressed 
under the native F13L promoter sequence (referred to as F13-V5) or the late A26 promoter sequence 
(referred to as (pA26)F13-V5), a schematic for their production is shown ( Figure 2-9). The C-terminal 
FLAG tag from pre-existing transfer vectors PJH014 and PJH015 was excised via restriction digestion 
with NotI and SacII. Oligonucleotides encoding the V5 epitope tag with overhangs compatible with 
NotI and SacII were annealed, phosphorylated and sub-cloned into PJH014 and PJH015, generating 
plasmids PJH018 and PJH019.   
 
 Figure 2-9. A schematic for the construction of F13-V5 transfer vectors.  
 PJH018 and PJH019. (A)Plasmids PJH014 and PJH015 were digested with NotI/SacII restriction 
endonucleases to extract the C-terminal 3xFLAG tag. (B) Complementary oligonucleotides encoding 
the V5 epitope tag sequence with overhangs compatible with NotI/SacII digestion were annealed and 
phosphorylated. V5 oligo duplexes were subcloned into digested PJH014 and PJH015 vectors, 
generating PJH018 and PJH019.  
 .   
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2.5 DNA Purification  
2.5.1 Plasmid DNA extraction   
Plasmid DNA used for molecular cloning was extracted from 1-2 mL liquid LB culture using 
an NEB monarch DNA Miniprep kit according to the manufacturer’s instructions. The DNA 
was eluted in 15 µL nuclease free water.  For applications requiring larger quantities of highly 
concentrated DNA, DNA was extracted from 200 mL liquid cultures were using the QIAGEN 
midiprep kit according to the manufacturer’s instructions. The DNA from midipreps was eluted 
in 500 µL nuclease free water.  
  
2.5.2 PCR product purification  
Amplified PCR products were purified using an NEB monarch PCR & DNA cleanup kit 
according to the manufacturer’s instructions. DNA was eluted in 15 µL nuclease free water. 
When PCR amplicons of a specific size needed to be purified, the desired PCR reaction 
products were first resolved via DNA gel electrophoresis (See 2.2.3), and migrating amplicons 
were visualized using a blue light transilluminator (Geneflow). The required amplicons were 
excised from the gel with a clean scalpel blade and the DNA was extracted using the Monarch 
DNA gel extraction kit (New England Biolabs). DNA was eluted in 15 nuclease free water.  
  
2.5.3 Preparation of crude viral DNA  
Crude viral genomic DNA was prepared from plaque purified recombinant virus or pure viral 
stocks as template for PCR/Restriction digestion analysis of recombinant viruses or viral 
stocks. 50 µL of plaque purified recombinant virus or 0.5 µL viral stock was added confluent 
BSC-40 monolayers in 24 well plates with 150 µL 2.5% DMEM. Cells were incubated in a 
humidified 37˚c incubator with 5% CO2, for 2 days or until cytopathic effect was observed. 
Infected cell monolayers were collected in their supernatants and transferred to 2ml screw 
capped tubes. Virus samples were transferred to -80c and subjected to three freeze/thaw cycles. 
DNA was extracted from the virus/cell suspension using the QIAmp DNA blood mini kit 
(Qiagen) according to the manufacturer’s instructions. DNA was eluted in 60 µL in nuclease 
free water.  
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2.6  DNA sequencing  
To verify the sequence of newly constructed plasmid DNA or recombinant virus, isolated 
plasmid DNA (refer to 2.5.1) or PCR amplified viral DNA (refer to section 2.8.6was subjected 
to Sanger sequencing. Samples were prepared in accordance with GENEWIZ guidelines. 
Briefly, up to 800ng of plasmid DNA or 40 ng of PCR amplified DNA was added to 10 µL 
nuclease free water and submitted with relevant primers at a concentration of 25 pmol. 
Sequencing was performed at GENWIZ UK LTD. The details of oligonucleotide primers used 
in the sequencing reactions are tabulated below in Table 2-16.   
  
Name  Used to sequence  
M13F  
PJH010; PJH011; PJH014; PJH015; PJH016; PJH017;   
PH018; PH019  
M13R  
SEQ 1  
PJH010; PJH011; vF13mCF; v(pA26)F13mCF  
SEQ  2  
PJH010; PJH011; PJH014; PJH015; PH018; PH019; 
vF13mCF; v(pA26)F13mCF; vF13-F; v(pA26)F13-F; 
vF13-F/A26-F; vF13-F/(pF13)A26-F; vF13-V5; 
v(pA26)F13-V5, vF13-V5/A26-F; vF13-V5/(pF13)A26-F; 
v(pA26)F13-V5/A26-F; v(pA26)F13-V5/(pF13)A26-F  
SEQ 3  
PJH010; PJH011; PJH014; PJH015; PH018; PH019; 
vF13mCF; v(pA26)F13mCF; vF13-F; v(pA26)F13-F; 
vF13-F/A26-F; vF13-F/(pF13)A26-F; vF13-V5; 
v(pA26)F13-V5, vF13-V5/A26-F; vF13-V5/(pF13)A26-F; 
v(pA26)F13-V5/A26-F; v(pA26)F13-V5/(pF13)A26-F  
SEQ 4  
PJH010; PJH011; PJH014; PJH015; PH018; PH019; 
vF13mCF; v(pA26)F13mCF; vF13-F; v(pA26)F13-F; 
vF13-F/A26-F; vF13-F/(pF13)A26-F; vF13-V5; 
v(pA26)F13-V5, vF13-V5/A26-F; vF13-V5/(pF13)A26-F; 
v(pA26)F13-V5/A26-F; v(pA26)F13-V5/(pF13)A26-F  
JH102  
vF13-F/A26-F; vF13-F/(pF13)A26-F; vF13-V5/A26-F; 
vF13-V5/(pF13)A26-F; v(pA26)F13-V5/A26-F; 
v(pA26)F13-V5/(pF13)A26-F  
JH103  
vF13-F/A26-F; vF13-F/(pF13)A26-F; vF13-V5/A26-F; 
vF13-V5/(pF13)A26-F; v(pA26)F13-V5/A26-F; 
v(pA26)F13-V5/(pF13)A26-F  
  
Table 2-16. Details of oligonucleotides used in sequencing reactions  
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2.7   Tissue culture   
2.7.1 Cells   
Cell cultures were routinely maintained in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% (v/v) Fetal bovine serum (FBS), and 1% penicillin/streptomycin (P/S) 
(Life technology). Cell lines used in this work are tabulated in (Table 2-18). Cultures were 
grown in 24 well plates, 6 cm dishes, 6 well plates, T175, T75 and T25 Flasks. Cells were 
passaged at 100% confluence. Confluent cell monolayers were washed two times with sterile 
1X PBS excess was removed via pipetting. To detach cells 2 mL 0.05% trypsin-EDTA solution 
(Invitrogen) was added to a confluent T175 flask rocking the flask to evenly coat the 
monolayer. Flasks were incubated with trypsin in a humidified 37°C 5% CO2 incubator for 5 
minutes.  Flasks were gently tapped to dislodge adherent cells. Cells were brought up to 10 mL 
with the addition of 8 mL DMEM (10% FBS,1% P/S) inactivating trypsin. The seeding volume 
of cells was derived from the following equation where: = surface area (cm2) to be seeded 
over growth ratio (g:r) of cell line . The seeding volume was diluted accordingly to the required 
plate/ flask format.    
  
   
      
Cell line  Cell origin  
 Growth 
ratio  
RK-13  Rabit Kidney   2.2  
BSC-1  
African Green 
monkey Kidney 
epithelial cells  
y  2.0  
BSC-40  
African Green 
monkey Kidne 
epithelial cells  
y  1.8  
Hek 293 T  
 Human Kidney   
1.5  
epithelial cells  
  
                 Table 2-17. A table of the of the growth ratio of each cell line used in this study  
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2.8 Virological methods   
2.8.1 Preparation of Viral stocks   
2.8.1.1 Master stocks  
To prepare a master stock of virus, two 25 cm2 flasks of confluent RK-13 cells was inoculated 
with 50 µL plaque purified recombinant virus (Refer to section 2.8.4) in 500 µL 2.5% DMEM 
and incubated at 37°C incubator at 5% CO2 for 90 minutes, rocking occasionally. After 
completion of infection, the inoculation media was aspirated and replaced with 5ml 2.5% 
DMEM and incubated for 48 hours. After incubation cells were harvested in their own media 
using a cell scraper (Starsted) and pooled. The infected cells were pelleted at 1000 rpm, 4°C 
for 10 minutes. The infected cell pellet was resuspended in 500 µL 2.5% DMEM and 
transferred to 2ml screw capped tubes and stored at -80°C. Vials were subjected to three cycles 
of freeze thaw (-80°C to 37°C). Upon first use vials were subjected to three cycles of sonication 
(40% amplitude, 30 seconds) with 30 second rests on ice in-between sonication rounds using a 
Qsonica sonicator. The homogenized infected cell lysate was transferred to a 15 ml Falcon and 
clarified at 1500 RPM, 4°C for 10 minutes. The clarified cell supernatant was transferred to a 
fresh 2 ml screw-capped tube and stored at -80. Viral titre was determined via plaque assay 
(refer to section 2.5.2).   
  
2.8.1.2 Sub-master stocks  
To prepare a sub-master stock, two 75cm2 flasks of confluent RK-13 cells were inoculated with 
master stock virus at a multiplicity of infection (MOI) of 0.1 - 2 plaque forming units per cell   
(PFU/cell) in 500 µL 2.5% DMEM.  Infections were performed at 37°C with 5% CO2 for 90 
minutes, rocking occasionally. Upon completion of the infection, the inoculum was aspirated 
from each flask, replaced with 10 mL 2.5% DMEM and incubated for 48 hours. Upon 
completion of the infection cells were harvested in their own media using a cell scraper 
(Starsted) and the contents of each flask pooled into a 50 mL falcon tube. The infected cell 
suspension was clarified via centrifugation at 1000 RPM at 4°C for 10 minutes. The supernatant 
was aspirated, and the infected cell pellet was resuspended in 1 mL 2.5% DMEM and 
transferred to a 2 mL screw capped tube and stored at -80. Vials were then subjected to three 
rounds of freeze thaw and sonication (40% amplitude, 30 seconds) with 30 second rests on ice 
in-between sonication rounds. The homogenized cell lysate was transferred to a 15 ml falcon 
tube and clarified at 1500 RPM at 4°C for 10 minutes. The clarified cell supernatant was 
transferred to a fresh 2 ml screw-capped tube and stored at -80. Viral titre was determined via 
plaque assay (refer to section 2.8.2).   
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2.8.1.3 Working stocks   
To prepare a working stock, four 175 cm2 flasks of confluent RK-13 cells were inoculated with 
sub-master stock virus at an MOI of 0.1- 2 PFU/cell in 1 mL 2.5% DMEM per flask. Infections 
were performed at 37°C with 5% CO2 for 90 minutes, rocking occasionally. Upon completion 
of infection, the inoculating media was aspirated and replaced with 20 mL 2.5% DMEM per 
flask and incubated at 37°C with 5% CO2 for 48 hours. Infected cells were collected their own 
media using cell scraper (Starsted) and the contents pooled and distributed into two 50 mL 
flacon tubes. The infected cell suspensions were then clarified at 1000 RPM at 4°C for 10 
minutes, after which the supernatants were aspirated. The infected cell pellets were 
resuspended in 1 mL 2.5% DMEM, pooled and transferred to a sterile 15 mL steel Dounce 
homogenizer (Warton) and homogenised (approximately 15 strokes).  The homogenized cell 
lystate was transferred to a 15 mL falcon and clarified via centrifugation at 1500 RPM, 4°C for 
10 minutes. The clarified supernatant was aliquoted into 2 mL screw capped tubes and stored 
at -80c before use. Viral titre was determined via plaque assay (refer to section 2.8.2).   
  
2.8.2 Titration via plaque assay   
Titration of viral stocks performed via a plaque assay (Dulbecco, 1952). Briefly BSC-1 seeded 
into 6 well plates to be confluent on the day of infection. Stock virus was thawed at 37°C and 
was subjected to two rounds of sonication for 30 seconds at 40% amplitude using a Qsonica 
Sonicator with a 30 second rest on ice in-between each sonication. Stock virus was then serially 
diluted in 10-fold dilution increments vortexing to mix. 500 µL of each dilution was used infect 
wells 6 well plate (two wells per dilution). Samples were incubated for 60-90 minutes in a 
humidified 37°C incubator with 5% CO2 incubator rocking every 15 minutes. Infected 
monolayers were overlaid with 2 mL of a 1:1 MEM/carboxymethyl cellulose (CMC) mix and 
incubated for 48-72h until CPE is observed.   
  
The MEM/CMC overlay was then aspirated, and cell monolayers were stained with 1 mL 5% 
crystal violet solution and incubated at room temperature for 1 hour. Monolayers were de-
stained and rinsed with H2O, plates were dried at room temperature before counting. Viral titre 
is derived from the number of plaque forming units (PFU) per millilitre (PFU/mL) the number 
of plaques was counted from each set of dilution well. Only wells containing 10 – 100 plaques 
were counted to minimize statistical error. PFU/mL of virus sample is derived from the 
following equation:  
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Measurement of plaque area:  
To quantitate plaque size, infected monolayers were stained with 5% crystal violet and detained 
with water. The stained monolayers were then placed in a flat-bed scanner and scanned at 1200 
dpi. Images were analysed in ImageJ software and the scale was calibrated for a 1 mm area 
(approximately 47 pixels per mm). Plaques were measured using the freehand selection tool 
and the resulting measurement data was imported into graphpad for further analysis.   
  
Transient Dominant selection:  
EcoGPT Selection media:  
Isolation of recombinant viruses via transient dominant selection requires EcoGPT selective 
media containing Mycophenolic acid (MPA), Hypoxanthine (HX) and Xanthine (X). A 
10mg/mL stock of each drug was prepared in 0.1M NaOH and filter sterilized and stored at 
20◦c until needed. EcoGPT selective 2.5% DMEM was prepared for the plaque purification of 
recombinant viruses and pre-treatment of BSC-1 monolayers. DMEM supplemented with 2.5% 
FBS, 1% PSG, MPA (1:400), HX (1:667) and X (1:40). EcoGPT selective 2xMEM was 
prepared for overlaying infected cell monolayers during plaque purification. 2XMEM was 
supplemented with MPA (1:200), HX (1:334) and X (1:20) and mixed 1:1 with 3% CMC, for 
the plaque purification of recombinant viruses.  
  
2.8.3 Infection/transfection   
To generate recombinant virus, transfer vectors containing desired sequences flanked by 
regions of homology and Escherisher coli guanine xanthine phosphoribsyl transferase 
(ECOgpt) selection cassette must be transfected into infected cells.   
Hek-293T cell monolayers were seeded for 60% confluence on the day of infection in 6cm 
dishes or T25 flasks. Monolayers were infected at a multiplicity of infection (MOI of 0.01) 
Volume of virus required for the desired MOI was calculated using the following formula.   
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Infected cells were transfected using Lipofectamine Trans-LT1 (Mirus). An appropriate volume 
of LT-1 (3µL per µg DNA) was added to optiMEM serum free media (50 ul per ug DNA). The 
LT-1/optiMEM mix was incubated at room temperature for 5 minutes. 10 ug of transfer vector 
was added to the transfection mix, flicked gently to mix and incubated for 25 minutes at room 
temperature. The transfection mixes were topped up to 4 mL with 2.5% DMEM and added 
directly to infected BSC-1 monolayers in T25 flasks. Flasks were incubated for 48h or until 
cytopathic effect was visible. Infected cells were harvested in their own media with a cell 
scraper (Sarstedt) and pelleted at 1000 rpm for 10 minutes. Pellets were re-suspended in 500 
µL EcoGPT selective 2.5% DMEM and subjected to three rounds of freeze thawing (-80°C to 
37°C) to release the virus. Before initial use samples underwent three rounds of sonication 
(40% amplitude, 20 seconds) with 20 second incubations on ice between sonication rounds. 
This cell lysate was used for the isolation of recombinant viruses by plaque purification.  
  
2.8.4 Plaque purification of recombinant viruses  
 Recombinant viruses were selected using the transient dominant selection method (Falkner and 
Moss, 1990), progeny virus from Infected/transfected sample (See 2.6.2) was used to infect 
BSC-1 monolayers in six well plates pre-treated for 16 hours with ecoGPT selective  
2.5%  DMEM.   Cell lysate from the infection/transfection process (2.6.2)  was serially diluted 
in ECOgpt selective 2.5% DMEM and 500ul of the desired dilition was then used to infect pre-
treated BSC-1 monolayers for 90 minutes rocking every 15 minutes. After Infection cell 
monolayers were overlain with a 1:1 mix of Ecogpt selective MEM and 3 % Agarose mix. 
Plates were incubated at room temperature for 10 minutes to solidify the agarose and plates 
were transferred to a humidified 37°C incubator with 5% CO2 for 48-72 hours.   
Fluorescent EGFP +ve plaques were visualized using a Zeiss TV100 fluorescence microscope 
and marked with a pen on the bottom of the plate. Intermediate virus plaques were picked into 
500 µl EcoGPT selective 2.5% DMEM and subjected to three rounds of plaque purification in 
the presence of ecoGPT selective media.  
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Plaques were subjected to three rounds of freeze thawing (-80°C to 37°C). Before initial use 
samples were sonicated (40% amplitude, 20 seconds) and passaged in the absence of ecoGPT 
selective 2.5% DMEM to induce a secondary recombination event. Isolated plaques were then 
subjected to genetic analysis.   
  
2.8.5 Genetic screening of recombinant viruses  
To verify the genomic content of recombinant viruses, viral genomic DNA was extracted and 
utilized as template for PCR amplification (refer to section 2.2.1). PCR amplificons were 
subjected to restriction digestion and resolved via DNA agarose gel electrophoresis (Refer to 
section 2.2.3). 24 well plates were prepared containing confluent BSC-40 monolayers, 
maintenance media was removed and replaced with 150 µL 2.5% DMEM or pre-treated when 
required with 150 µL 2.5% ECOgpt selective DMEM overnight. 50 µL of plaque purified virus 
added to each well and incubated for 48 hours at 37°C with 5% CO2. Cells were harvested in 
their own media, collected into 2 ml tubes and subjected to three freeze thaw cycles to release 
the virus. Viral genomic DNA was extracted from these infected cell suspensions using a 
Qiagen mini blood kit (Qiagen) according to the manufacturer’s instructions, DNA was eluted 
into 60 µL and was subjected to PCR amplification, restriction digestion analysis (refer to 
section 2.5.3, section 2.2.4 and section 2.5.5).  
  
2.9 Viral In vitro growth curves   
2.9.1 One step growth curves  
Confluent BSC-40 monolayers in 3.5 cm2 dishes were prepared for each time point in triplicate 
and infected with virus at an MOI of 5 PFU/per cell for 90 minutes at 37°C with 5% CO2, 
rocking every 15 minutes. The virus inoculum was aspirated, and unbound virus was removed 
by three consecutive 1 mL washes of 2.5% DMEM, after which 2 ml of 2.5% DMEM was 
added to each dish. The 0 hpi samples were harvested immediately after the addition of 
covering media. The culture supernatants were collected and titrated immediately on confluent 
BSC-40 monolayers. The cell associated fraction was collected using a cell scraper (Sarstedt) 
in 1 mL 2.5% DMEM. The remaining dishes were incubated for 24 hours and harvested in the 
same manner. The cell associated fractions were subjected to three rounds of freeze thaw and 
titrated as described previously (Section 2.8.2).   
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2.9.2 Multi step growth curves   
Confluent BSC-40 monolayers in 3.5 cm2 dishes were prepared for each time point in triplicate. 
The cells were infected with virus at an MOI of 0.001 PFU/cell for 90 minutes at 37°C with 
5% CO2, rocking every 15 minutes. Residual unbound virus was removed by three consecutive 
1 mL washes with 2.5% DMEM and then replaced with 2 mL of 2.5% DMEM. The 0 hpi 
samples were harvested immediately, the culture supernatants were collected and titrated on 
BSC-40 monolayers in 6 well plates. The cell associated fraction was collected in 1 mL 2.5% 
DMEM and frozen at -80. Samples were collected at 24, 48 and 72 hours pi and titrated as 
described previously (See section 2.5.2)  
  
2.10 Sucrose cushion enrichment of cell associated virus particles   
When required cell associated virion fractions were enriched via centrifugation through a 36% 
sucrose cushion.  
2.10.1 Preparation of virus samples   
Two confluent 175cm2 flasks were prepared for each time point and were infected with the 
required recombinant virus at an MOI of 5 PFU/cell in 5 mL of 2.5% DMEM per flask. 
Infections were performed at 37°C at 5% CO2 for 60 minutes, rocking occasionally. Upon 
completion of infection the inoculating media was aspirated, and the flasks were topped up 
with 20 mL 2.5% DMEM and incubated for 10 and 24 hours. Cells were harvested in their 
medium using a cell scraper (Sarstedt) at 10 and 24 hours post infection and decanted into 50 
mL falcon tubes. The infected cell suspensions were centrifuged at 2000 RPM for 10 minutes 
at 4°C. The culture supernatants were discarded, and the infected cell pellets were resuspended 
in 500 µL ice cold 10mM Tris (pH 9.0) and incubated on ice for 15 minutes. The cells were 
then homogenised using a 15 mL stainless steel homogenizer with 20 strokes on ice. The 
homogenate was then transferred to a 15 mL falcon tube and clarified at 800 rpm. The 
supernatants were collected into 2 mL screw capped tubes and kept on ice. The remaining cell 
pellets were resuspended in 500 µL ice cold 10mM Tris (pH 9.0) and homogenised with 20 
strokes on ice. The homogenate was transferred to clean 15 ml falcons and clarified at 800 rpm, 
supernatants were then pooled with the previously collected supernatants and stored at -80°C.   
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2.10.2 Sucrose cushion centrifugation  
Virus supernatants prepared previously (Refer to section 2.10.1) were thawed at 37°C and 
carefully layered on the top of 11.5 mL of 36% sucrose solution in thin walled polypropylene 
ultracentrifuge tubes (Beckman Coulter). Samples were centrifuged at 14, 740 rpm for 80 
minutes at 4°C using a SW41 Ti swinging bucket rotor in a Sorvall Discovery SE 
ultracentrifuge (Thermo Fisher Scientific). After centrifugation, the sucrose solution was 
carefully aspirated, and the virus pellet was resuspended in 200 µL PBS.   
  
2.11 Forward kinetic infection assay:  
To assess the expression kinetics of temporally altered morphogenesis proteins cells were 
infected in a forward kinetic manner.  Confluent BSC-40 monolayers were prepared in 3.5 cm2 
dishes and pre-chilled on ice in a 4°C cold room for 60 minutes. Virus inoculum was prepared 
to infect cells at an MOI of 5 PFU/Cell and pre-chilled on ice. The culture medium of the pre-
chilled cells was aspirated and replaced with 500 µL ice cold inoculum, placed back on ice and 
incubated in 4°C cold room for 60 minutes, rocking occasionally. The prechilled cells were 
then transferred to a 37°C incubator with 5% CO2 for 90 minutes to initiate infection 
synchronously. Dishes were rocked occasionally to distribute virions. Upon completion of 
infection, the inoculum was aspirated and replaced with 2 mL 2.5% DMEM and returned to 
the incubator. The 0 h time point was harvested immediately. The virus inoculum was aspirated, 
and the cell monolayer was washed gently with 1 mL ice cold PBS and stored at -20°C. Samples 
were harvested every 2 hours thereafter until completion of the time course. Samples were then 
subjected to SDS-page.  
  
2.12 Western blot   
Viral proteins from forward kinetic infections (Section 2.11), virions enriched via sucrose 
cushion sedimentation (refer to 2.10) and other cell lysates were resolved via SDS-PAGE gel 
electrophoresis and Immunoblotted via western blot.    
  
Sample preparation:  
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2.12.1 Cell lysates  
Cell monolayers destined for SDS-PAGE were thawed on ice and washed gently with 1X PBS. 
PBS was then aspirated from the monolayer and cells were harvested using a cell lifter in 250 
µL of cell lysis buffer with protease inhibitor (Roche). Samples were incubated for 20 minutes 
at 4°C in rotation to ensure complete lysis of cells. Lysates were clarified via centrifugation at 
13,000 rpm at 4°C for 20 minutes to pellet cellular debris. The cleared lysate was collected and 
mixed with appropriate volume of 4x sample buffer and boiled at 100°C for 4 minutes.  
  
2.12.2 Cell lysates for non-reducing SDS-PAGE    
To maintain interaction between viral proteins A26 and A27 and prevent disulphide interchange 
within cellular lysates, cell lysis buffer was supplemented with 100 mM Nethylmaleimide as 
described previously (Howard et al., 2008). Lysates were processed as above (refer to section 
2.10.1) and the cleared lysate was mixed 4xLDS sample buffer (Invitrogen). without reducing 
agent.  
  
2.12.3 Virion preparations    
Cell associated virions enriched via sucrose cushion (refer to section 2.8) were resolved via  
SDS PAGE under reducing and non-reducing conditions. 30 µL of enriched virions were mixed 
with 10 µL 4x loading buffer with 2-mercaptoethanol (reducing) or 10 µL 4X LDS sample 
buffer (non-reducing).  
 
2.12.4 SDS-PAGE electrophoresis:  
Samples were resolved via Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) on NuPage 4-12% Bis-Tris protein gels in nuPAGE MES-SDS running buffer 
(Invitrogen). Proteins resolved via SDS-PAGE were transferred to nitrocellulose membranes 
using a semidry transfer machine (Biorad), equilibrated with 1x Transfer buffer (20% v/v 
Methanol) for 5 minutes. Transfer was achieved at 25 volts for 25 minutes. The membranes 
were then blocked in 5 ml 5% PBSTM for 1 hour at room temperature with agitation. Proteins 
were analysed via western blot using relevant primary antibodies (refer to section 1.1.1). 
Primary antibodies were diluted appropriately in 5 mL 5% PBSTM and incubated with 
membranes in rotation for 24-48 hours at 4°C. Following incubation with primary antibody, 
the primary milk was discarded, and membranes were subjected to three 5-minute washes in 5 
mL PBST. The membranes were then probed with florescent secondary antibodies (LICOR 
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Biosciences) diluted in 5 mL PBSTM and incubated in rotation at room temperature for 60 
minutes. The membranes were then washed three times in 5 mL PBST. The membranes were 
scanned, and proteins were visualized by a LI-COR odyssey CLX scanner (LICOR 
Biosciences).  
  
2.12.5 Near infrared (NIR) signal quantification  
Signal intensity from infrared secondary antibodies was quantitated using image studio 
software (LI-COR Biosciences). Membranes were scanned in a LI-COR odyssey CLX scanner, 
the resulting signal intensity from resolved bands was quantitated and plotted or normalized to 
relevant proteins of interest.   
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3  A strategy to determine phenotypic changes imposed by 
the architecture of the VACV genome  
3.1 F13L and A26L as a model to study phenotypic variation  
The architecture of a virus genome imposes limitations in its ability to mutate and adapt to the 
environment. The acquisition of new phenotypes can therefore be limited by the structure and 
location of the genes and their regulatory sequences, even in the absence of mutations altering 
the genetic coding sequence. In this work, the viral proteins F13 and A26 have been taken as a 
working model to demonstrate to which extent phenotypic variation can be modulated by the 
location of control sequences and their properties. Both F13 and A26 proteins are specific 
markers for EEV and IMV, respectively. The F13L ORF spans from nucleotide position 40,831 
to 41,949 whereas the A26L ORF spans from nucleotide position 138,461 to 139,963 within 
the VACV genome. F13L and A26L are temporally separated in their expression: F13L is 
expressed 4 hpi reaching maximal expression at 12 hpi, whereas A26L first appears at 6 hpi 
and reaches maximal expression significantly later at 18-21 hpi. Like most VACV genes both 
F13L and A26Lexpression are regulated by distinct promoter sequences (Table 3 1).  
  
Gene  Promoter sequence  Genomic location  Conservation  
F13L  5’ GTTTTTATGTTAACTAAATG ‘3  41,947- 41,966  
MPXV  
ECTV  
CPXV  
VACV  
A26L  5’ AAAAAATGAGTTATATAAATG ‘3  139,961- 139,981  
VARV  
MPXV  
CPXV  
VACV  
  
Table 3-1. A of F13L and A26L promoter sequences and their conservation among OPXVs.  
  
Both F13L and A26L promoter sequences fall under the “late” class of temporal expression, 
and as such they conform to the consensus sequence of late promoters, consisting of an A/T 
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rich spacer and a highly conserved (1-)TAAT(+1) element required for initiation of transcription 
(Davison and Moss, 1989a). Despite sharing the architecture of the late promoters, F13L is 
expressed slightly earlier than A26L and it is considered an intermediate gene. The time of 
expression of F13 correlates with the appearance of EEV and the time of expression of A26 
correlates with the accumulation of IMV (Ulaeto et al., 1996). The production of EEV and IMV 
can be measured by standard virological techniques such as plaque assay and growth curves. 
Therefore, F13 and A26 provide an excellent model to probe for the impact of the genomic 
architecture on virus replication and the acquisition of phenotypic changes.  
  
F13L and A26L possess unique promoter sequences resulting in discreet expression kinetics of 
both proteins. To alter the expression kinetics of these genes via alteration of their promoters, 
a strategy was defined to exchange the promoter elements of F13L and A26L and introduce 
these changes into VACV. Viruses in which these genes were controlled by their own cognate 
promoters were also designed and generated as controls. Both F13 and A26 will be introduced 
into the VACV genome fused with fluorescent marker proteins at the C terminus together with 
an additional epitope tag consisting of 3 copies of the FLAG sequence. Fusion of fluorescent 
markers to these proteins facilitates the selection of recombinants, but also allow for the 
localisation and kinetics of expression to be visualised via time lapse confocal and fluorescent 
microscopy. C-terminal FLAG tagging of each fusion protein enables the kinetics of expression 
to be examined via immunoblotting.   
  
These viruses were generated using transient dominant selection (Falkner and Moss, 1990). 
This is a technique based on homologous recombination that takes advantage of the capacity 
of VACV genomes to integrate large fragments of exogenous DNA. Cassettes are designed so 
that the modified sequence is flanked by homology arms of 250-300 bp. These homology arms 
direct the location of insertion of the modified allele. The desired cassette is incorporated into 
a plasmid transfer vector containing a selection marker such as the Escherichia coli guanine 
phosphoribosyltransferase (eco-gpt) gene. Incorporation of the entire transfer vector into the 
VACV genome is achieved by an initial recombination event resulting in an intermediate virus 
resistant to mycophenolic acid (MPA). When drug selection is removed a second internal 
crossover between homology regions in the transfer vector and viral genome integrates the 
desired allele whilst ejecting exogenous transfer vector DNA. This results in the generation of 
the recombinant virus of interest (Falkner and Moss, 1990). Depending on where this second 
cross-over takes place recombination can also restore the genome of the parental virus. See 
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schematic (Figure 3-1). Therefore, the first step in the generation of a recombinant VACV is 
the production of a transfer vector armed to recombine with the viral genome.   
 
  
Figure 3-1. A schematic of the transient dominant selection principle.   
A plasmid containing an EcoGPT selection cassette, a modified A26 allele (A26m) and left and right 
homology regions (tA26L and tA26R) corresponding to the desired insertion site within the viral 
genome. A single crossover event integrates the plasmid into the genome, generating an unstable 
intermediate sensitive to ECOgpt selective media. After sequential passage and purification of the 
intermediate under ECOgpt selection, the virus is passaged without selection inducing a second internal 
crossover event between the homology regions of the plasmid and viral genome. This crossover event 
results in the integration of the desired allele into the viral genome or ejection of the plasmid leading to 
a reversion to the wild-type parental virus. Figure adapted from (Falkner and Moss,  
1990)  
  
A transfer vector was designed to generate a recombinant virus expressing F13 fused to a C-terminal 
mCherry fluorescent protein from the F13L natural locus. This plasmid contained the F13L ORF fused 
to mCherry and 3 copies of the FLAG epitope, and this ORF was flanked by the homology arms 
surrounding the F13L locus. This transfer vector was named PJH010 and the strategy used to build it is 
depicted in figure 3-2 and detailed in section 2.4.1. 
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Figure 3-2. A schematic of the cloning strategy for PJH010.   
A. pSJH plasmid DNA was PCR amplified with primer pair JH090/JH091 with BamHI and NotI 
restriction sites, yielding the PCR product LF-F13mCherry.B. 3xFLAG-RF was digested from Geneart 
plasmid using NotI/XbaI restriction endonucleases and sub cloned into digested PJH012 transfer vector. 
Generating the intermediate plasmid pUC-13-3xFLAG-F13R. C. PCR amplified LFF13mCherry 
product was restriction digested with BamHI/NotI endonucleases and sub-cloned into pUC-13-
3xFLAG-F13R, generating plasmid PJH010.   
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3.2 Generation of the transfer vector PJH011  
The plasmid PJH010 contains the F13L ORF and its natural upstream flanking region. 
Therefore, its expression is controlled by its natural regulatory sequences. To change the 
promoter sequence of F13L for that of A26L a second transfer vector was produced. An 
overlapping PCR was employed to amplify two fragments with complementary overhangs 
encoding the A26 promoter sequence. These fragments anneal at the A26 promoter overhangs 
and external primers amplifying from the terminus of each fragment generated a fused product. 
The fused product was inserted by taking advantage of the BspEI restriction site within the 
F13L locus. The strategy designed to build PJH011 is depicted in Figure 3-3 and detailed in 
section 2.4.2. 
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Figure 3-3. A schematic for the construction of PJH011.  
(A) PJH10 was used as template DNA for a PCR reactions generating with primer pairs JH090/JH086 
and JH082/JH083 generating 388 bp and 639 bp fragments (F1 and F2) containing complementary 
strands of the A26 promoter. (B) Fragments F1 and F2 were fused using an overlap extension PCR with 
terminal primers JH090 and JH083.C Fragment F3 was digested with restriction endonucleases BamHI 
and BspEI and subcloned into PJH010, generating plasmid PJH011.  
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3.3   Generation of recombinant VACV expressing F13 fusions from 
the F13L or A26L promoters  
Having built the required transfer vectors, the generation of recombinant viruses took place. A 
VACV strain WR lacking F13, vΔF13, was obtained from Dr Bernard Moss. This virus is 
defective in its ability to produce EEV and CEV reducing its capability to spread in tissue 
culture. It therefore has a significantly reduced plaque size compared to wildtype WR. vΔF13 
was generated by replacing F13 for the EcoGPT gene (Blasco and Moss, 1991). Consequently, 
this virus does not allow selection by MPA. However, given its severe plaque size reduction 
reconstitution of the F13 locus was expected to render a significant increase in plaque size. In 
addition, the transfer vectors to be used expressed mCherry and EGFP, facilitating selection of 
recombinant virus based on fluorescence. Therefore, the parental vΔF13 virus was 
complemented with the F13mCherry3xFLAG alleles expressed under the native F13L 
promoter sequence (PJH010) or the heterologous A26L promoter (PJH011).   
  
Recombinants were produced via transient dominant selection. HEK-293T cells at 60 % 
confluence were infected with a multiplicity of infection (MOI) of 0.01 plaque forming units 
(PFU) per cell of vΔF13 or left uninfected. After 90 mins of infection the inoculum was 
removed, and the cells were transfected with 10 μg of PJH010 or PJH011. The cells were 
incubated until extensive cytopathic effect (CPE) was observed. The cell monolayer was then 
scrapped, subjected to 3 cycles of freeze-thawing and used to inoculate fresh monolayers of 
BSC-1 cells. Newly formed plaques were identified by microscopy and analysed for their 
expression of mCherry and EGFP, confirming the integration of the transfer vector into the 
viral genome. Positive plaques were isolated and labelled as intermediate virus and enriched in 
24 well plates of BSC-1 cells. These enriched intermediate viruses were plaque purified on 
monolayers of BSC-40 cells. The resulting plaques were screened for mCherry+, EGFP- 
fluorescence. These plaques followed a second internal recombination event generating a virus 
carrying the F13mCherry fusion allele but not the rest of the transfer vector. These resolved 
plaques were isolated and labelled vF13mCF when deriving from the PJH010 transfection or 
v(pA26)F13mCF when deriving from PJH011 transfection.   
  
Genetic screening of these plaques took place by PCR. Primers JH090 and JH083, which 
located external to the F13L allele coding sequence on each flanking region, were used to 
amplify the entire F13 cassette. This PCR generated a ~2.2 kb band that was present in the 
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original transfer PJH010 or PJH011 transfer vector as well as the intermediate and resolved 
viruses Figure 3-4A and Figure 3-4B. A band of a similar size was also observed in the vΔF13 
virus, which resulted from the fact that the EcoGPT gene that replaces F13L in the F13L locus 
of this virus. In addition, the residual F13L sequences within were of a length similar to the 
F13mCherry fusions.   
  
  
  
  
 
  
Figure 3-4. PCR analysis of vF13mCF and v(pA26)F13mCF.    
Genomic DNA was extracted from vF13mCF (A) or v(pA26)F13mCF (B) EGPF + (Intermediate) and 
EGFP - (resolved) plaques and amplified with primer pair JH090/JH083. Amplicons were compared to 
PCR products of parental vΔF13 virus and relevant plasmid controls: PJH010 (A) or PJH011 (B) 
amplified with JH090/JH083. PCR reaction products were resolved by DNA gel electrophoresis.  
Amplification of the F13L loci of these templates results in generation of a 2.4 kb DNA fragment.   
  
To discriminate between the F13mCherry fusions and this unexpected band, amplicons were 
purified and digested with BspEI, a restriction enzyme cleaving the F13L gene but not EcoGPT, 
together with NotI, a restriction enzyme cleaving between mCherry and the 3xFLAG. Digested 
PCR products were analysed by electrophoresis. As predicted NotI/BspEI digestion converted 
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the original ~2.2 kb band from the transfer vector into 3 bands of approximately 1.2, 0.8 and 
0.3 kb. This pattern was not observed when digesting vΔF13 amplicons but was present in the 
intermediate and resolved virus lanes (Figure 3-5A and Figure 3-5B).  Importantly, no 
remaining 2.2 kb band was observed for the resolved viruses after digestion, confirming these 
viruses had gone through a second recombination event to retain the F13mCherry fusions.   
  
 
  
Figure 3-5. Restriction digestion of vF13mCF and v(pA26)F13mCF virus amplicons.   
PCR fragments derived from vF13mCF (A) or v(pA26)F13mCF (B) EGPF + (Intermediate) and EGFP 
- (resolved)  virus plaques, relevant control plasmids PJH010 (A)  and PJH011 (B) and parental vΔF13 
genomic DNA were digested with NotI/BspEI and resolved via DNA gel electrophoresis. Digestion of 
resolved amplicons generates fragments that migrate at  1.2 kb, 800 bp, and 350 bp, derived from the 
original 2.4kb fragment. The fragmentation pattern corresponds to digested plasmid control amplicons 
PJH010 (A) and PJH011 (B). Migration of a 2.4 kb band after NotI/BspEI digestion of vΔF13 and 
Intermediate fragments indicate presence of the parental F13L loci.    
  
PCR amplification coupled to restriction enzyme digestion could not discriminate the identity of the 2 
F13 alleles and hence of vF13mCF and v(pA26)F13mCF. These alleles were identical in size and their 
qualitative difference on the promoter region upstream of the F13L locus did not generate any suitable 
restriction enzyme site to be exploited. Therefore, these viruses were distinguished by sequencing 
(Figure 3-6). Sequences obtained from the 2 resolved viruses demonstrated the successful incorporation 
of the A26 promoter in front of the F13 gene in v(pA26)F13mCF   
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Figure 3-6. Sequence verification of vF13mCF and v(pA26)F13mCF.   
Sequence chromatogram files of the F13L promoter regions of vF13mCF (A) and v(pA26)F13mCF  
(B)  indicating  presence  of  the  cognate  F13L  promoter  sequence  (  
5’GTTTTTATGTTAACTAAATG‘3)  (A)  or  the  A26  promoter  sequence:  
(5’AAAAAATGAGTTATATAAATG‘3) (B).  
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3.4  Expression  of  F13.mCherry  fusions  from  vF13mCF 
 and v(pA26)F13mCF  
Following the construction of the recombinant viruses vF13mCF and v(pA26)F13mCF both 
viruses were to be characterised. First, expression of the F13mCherry allele was studied by 
microscopy. BSC-1 cells were infected with vF13mCF and v(pA26)F13mCF at 100 PFU per 
well, and plaques were visualized for mCherry florescence 4 days post infection. From these 
initial observations of vF13mCF and v(pA26)F13mCF plaques via fluorescence microscopy 
expression of mCherry was confirmed (Figure 3-7). Interestingly, a significant reduction in 
plaque size was observed when F13mCF was expressed under the A26 promoter sequence.  
This suggested that delayed expression of F13 results in an  reduction of plaque size.   
 
  
Figure 3-7. Fluorescence microscopy of vF13mCF and v(pA26)F13mCF plaques.   
BSC-1 cell monolayers were infected at 50 PFU/well with vF13mCF (A) or v(pA26)F13mCF (B), 
overlain with semisolid media and incubated for 4 days. After 4 days post infection plaques were imaged 
for mCherry fluorescence using a fluorescence microscope. Representative sequence chromatograms 
for the F13L promoter regions are depicted below.   
  
  
In order to assess the expression of the F13mCherry fusion, the newly created recombinant 
viruses were expanded into working stocks. BSC-1 cells were infected with 5 PFU/cell of 
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vF13mCF or v(pA26)F13mCF for 3, 6, 9 and 12 h in a reverse kinetics infection. Lysates were 
resolved via SDS-page and immunoblotted for FLAG, the viral protein D8 and tubulin (Figure 
3-8). Expression of the F13-mCherry fusion in both viruses was verified by a band migrating 
at 66 kDa corresponding to the combined molecular weight of F13L and the Cterminal 
mCherry3xFLAG tag. Surprisingly, despite the reduced plaque size observed earlier, no 
detectable difference in F13 expression kinetics was observed between the two viruses.  
  
  
  
Figure 3-8. Expression kinetic profile of F13Mcf in vF13mCF and v(pA26)F13mCF.   
BSC-1 cell monolayers were infected with 5 PFU/cell with either vF13mCF or v(pA26)F13mCF and 
harvested at 3, 6, 9 and 12 hours post infection. Lysates were resolved via SDS-PAGE and 
immunoblotted for FLAG, viral D8 and tubulin. A representative experiment of two replicates is shown.  
3.4.1    Plaque size analysis of vF13mCF and v(pA26)F13mCF viruses  
After verifying the expression of the F13-mCherry-FLAG fusion cassette in vF13mCF and 
v(pA26)F13mCF, both viruses were characterised via plaque assay to determine the effect of 
synchronising F13L expression with A26L on the formation of plaques. BSC-40 cells were 
infected with ~100 PFU per well and plates were stained with crystal violet 4 and 7 dpi. Plates 
were scanned, and plaque area determined with Image J (Figure 3-9A). Results showed that the 
v(pA26)F13mCF generated smaller plaques compared to those from vF13.mCF. This 
difference was statistically significant both at 4 and 7 dpi (Figure 3-9B). These data agreed 
with previous observations and implied that delaying expression of F13L using the A26L 
promoter resulted in a reduction in plaque size. Collectively, this confirmed that intermediate 
expression of F13 is required for optimal plaque formation.   
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Figure 3-9. Plaque size comparison of F13mCherry viruses.   
(A) BSC-1 monolayers infected with v(pA26)F13mCF or vF13mCF at 100 pfu/well . At 4 and 7 days 
post infection monolayers were stained with crystal violet solution and scanned. (B) Average plaque 
area of vF13mCF and v(pA26)F13mCF at 4 and 7 days post infection n=20, Significance derived from 
one way ANOVA p ≤ 0.0001 ****. Representative data from two replicate experiments.   
  
3.4.2     F13mCherry fusions reduce plaque size  
Following production of vF13mCF and v(pA26)F13mCF viruses the ability of the viruses to 
spread was assessed via plaque assay. Despite complementing ΔF13L with an F13mcherry 
allele the recombinant viruses did not appear to form plaques at the expected size. Both 
vF13mCF and v(pA26)F13mCF had a significantly reduced plaque size when compared to 
wildtype VACV WR that was detectable by the naked eye. To verify this, a side-by-side 
comparison was carried out. BSC-1 monolayers were infected with VACV WR (wild-type 
control), ∆F13 (parental) or recombinant F13mCF viruses and v(pA26)F13mCF. Monolayers 
were overlain with semisolid overlay to facilitated plaque formation and incubated for 4 days. 
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After 4 days post infection, plaques were imaged via bright field microscopy before staining 
with crystal violet. Stained monolayers were scanned, and plaque area was measured using 
image J software and plotted. Inclusion of F13mCherry fusions significantly reduce plaque 
size, nevertheless a significant plaque size reduction was observed when F13mCF was 
expressed under the A26L promoter sequence (Figure 3-10).   
  
Figure 3-10. F13mCherry fusions reduce plaque size significantly.  
 (A) BSC-1 cell monolayers were infected at 100 pfu with relevant virus and incubated with semisolid 
overlay. After 4 days monolayers were stained and scanned, plaque area was quantified using ImageJ 
software. (B) Bright field images of VACV WR, ΔF13, vF13mCF and v(pA26)F13mCF plaques 4 dpi. 
F13mcherry fusions drastically reduce plaque size when compared to VACV WR. Significance from 
unpaired t-test p≥0.01 **. Representative data from two replicate experiments.   
  
  
3.4.3     Delaying F13L expression under the A26 promoter facilitates escape mutants  
Rescue of vΔF13 with F13mCF under the control of the A26 promoter results in a reduction in 
plaque size when compared to vF13mCF. This is due to the presumably delayed expression of 
F13L which leads to inhibition of plaque size. After the second passage of v(pA26)F13mCF 
aberrant plaques were observed which had a significantly larger phenotype than the typical size 
recorded for v(pA26)F13mCF either at 4 or 7 dpi (Figure 3-11). These aberrant plaques were 
only observed within v(pA26)F13mCF, but not vF13.mCF, stocks. A large plaque was picked 
and designated anomalous plaque 1 (vAP-1) and expanded for further characterisation.   
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Figure 3-11. Plaque phenotype and PCR analysis of Escape mutant vAP-1.   
(A) BSC-1 monolayers were infected with v(pA26)F13mCF at 50 PFU/well and overlain with 
MEM/CMC semi-solid overlay. After 4 and 7 DPI large plaques (designated vAP-1) were identified via 
light microscopy and picked before staining with crystal violet. B PCR analysis of isolated vAP-1 
plaques. The F13L loci from plasmid DNA (JH011), VACV WR and vAP-1 genomic DNA was 
amplified using primer pair JH090/JH083. The resulting PCR amplicons were resolved via DNA gel 
electrophoresis, amplification of a 2.4 kb fragment indicates the presence of the F13mCF cassette, 
whereas the 1.4 kb fragment from WR indicates the presence of the wild-type F13L locus.  
  
PCR amplification of the F13L region within vAP-1 yielded a 2.4kb fragment, consistent with 
the size of the F13mCF fusion cassette, and much larger than the F13L locus in WR which 
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lacks the mCF tag (Figure 3-11B). The presence of the full length F13mCF cassette thus 
suggested that a further mutation may have driven an increase in plaque size.   
 3.4.4     A mutation disrupting mCherry expression in v(pA26).F13mCF restores plaque  
size significantly  
The presence of F13 and the lack of mCherry expression in vAP-1 indicated that a spurious 
mutation must have occurred in this virus hindering the expression of mCherry. The fact that 
vAP-1 had significantly larger plaques than its parental virus together with the detection of a 
F13 protein band indicated that the probable mutation prematurely terminated mCherry 
expression leaving the F13L ORF uninterrupted. To test this hypothesis the F13mCF cassette 
that was PCR amplified from vAP-1 previously was sequenced and aligned with the parental 
F13mCF allele from v(pA26)F13mCF (Figure 3-12).  
  
 
  
Figure 3-12. Sequence chromatogram alignment of vAP-1 and vpA26)F13mCF.  
Sequencing of vAP-1 revealed a mismatch within the terminal codon of the F13L loci (highlighted red). 
The predicted amino acid is also shown.  
  
Sequence analysis of vAP-1 revealed a +1-frame shift mutation at codon 372 (I-372-N), generating a 
premature stop codon 17 amino acid downstream of it that terminated mCherry expression. This 
insertion occurred within the terminal codon of the F13L sequence, perhaps indicating the importance 
of the C-terminal domain of the F13L gene. The promoter regions of vAP-1 and v(pA26)F13mCF were 
also sequenced and aligned (data not shown).The heterologous A26L promoter in v(pA26)F13.mCF 
was unchanged indicating that the increase in plaque size of vAP-1 relative to v(pA26)F13mCF derived 
from the lack of the mCF tag expression.   
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To verify expression of the F13mCF fusion in vAP-1, plaques were first visualised via 
fluorescence microscopy. BSC-1 cells were infected with ~100 PFU/cell of a number of viruses 
including the recombinant viruses carrying the F13mCF alleles and the escape mutant vAP-1. 
In conditions in which the mCherry fluorescence was detectable for vF13.mCF and 
v(pA26)F13mCF, no signal could be observed for vAP-1 (Figure 3-13). These results indicated 
that despite containing the full F13mCF allele, this was not functional and no mCherry 
expression occurred.   
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Figure 3-13. vAP-1 lacks mCherry fluorescence.   
BSC-1 monolayers were infected with <100 pfu VACV WR, ∆F13 (non-florecent controls) and  
vF13mCF, v(pA26)F13mCF (flourecent controls) or AP-1. Individual plaques were imaged for 
mCherry at 4 dpi using a Zeis TV100 flourecence microscope.   
  
 
mCherry 
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To further confirm the absence of F13mCherry expression, a western blot. BSC-1 cells were 
infected with 5 PFU/cell of v(pA26)F13mCF, its derived mutant vAP-1 as well as WR as a 
control, or mock-infected. After 8 h lysates were collected and resolved via SDS-PAGE and 
immunoblotted for FLAG and the viral proteins F13 and D8 (Figure 3-14). Immunoblotting for 
protein D8 demonstrated a successful and equivalent infection for all three viruses. In those 
conditions, the F13mCherry fusion protein was undetectable within vAP-1, in contrast to its 
parental v(pA26)F13mCF. A band for F13 was, however, observed for vAP-1 when using anti-
F13 serum and this had a similar size to the F13 band observed for WR. Moreover, 
v(pA26)F13mCF was also positive for this band that resolved at 37 kDa, as opposed to the 
F13mCherry fusion product that resolved at 66 kDa. These results reflected that 
v(pA26)F13mCF was comprised of  a mixed population expressing the full length F13mCF 
product (66 kDa) and an escape mutant population expressing a truncated cassette (37 kDa).  
  
 
  
  
Figure 3-14. Western blot analysis of vAP-1.  
BSC-1 monolayers were mock infected or infected with vΔF13, v(pA26)F13mCF or vAP-1at an MOI 
of 5 and harvested 8 at 8 hours post infection. Infected cell lysates were resolved via SDS-PAGE under 
reducing conditions and immunoblotted for FLAG and viral proteins F13 and D8. * indicate non-
specific bands. Representative data from two replicate experiments.   
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To formally assess the impact of this mutation on plaque size, a further comparative analysis 
was conducted. Plaques from BSC-1 cells infected with different viruses including vAP-1 were 
measured and compared. vAP-1 infection generated plaques that were significantly larger than 
its parental v(pA26)F13mCF (Figure 3-15). These plaques were not, however, as large as those 
from WR. This indicated that in vAP-1 plaque size was only partially restored. Therefore, it 
can be concluded that in vAP-1 either the 17-amino acid remaining tail or, more likely, the 
presence of the A26 promoter had a negative impact in plaque formation.   
  
  
 
Figure 3-15. vAP-1 plaque size comparison.  
BSC-1 monolayers were infected with ΔF13, vF13mCF, v(pA26)F13mCF, AP-1 and VACV WR at 
<100 pfu. Monolayers were stained at 4 dpi and scanned, average plaque area was calculated using 
ImageJ software and the averages plotted (n=40). Significance from unpaired t-test p ≤ 0.0001, p ≤  
0.001 Representative data from two replicate experiments.   
  
Interestingly, escape mutants were only observed within v(pA26)F13mCF stocks and were 
absent when the F13mCF allele was expressed under the cognate F13L promoter sequence. 
The vF13mCF virus was stable after multiple passages indicating that despite both viruses 
possessing a mCherry-FLAG fusion, which was clearly deleterious, the presence of A26 
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promoter sequence conferred an additional selection pressure that facilitated the appearance of 
escape mutants.   
  
Due to the instability of mCherry-tagged F13 viruses and the clear negative impact mediated 
by mCherry on F13, these viruses could not be used for further studies. Therefore, an alternative 
approach was formulated that would replace mCherry with a 3XFLAG tag. These F13-
3XFLAG viruses would then be complemented with FLAG tagged A26 alleles.   
  
3.5    Summary  
In summary these data show the production of transfer vectors encoding F13mCF under the 
control of F13L or A26L promoter sequences. When F13mCF constructs were used to 
complement a ΔF13 parental virus abnormal plaque size was observed in vF13mCF and 
v(pA26)F13mCF. Despite significant reduction in plaque size when compared to wildtype 
VACV WR, delaying F13 expression under the late A26L promoter sequence resulted in a 
reduction in plaque size when compared to the wild-type control vF13mCF. These differences 
were small, but significant and characterisation of these viruses was frustrated by the apparent 
negative effects of mCherry fusions. These effects include a drastically reduced plaque size 
and genomic instability which facilitated escape mutant formation. These data recapitulate the 
findings of another group that was concurrently tagging F13 with mCherry for other purposes 
(Carpentier et al., 2017). This group demonstrated that mCherry-tagged F13 alleles have severe 
defects in wrapping of EEV, thus providing a mechanistic explanation for the reduced plaque 
size. Taken together, these data provided proof-of principle validation that a phenotypic change 
in VACV can be induced by altering promoter sequences and the architecture of the genome. 
The approach taken with the use of fluorescently tagged proteins was, however, not optimal to 
further explore these observations and hence an alternative strategy was designed.  
  
4 A26 is a negative regulator of VACV spread  
4.1 A new strategy to study the roles of F13L and A26L in VACV spread  
Previous work showed that tagging F13 with a large fluorescent protein such as mCherry is 
detrimental for the virus spread and generates very small plaques. Data from Carpentier et al. 
demonstrate that addition of mCherry on the C terminus of F13 directly hinders wrapping of 
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virions, as observed via electron microscopy (Carpentier et al., 2017). Therefore, even if 
delaying F13 expression with the A26 promoter reduces plaque size in the recombinant viruses 
carrying mCherry-tagged F13 alleles, these viruses are not a good model to assess the real 
impact of F13 and A26 on VACV spread. Due to these concerns a new set of viruses was 
conceived in which F13 would be tagged with a FLAG tag. The FLAG epitope is much smaller 
than mCherry, so it was thought not to interfere with F13 wrapping. Additionally, these new 
viruses were to include A26 alleles also tagged with FLAG. Tagging both F13 and A26 with 
FLAG allowed for the expression kinetics of both proteins to be determined using a singular 
FLAG antibody, negating the effect of differing sensitivity of A26 and F13 specific sera. In 
order to generate these viruses, additional transfer vectors were first constructed with F13L 
either under its own promoter or that of A26L directly fused to a 3xFLAG tag at the Cterminus.   
  
4.2. Generation of the transfer vectors PJH014 and PJH015  
In order to introduce 3xFLAG to the C-termini of F13 the 3XFLAG-F13L-RF fragment from 
PJH010 needed to be amplified with primers introducing a NotI site at the beginning of the 
3xFLAG sequence in addition the corresponding F13L coding region and left flank expressed 
under the cognate F13L promoter (LF-F13 or the A26 promoter sequence (LF-(pA26)F13). 
These fragments were then sub-cloned into an existing pUC-13 ECOgpt transfer vector 
(PJH012) generating plasmids encoding F13-FLAG or (pA26)F13-FLAG (PJH014 and  
JH015). A schematic for the construction of these plasmids is outlined (Figure 4-1).   
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Figure 4-1. Schematic for the construction of PJH014 and PJH015 transfer vectors.  
 (A) 3xFLAG-RF was PCR amplified with primer pair JH096/JH095 incorporating NotI/XbaI 
restriction sites. 3xFLAG-LF was subcloned into PJH012 generating intermediate plasmid PJH012RF-
F13-FLAG. (B) The Left flank and F13L coding region from PJH010 and PJH011 was PCR amplified 
using primer pair PJH091 and PJH097, generating LF-F13 and LF-(pA26)F13 amplicons incorporating 
BamHI and NotI restriction sites. LF-F13 or LF-(pA26)F13 were subcloned into PJH012-RF-F13-
FLAG generating plasmids PJH014 and PJH015.    
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4.3 Generation of recombinant VACV expressing FLAG-tagged F13 from 
the F13L or A26L promoters  
4.3.1     Genetic analysis of vF13-F and v(pA26)F13-F  
Previously constructed PJH014 was used to transfect Hek-293T cells infected with ΔF13L. The 
resulting progeny were isolated in the absence of Ecogpt selection as rescue of vΔF13L with a 
functional F13L cassette restores plaque size and thus provides strong positive selection. 
Double recombinant plaques were selected on the basis of large plaque phenotype and absence 
of EGFP fluorescence and subjected to three rounds of plaque purification.   
  
Resolved viruses were amplified in a 24wp of BSC-40 cells. Viral genomic DNA was extracted 
and subjected to PCR analysis to verify insertion of the F13-FLAG cassette. Amplification of 
the F13L loci with primers (JH0100/JH0101) was performed via PCR and the resulting 
fragments were purified and resolved via DNA gel electrophoresis.  
  
PCR amplification with (JH0100/JH0101) generated a 1.4kb fragment consistent with the F13-
FLAG cassette. As the viruses cannot be distinguished by amplicon size the PCR fragments 
digested with restriction enzymes BspEI and NotI. A BspEI restriction enzyme site is present 
within the natural F13L loci, digestion with NotI confirms the presence of the FLAG tag. Co-
digestion with BspEI and NotI results in three fragments, absence of a full length undigested 
1.4kb fragment indicates that the virus is fully resolved (Figure 4-2).   
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Figure 4-2. Genetic analysis of vF13-F and v(pA26) recombinant viruses.   
Genomic DNA from resolved (EGFP –ve) vF13-F (A) or v(pA26)F13-F (C), parental virus vΔF13 or 
control plasmids PJH014 and PJH015 was subjected to PCR analysis using primer pair 
JH0100/JH0101.Generating 1.8kb amplicons corresponding to the F13L loci. 1.8 kb amplicons from 
PCR analysis were digested with NotI/BspEI. Digestion of 1.8 kb fragments derived from resolved 
vF13-F (B) and v(pA26)F13-F (D) viruses generates 350, 600 and 800 bp fragments, corresponding to 
the fragmentation pattern of the plasmid controls PJH014 (B) and PJH015 (D).  
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4.4. Characterisation of recombinant VACV expressing FLAG-tagged 
F13 from the F13L or A26L promoters  
Once the new set of viruses expressing FLAG-tagged F13 from the F13 or the A26 promoter 
was completed, their characterisation took place. Monolayers of BSC-1 cells were infected 
with ~100 PFU/cell of vF13-F, v(pA26)F13-F as well as vΔF13 and WR as controls. After 4 
days plates were stained with crystal violet and plaques visualised (Figure 4-3). Rescue of 
vΔF13 with a C-terminal F13-FLAG fusion restored plaque size as compared to vΔF13. In 
agreement with previous data obtained with the F13mCF fusions, replacing the F13L natural 
promoter for that of the A26L gene reduced plaque size. Surprisingly, vF13-F did not show 
plaques as large as WR indicating that the F13-FLAG allele was not completely functional. 
Although this effect was not as deleterious as the phenotype observed with a C-terminal 
mCherry tag, this revealed that even a minimal epitope tag such as FLAG have an impact upon 
the function of F13.   
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To quantitate the observed defect in plaque size in v(pA26)F13-F, >80 plaques were measured 
and their area calculated and plotted as a dot plot (Figure 4-4). v(pA26)F13-F consistently 
generated smaller plaques than vF13-F and this difference was statistically significant. These 
results further confirmed that delaying F13 expression negatively impacted on plaque size 
formation.   
  
  
  
 
  
Figure 4-4. vF13-F and v(pA26)F13-F plaque size comparison.  
 BSC-1 monolayers were infected with the indicated viruses at 100 PFU/well. Monolayers were stained 
with crystal violet at 4 DPI and scanned. 85 individual plaques were measured using image J and plotted 
as a dot plot showing the mean and SEM. Statistical analysis was determined by using an unpaired 
Student’s t test (**** p <0.0001).  Representative data from two replicate experiments.   
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4.5. Generation of recombinant VACV expressing FLAG-tagged A26 from 
the F13L or A26L promoters  
The reduced plaque size observed in v(pA26)F13-F was a consequence of delaying F13 
expression synchronising it to A26 expression. Although A26 is a marker for IMV production 
and is not known to have a role in VACV spread, the potential of effect of synchronised A26 
and F13 expression is unknown, because the 2 proteins are naturally expressed at different 
times during the VACV life cycle. Therefore, a question arose as to whether synchronising A26 
expression to that of F13 by placing both genes under the F13L natural promoter could have a 
detrimental effect on plaque size as observed with v(pA26)F13 viruses.   
 
To observe the effect of intermediate A26 expression on viral spread, recombinant viruses were 
constructed with N-terminal FLAG-tagged A26 alleles under the control of either the native 
A26L promoter or the intermediate F13L promoter, the construction of these plasmids is 
detailed in Section 2.4.4. 
 
The transfer vectors PJH016 and PJH017 were used to transfect HEK-293T cells previously 
infected with 0.01 PFU/cell of the vF13-F virus. Once CPE was observed monolayers were 
harvested and subjected to 3 freeze-thawing cycles. These extracts were used to infect fresh 
monolayers of BSC-1 cells previously treated with selective medium containing MPA, 
xanthine and hypoxanthine (hereto referred to as selective medium). The resulting GFP positive 
plaques were picked and subjected to three rounds of plaque purification in selective medium. 
Stable intermediate plaques were then passaged in the absence of selection. Plaques were 
screened for the absence of GFP fluorescence and subjected to three rounds of plaque 
purification. Finally, isolated plaques were expanded in BSC-40 cells and subjected to genetic 
analysis to verify the incorporation of the FLAG-tagged A26 alleles.   
  
DNA was extracted from vF13-F/A26-F and vF13-F/(pF13)A26-F, amplified via PCR using 
primer pairs JH0100/JH0101  and JH0102/JH0103. Amplification of the F13L locus resulted 
in a 1.4 kb fragment, whereas amplification of A26L locus yielded a 840 bp fragment. 
Digestion of the F13-F product with HpaI and NotI yields fragments at 1.2kb, 350 bp and 
150bp. HpaI digestion of A26-F results in an undigested amplicon which migrates at 840 bp 
whereas digestion of (pF13)A26-F yielded 350 and 420 bp fragments, due to the presence of 
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an HpaI site in the F13L promoter sequence. These fragmentation patterns were initially 
verified by digesting the transfer vectors used to generate the viruses (4-5A). Subsequently, 
PCR amplicons derived from the viral genome were digested and the patterns compared to 
those of the plasmids (4-5B and 4-5D). These results confirmed the successful generation of 
FLAG-tagged F13 viruses expressing FLAG-tagged A26 alleles under the A26L or F13L 
promoter.   
  
 
  
Figure 4-5. Genetic analysis of vF13-F/A26-F and vF13-F/(pF13)A26-F recombinant viruses.  
(A) PCR amplicons of F13-F (PJH014) using primer pair JH0100/JH0101 or A26-F (PJH016) and 
(pF13)A26-F (PJH017) derived from plasmid DNA digested with either NotI and HpaI (F13-F) or HpaI 
(A26-F and (pF13)A26-F). (B, C) Restriction digestion of F13-F and A26-F PCR amplicons derived 
from vF13-F/A26-F (B) and v(pF13)A26-F (C).  
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4.6. Characterisation of recombinant VACV expressing FLAG-tagged 
A26 from the F13L or A26L promoters  
To demonstrate that substituting the A26 promoter for that of F13 impacted on A26 expression, 
kinetics of expression of both F13 and A26 in the newly generated recombinant viruses was 
addressed. BSC-40 cells were synchronised and infected at an MOI of 5 PFU/cell with vF13-
F/A26-F or vF13-F/(pF13)A26-F in a forward kinetic manner. Lysates were collected at 
multiple time points post-infection and subjected to SDS-PAGE and immunoblotting for FLAG 
(F13 and A26) as well as the viral late protein D8 (Figure 4-6). Protein F13 was detected at 6 
hpi in both viruses and peaked at around 9 hpi. In the case of vF13-F/A26-F protein A26 could 
barely be detected in this 10 h kinetics in agreement with its recorded expression at 10-12h 
(Ulaeto et al., 1996). However, in the case of vF13F/(pF13)A26-F FLAG-tagged A26 became 
detectable from 6 hpi onwards. Immunoblotting for D8 as well as F13 confirmed equal levels 
of infection for both viruses and the absence of deleterious effects on viral replication. These 
data showed that expression of A26 under the F13L promoter alters both the temporality and 
expression levels of A26 to match those of F13.   
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Figure 4-6. Kinetics of expression of A26 from recombinant viruses expressing FLAG-tagged A26 from 
the F13L or A26L promoters.  
Confluent BSC-40 cell monolayers were synchronized at 4 C orf 1 h and infected with vF13-F/A26-F 
(left) or vF13-F/(pF13)A26-F (right) at an MOI of 5 PFU/cell. Samples were harvested at 1 h intervals 
and frozen. At the end of the time course lysates were prepared, resolved via SDS-PAGE and 
immunoblotted for FLAG and the viral protein D8. (* indicates nonspecific band).  Molecular weight 
sizes are indicated on the left. The identity of the protein bands is shown on the right. Hpi, hour’s post-
infection. Representative data from two replicate experiments.   
  
To determine the effects of intermediate A26 expression on virus spread a plaque assay was performed. 
Monolayers of BSC-40 cells were infected with 50 PFU/well of vF13-F/A26-F or vF13F/(pF13)A26-F 
and their plaque size at 4 dpi was calculated. Surprisingly, vF13-F/(pA26)A26-F consistently showed 
smaller plaques than vF13-F/A26-F and this difference was statistically significant (Figure 4-7). 
Collectively, these data demonstrated that intermediate expression of A26 under control of the F13L 
promoter dramatically reduces plaque size without an apparent impact on viral replication.   
  
  
134  
  
 
  
Figure 4-7. Plaque size analysis for recombinant viruses expressing FLAG-tagged A26 from the F13L 
or A26L promoters. (A) BSC-40 monolayers were infected with either vF13-F/A26-F or vF13-
F/(pF13)A26-F at 50 PFU/well. Monolayers were stained with crystal violet at 4 days post infection 
(dpi) and scanned. Representative images are shown. B) Plaque area from the scanned plates was 
measured using Image J. Data collected from 50 individual plaques are shown in a dot blot. Mean and 
SEM are shown. Statistical significance was determined by using an unpaired Student’s t-test. **** p 
≤ 0.0001. Representative data from two replicate experiments.  
  
  
4.7. Generation of revertant virus expressing FLAG-tagged A26 from its  
natural promoter  
Synchronizing the expression of A26 with that of F13 resulted in a significant reduction of plaque size. 
In order to confirm that the observed phenotype was not caused by a spurious mutation elsewhere within 
the genome, revertant viruses were constructed from the parental vF13F/(pF13)A26-F where the A26 
promoter was reintroduced in its natural location by transient dominant selection. Cells were infected 
with vF13-F/(pF13)A26-F and transfected with plasmid PJH016. Intermediate viruses were isolated and 
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purified for their ability to grow in selective medium and express GFP, and eventually allowed to resolve 
in the absence of selective pressure. Resolved viruses were purified and isolated for further analysis. A 
PCR encompassing the entire A26 allele was performed using primers JH102 and JH103, and the 
amplicons were digested with HpaI to determine the presence of the F13L promoter sequence. Digestion 
with HpaI cleaved the (pF13)A26-F allele in 2 separate products, whereas it had not effect on the A26-
F allele (Figure 4-8). Based on this discrimination several viruses contained HpaI-resistant alleles and 
2 of them, named R6 and R11, were picked for further characterisation. Similarly, 2 viruses that retained 
the (pF13)A26-F allele, named M9 and M14 were also taken forward as controls.   
  
  
 
  
Figure 4-8. Genetic analysis of revertant A26-FLAG viruses.  
Amplicons from plasmid PJH017 containing the (pF13)A26-F allele and PJH016 containing the A26F 
allele as well as purified virus plaques were digested with HpaI and analysed by electrophoresis. 
Successful digestion with HpaI generated fragments which migrated at 405 bp and 300 bp. Molecular 
weight marker is shown on the left.   
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4.8. Restoring late A26 expression from its natural promoter rescues plaque 
size  
Revertant viruses R6, R11 and mutant parental viruses M9 and M14 were selected and expanded for 
characterisation via plaque assay. Infection of BSC-40 monolayers with two revertant viruses generated 
plaques with a larger area than those observed with the parental control viruses (Figure 4-9). Plaque 
size is largely determined by the rate of EEV production, egress and entry of EEV to neighbouring 
uninfected cells. If expression of A26 is enhanced under the F13L promoter, the levels of both A26 and 
F13 gain equivalence. As such, where there is parity in the expression of F13 and A26 both proteins 
compete to form IMV, CEV and EEV respectively. An abundance of IMV at the intermediate times 
post infect infection should result in a reduction in EEV and CEV release as IMV cannot be wrapped. 
This reduction in the levels of CEV and EEV release result in a reduction in plaque size which is 
observed within the mutant viruses M9 and M19. When the levels of A26 expression are restored to 
their wild-type levels at late times post infection plaque size is restored, as observed in revertant viruses 
R6 and R11.  
 
 
 
 
 
 
137  
  
 
  
Figure 4-9. Plaque size analysis of intermediate A26 revertant viruses.  
Confluent BSC-40 monolayers were infected with 30 PFU/well of isolated revertant viruses R6 and R11 
and mutant parental viruses M9 and M14. After 3 days plates were stained and were scanned. Plaque 
area was quantitated using the ImageJ software. Data collected from 15 individual plaques are shown 
in a dot blot. Mean and SEM are shown. Statistical significance was determined by using an unpaired 
Student’s t-test. **** p ≤ 0.0001. Representative data from two replicate experiments.   
 
To confirm that the observed recovery was due to re-establishing A26 expression late during 
infection, the kinetics of expression of vF13-F/(pF13)A26-F and its revertant virus were 
compared (Figure 4-10). As expected protein F13 was detected from 6 hpi onwards in both 
viruses. In the case of vF13-F/(pF13)A26-F protein A26 was also detected at 6 hpi and 
accumulated during the infection. However, in the case of the revertant virus FLAG-tagged 
A26 was barely detectable in the time frame of the study in agreement with previous data 
collected for vF13-F/A26-F. Immunoblotting for D8 as well as F13 confirmed equal levels of 
infection for both viruses.    
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Figure 4-10. Kinetics of expression of FLAG-tagged A26 and F13 from vF13-F/(pF13)A26-F and R6.  
Synchronised confluent BSC-40 monolayers were infected with vF13-F/(pF13)A26-F (mutant virus 
M9) and its revertant virus (R6) at an MOI of 5 PFU/cell.  Samples were harvested at the indicated 
hours post-infection (hpi) and frozen. At the end of the time course lysates were prepared, resolved via 
SDS-PAGE and immunoblotted for FLAG and the viral protein D8 (* indicates non-specific band). 
Molecular weight sizes are indicated on the left. The identity of the protein bands is shown on the right. 
Representative data from two replicate experiments.   
 
Taken together these data indicated that expression of A26 under the F13 promoter significantly 
advanced its expression kinetic, rendering A26 detectable at 5-6 hpi coinciding with F13 
detection. Intermediate A26 expression impacted negatively on virus spread and plaque size, 
parameters that are controlled by F13-mediated wrapping and the production of EEV. Thus, 
these data indicated that A26 can act as a negative regulator of EEV formation.   
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4.9. Interaction between A26 and the IMV membrane protein A27  
Following confirmation that intermediate A26 expression is responsible for diminished plaque 
size, a mechanism was sought by which A26 could negatively regulate EEV formation. A26 is 
anchored to the MV membrane by its interaction with the membrane associated protein A27. 
The A27 protein is comprised of 110 aa with a molecular weight of 14 kDa and possesses 
multiple functions within the morphogenesis cycle. A27 mediates locomotion of MV via the 
host cell microtubule network to the cell periphery and trans-golgi network and facilitates 
wrapping of MV forming IEV. When A27 is deleted viruses are unable to form IEV and exhibit 
severely reduced growth kinetics and plaque size (Rodriguez and Smith, 1990). Whilst A27 is 
required for the formation of enveloped virions, deletion of A27 results in the production of 
A27 negative MV that are localised next to viral factories and are unable to be trafficked to the 
cell periphery for wrapping (Sanderson et al., 2000). In addition, the absence of A27 would 
mean that A26 cannot associate to the MV meaning that IMV would not be produced. During 
a typical infection with wildtype VACV, A27 associates with A17 on the surface of the MV as 
a trimeric or dimeric complex of A27 monomers in the viral factory. These A27 complexes 
then associate with A26 via a disulphide bond forming IMV (Howard et al., 2008). The 
interaction of A27 and A26 has been explored in detail, A26 is stabilized when bound to A27 
and is rapidly degraded when unbound. When A27 is deleted minimal amounts of A26 are 
detected (Howard et al., 2008).  
Due to the essential role of protein A27 in the formation of EEV, both in wrapping and 
locomotion of MV, coupled to the observation that A26 is absent on EEV, we hypothesised 
that intermediate expression of A26 could negatively regulate EEV production. The expression 
of A27 is temporally segregated form that of A26, occurring at approximately 6 hpi and 
coincides with maximal expression of the key EEV morphogenesis proteins F13 and B5 (Ulaeto 
et al., 1996, Englestad et al., 1992, Dallo et al., 1987). Presumably if the kinetics of A26 
expression are synchronized then association with A27 would occur during IEV production, 
hindering the function of A27, thereby causing a decrease in EEV and plaque size.  
To investigate this hypothesis an experiment was devised to assess the ability of viruses 
expressing A26 under an intermediate promoter to form A26/A27 complexes within infected 
cell lysates. It has been shown that A26 associates with dimeric and tetrameric A27 complexes 
during infection, forming complexes that migrate at 78 and 93 kDa, respectively (Howard et 
al., 2008). Therefore, multimerization of A27 is a read-out to assess A26/A27 complex 
formation, giving an indication of the shift in production from the MV, which is negative for 
A26 and positive for A27, to the IMV which is positive for both A26 and A27. To determine 
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the effect of enhancing A26 expression on the formation of these complexes, a panel of viruses 
expressing A26-FLAG under its native promoter sequence (vF13-F/A26-F) or the heterologous 
F13L promoter sequence (vF13F/(pF13)A26-F) were compared in addition to the revertant 
virus vR6. BSC-40 cells were infected synchronously at an MOI of 5 pfu/cell over a 16-hour 
time course. Infected cell lysates were harvested at two-hour intervals, resolved via SDS-PAGE 
under non-reducing conditions and immunoblotted for FLAG and a VACV early protein C6 
(Figure 4-11).  
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Figure 4-11. A26/A27 complex formation in cells infected with recombinant virus expressing A26 from 
intermediate or late promoters.   
Synchronised confluent BSC-40 monolayers in 3.5 cm dishes were infected in a forward kinetic manner 
with 5 PFU/cell of vF13-F/A26-F (A), vF13-F/(pF13)A26-F (B) or  its revertant virus (vR6). (C) The 
infected cells were washed with ice-cold PBS and harvested at 2 h intervals in lysis buffer containing 
50 mM NEM to maintain A26/A27 complexes and prevent disulphide interchange. The cell lysates were 
resolved via SDS-PAGE under non-reducing conditions and immunoblotted for FLAG and VACV early 
protein C6. Representative data from two replicate experiments.   
142  
  
Analysis of infected lysates probed for FLAG revealed that vF13-F/(pF13)A26-F formed 
trimeric 90 kDa  complexes as early as 8 hpi. By comparison the wild type analogue virus 
vF13-F/A26-F and revertant virus vR6 formed A26/A27 complexes at ~10-12 hpi. It should be 
noted that the 90 kDa band migrated as a doublet, indicating that A26 can associate with A27 
dimers and trimers, which was consistent with previous findings (Howard et al., 2008). A26 
associated with A27 dimers appeared to be more abundant than trimeric A27, indicating that 
doublet formation was enhanced in vF13F/(pF13)A26-F. These data revealed that A26 
expressed from the F13 promoter has the capacity to associate with A27 and that if these 
complexes are produced at ~12 hpi late during infection is because A26 is expressed from its 
relatively weak natural promoter. Therefore, weak expression of A26 acts as a mechanism to 
prevent A26/A27 complex formation earlier during infection.  
  
In addition, A26 migrated at its native size of 60 kDa and at 74 kDa. Both monomeric A26 and 
A26/A27 complexes were clearly more abundant than in the wild-type control viruses, 
indicating that complex formation is dependent upon the levels of free A26. The enhanced 
levels of monomeric A26 when compared to the wild-type control viruses is notable 
considering that others have shown that within the cellular environment excess A26 is degraded 
(Howard et al., 2008). Indeed, monomeric A26 was barely detectable in vF13-F/A26-F and 
vR6 infected lysates. These data indicate that enhanced expression of A26 leads to increased 
A26/A27 complex formation, although in these experiments A27 was detected indirectly.   
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4.10. A26/A27 complex formation is advanced in recombinant virus 
expressing A26 from the F13L promoter  
To fully establish the effect of A26 expression on A26/A27 complex formation, an additional 
experiment was performed where infected lysates were immunoblotted for A27 using specific 
serum obtained from Dr David Ulaeto (DSTL). In this experiment confluent monolayers of 
BSC-40 cells were infected as above and the time course analysis was extended to 24 h. The 
cell lysates were processed and immunoblotted against FLAG (A26 and F13) and A27 (Figure 
4-12). Because the FLAG antibody was raised in rabbits and the A27 serum was raised in mice, 
proteins could be visualized using near-infrared secondary antibodies specific for each species 
and tagged dyes emitting at 700 and 800 nm. By overlapping these images, the potential co-
localisation of A26 and A27 in a complex could be demonstrated.   
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Upon infection with vF13-F/A26-F and vR6 a 90 kDa band could be detected at 24 hpi. This 
band consisted of an A26/A27 complex because it coloured yellow upon merging the red 
(FLAG, A26) with the green (A27) channels (Figure 4-12 , top panels A-C). In agreement with 
previous observations, vF13-F/(pF13)A26-F expressed A26 much earlier at 6-8 hpi and this 
was detected both as a monomer at 60 kDa and as a multimeric form at 74 and 90 kDa. 
Remarkably, all those multimeric forms were revealed to be A26/A27 complexes by image 
merging. Therefore, A26 complexed with A27 as soon as both proteins were expressed at 6 hpi 
and these complexes remained stable throughout the infection. Importantly, the intensity of the 
A26/A27 complex observed at 6-8 hpi during vF13-F/(pF13)A26-F infection mimicked that 
observed at 24 hpi during vF13-F/A26-F and vR6 infections, thus confirming that A26 can 
exert its function at different times pi and this is determined by its expression level.   
    
Immunoblotting for F13 and A27 revealed equal levels of infection for all viruses.  
Interestingly, A27 was detected as a monomer, dimer and trimer in all three infections   
(Figure 4-12 D,F). This indicated that despite the enhanced expression of A26, not all the A27 
molecules complexed with it. Therefore, only a selected pool of A27 molecules associate with 
A26. Probing A26-FLAG and A27 on the same membrane revealed co-migratory bands with 
sizes consistent with A26/A27 complexes. Significantly, when A26 expression enhanced under 
the F13 promoter A26/A27 dimers and trimers were observed as early as 6 hours post infection. 
This observation indicates that A26 competes for free A27 multimers in a concentration 
dependant manner. In contrast, equivalent levels of the A26/A27 complex were not reached in 
the wild-type control viruses: vF13F/A26-F and vR6 until 24h post infection. Indicating that 
under normal circumstances, weak expression of A26 is sufficient to prevent A26-A27 
interaction until late times as the concentration of A27 at early times is not limited. Within the 
same blot the levels of Uncomplexed A27 and F13 were observed (Figure 4-15 D,E,F), at sizes 
consistent with A27 monomers, dimers and trimers.  
  
To gain further insight into the relationship between enhanced A26 expression and its effect on 
A27 the quantitative properties of NIR western blot was exploited. The total signal of each 
protein (A26, A27 and F13) was plotted generating signal curves representative of the kinetic 
profile of each protein in the viruses tested (Figure 4-13).   
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Figure 4-13. Kinetic plot of F13, A26 and A27 expression.  
 Total signal intensity (AU) of F13 (A), A26 (B) and A27 (C) was obtained from a NIR western blot of 
infected cell lysates using image studio software (licor Biosciences) and plotted at indicated times.  
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The data showed that F13 expression across all viruses tested remained constant over time. In 
contrast, the expression of A26 was dramatically enhanced when expressed under the 
intermediate F13 promoter sequence, whereas it remained significantly lower in the wild-type 
control viruses. Interestingly the total amount of A27 (Uncomplexed and complex bands) 
appeared to increase in proportion to the A26 in vF13-F/(pF13)A26-F, in comparison to both 
wild-type controls.  A hypothetical explanation for this increase could be because A27 is 
stabilized in the presence of A26. Additionally, in conditions were A26 expression is at wild-
type levels (vF13-V5/A26-F) available A27 is not complexed with A26 but incorporated into 
with CEV bound to cellular membranes. As the lysates used in the blot were clarified by high 
speed centrifugation it is plausible that the majority of these CEVs were pelleted with cellular 
membranes. Therefore the proportion of soluble A27 within the vF13-F/A26-F lysate is 
decreased when compared to vF13-F/(pF13)A26-F as some is retained on CEV associated with 
cellular membranes. 
  
To further assess the effect of advanced A26 expression on the formation of A26/A27 
complexes, the total signal of complexed A27 was compared to the total signal of uncomplexed 
A27 for each virus. The signal of uncomplexed and complexed A27 for each time point was 
normalised to that of F13 and plotted (Figure 4-14).  F13 remained constant across all 3 
infections so it served as an internal control for normalisation.   
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Figure 4-14. Kinetic analysis of A27 complex formation.  
Total complexed A27 (A) or total uncomplexed A27 (B) IR western blot signal per time point was 
normalized to F13 signal at each timepoint and plotted.   
  
  
The data showed that when A26 expression is synchronized with F13, the rate of A26/A27 
complex formation was dramatically enhanced (Figure 4-14A). This increase in complexed 
A27 signal was concomitant to a decrease in uncomplexed A27. In contrast, levels of 
uncomplexed A27 increased over time when expression of A26 occurred from its late promoter 
during infection with vF13-F/A26-F and the revertant virus (Figure 4-14B). These data 
indicated that the formation of A26/A27 complexes is dependent upon elevated levels of A26, 
indicating the transition of MV to IMV can be instigated by altering the expression levels of 
A26. Association between A26 and A27 prevents A27 function in wrapping MV and hence 
formation of IEV, thus offering a potential mechanism for A26 mediated plaque size inhibition.  
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4.11. Summary  
In summary, this chapter presents the successful construction of F13-FLAG tagged viruses. 
The phenotypes of these recombinant viruses recapitulate those of F13mCherry. Importantly, 
the inclusion of a C-terminal FLAG epitope is far less deleterious than mCherry. Allowing 
meaningful comparisons to be drawn. In addition, these data demonstrate the effect of altering 
the temporal kinetics of A26. Expression of A26 under the F13L promoter sequence profoundly 
altered the expression kinetic of the protein, expression of A26 in vF13F/(pF13)A26-F was 
first observed at 5-6 hours post infection. By comparison, when under its native promoter 
sequence A26 expression is barely detectable at 9-10 hours post infection. This substantially 
altered expression kinetic coincided with a significant reduction in plaque size, indicating that 
intermediate A26 expression could affect EEV production. This small plaque phenotype was 
rescued by incorporation of an A26-FLAG allele expressed under its native promoter sequence 
restoring late A26 expression.   
In addition to its effect on plaque size, the interaction of A26 with A27 was also investigated. 
When A26 is expressed under the F13L promoter it significantly enhanced formation of 
A26/A27 complexes, forming at 8 hpi in vF13-F/(pF13)A26-F, whereas in the wildtype and 
revertant viruses vF13-F/A26-F and vR6 complex formation was only observed at 10-12 hpi. 
When the experiment was repeated with an extended timecourse, A26/A27 complex formation 
was observed as early as 4 hpi in vF13-F/(pF13)A26-F. This level of complex formation was 
only matched by vF13-F/A26-F and vR6 at 16-24 hpi.   
When the levels of A27 were quantitated it was observed that the proportion of A26/A27 
complexes increases relative to A26. Furthermore, levels of uncomplexed A27 decrease when 
A26 is expressed under the intermediate F13L promoter sequence.  These data indicate that in 
normal conditions A26 is limited, and temporally segregated from A27 which is abundant from 
6 hpi onwards. Expression of A26 at various timepoints; 4 hpi in the mutant virus 
vF13F/(pF13)A26-F and at 16-24h in vF13-F/A26-F and vR6 is sufficient to form complexes 
with A27.    
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5 A mechanism for A26 regulation of EEV production  
5.1. Generation of recombinant virus expressing V5-tagged F13 and 
FLAG-tagged A26 from intermediate and late promoters  
The data presented in previous chapters reveals the effect of altering the promoter sequence of 
A26 on its expression kinetics and plaque size and its interaction with the virion protein A27. 
Intermediate expression of A26 was shown to inhibit plaque size, a phenotype that was 
reversible upon restoring A26 late expression. In addition, temporally advanced expression of 
A26 significantly enhanced the rate of A26/A27 complex formation in infected cell lysates and 
resulted in a progressive reduction of uncomplexed A27. Collectively, these data indicated that 
A26 is a potential negative regulator of VACV spread, a feature that is mediated by EEV 
formation, and provided a plausible mechanism for this suppression. A hypothesis deriving 
from these data is that if A27 is complexed with A26, the functions of A27 regarding wrapping 
of MV are inhibited. This hypothesis is strengthened by the observation that A26 is exclusive 
to IMV, not IEV or EEV, and that its incorporation on to the MV membrane is dependent upon 
A27 (Howard et al., 2008). To further support the hypothesis that altering the temporal 
regulation of F13 and A26 can alter not only the resulting phenotype of virus but alter the 
sequence of protein/protein interactions during viral morphogenesis, a full suite of promoter 
swapped viruses needed to be produced. This necessitated production of a wildtype control 
virus where F13 and A26 are expressed under their native promoters. In addition, single 
promoter swapped viruses where constructed where the expression kinetics of F13 or A26 was 
altered independently. Finally, a double promoter swapped virus was produced where the 
promoters sequences controlling F13 and A26 were exchanged.    
  
Initially, following from the generation of a recombinant expressing intermediate A26 under 
the control of the F13L promoter in a virus expressing FLAG-tagged F13 (aka 
vF13F/(pF13)A26-F), attempts were made to complement v(pA26)F13-F with FLAG-tagged 
A26 under control of its cognate promoter or that of the F13L gene (allele (pF13)A26-FLAG). 
These attempts were unsuccessful, and it was thought that the use of the FLAG-tagged F13 (an 
allele suboptimal for plaque formation) together with the delayed expression kinetic of F13 
expressed under the A26 promoter made isolation of recombinant virus unlikely. A final 
attempt was then made to generate a full panel of recombinant viruses by substituting the 
3XFLAG epitope tag on the C terminus of F13 by a single copy of the V5. The following panel 
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of recombinant viruses were constructed using transient dominant selection methods described 
previously (Table 5-1).   
  
Designation  Expression kinetic   
vF13-V5/A26-F  Wild-type control  
vF13-V5/(pF13)A26-F  Single swap (Intermediate A26 expression)  
v(pA26)F13-V5/A26-F  Single swap (Late F13 expression)  
v(pA26)F13- 
V5/(pF13)A26-F  
Double swap (late F13 expression / Intermediate A26  
expression)  
  
Table 5-1. Recombinant promoter swap viruses  
  
Plasmids PJH016 or PJH017 constructed previously (section  2.4.4) were used to transfect 
HEK-293T cells infected with vF13-V5 or v(pA26)F13-V5. Resolved viruses were picked and 
subjected to three rounds of plaque purification before expansion and genetic analysis. Isolated 
recombinant viruses were expanded on confluent BSC-40 monolayers and the viral DNA was 
extracted using a QIAGEN mini kit. The resulting viral DNA was PCR amplified using primers 
specific to the F13 (JH0100/JH0101) and A26 (JH0102/JH0103) loci.  
  
In order to detect the presence of the F13 promoter sequence the unique restriction enzyme site 
HpaI (present within the natural F13L promoter sequence) and BspEI within the F13L coding 
sequence were exploited. To differentiate the A26 amplicons, fragments were digested with 
either HpaI or NotI within the FLAG tag. Digestion of the F13-V5 amplicon with BspEI and 
HpaI will result in three fragments of 103, 631 and 803 bp in size (Figure 5-1A) indicating the 
presence of the F13L promoter sequence. In contrast digestion of the (pA26)F13-V5 amplicon 
will result in the production of two co-migratory fragments 803 bp in size (Figure 5-1B). To 
differentiate A26-FLAG alleles amplicons will be digested with NotI (exclusive to the nFLAG-
A26 loci) and HpaI to screen for the presence of the F13 promoter sequence. Digestion of A26-
F amplicons with NotI or HpaI independently will produce fragments of 400 and 460 bp in size 
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(Figure 5-1 C,D). However, (pA26)A26-F will be resistant to HpaI digestion due to the absence 
of the F13L promoter. Digestion of an (pA26)A26-F amplicon will yield fragments of 400 and 
460 bp in size.    
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Figure 5-1. Schematic of restriction digest analysis of F13 and A26 loci.   
PCR amplification of F13L with primer pair JH0101/JH0102 generates a 1.6kb fragment (A,B) and A26 
loci with primer pair JH0102/JH0103 generates a 860 bp fragment (C,D). The fragment sizes produced 
by HpaI/BspEI (A,B) and NotI or HpaI digestion are indicated (C,D).    
  
Restriction digestion of isolated recombinant viruses indicated successful production of promoter 
swapped viruses (Figure 5-2).    
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Figure 5-2. Restriction digest analysis of recombinant V5 viruses.   
A26 amplicons generated from control plasmids PHJH016 (A26-F) , PJH017  (pF13)A26-F) were 
digested with NotI or HpaI yielding 400 and 460 bp fragments. F13 amplicons generated from control 
plasmids PJH018 (F13-V5) and PJH019 (pA26)F13-V5 were digested with BspEI and HpaI, yielding 
either 803 bp fragments corresponding to  (pA26)F13-V5 or 803, 631 and 160 bp fragments 
corresponding to F13-V5 .  
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5.2. Characterisation of recombinant virus expressing V5-tagged F13 
and FLAG-tagged A26 from intermediate and late promoters  
Following the successful generation of the complete set of promoters swapped viruses produced in an 
F13-V5 background, these viruses were characterised to assess the effect of altering the temporal 
expression kinetics of F13 and A26. First, the ability of the viruses to form plaques was compared using 
a standard plaque assay (Figure 5-3A). When the plaque area of each virus was quantified the data 
revealed a sequential plaque size reduction when the kinetics of F13 and A26 are modified (Figure 5-
3B). The plaque size defect as a result of delayed F13 expression under the A26 late promoter 
v(pA26)F13-V5/A26-F was equivalent to that observed when A26 was expressed by the intermediate 
F13L promoter in vF13-V5/(pF13)A26-F. Moreover, when the negative effects of intermediate 
expression of A26 and late expression of F13 were combined in the double-swapped virus v(pA26)F13-
V5/(pF13)A26-F, a further plaque size defect was observed and this was statistically significant when 
compared to any of the single-swapped viruses. These data recapitulated the phenotypes observed in 
the F13-FLAG virus set. In addition, they confirmed the initial prediction that modifying the regulatory 
sequences of A26 or F13L either in isolation or sequentially leads to a significant plaque size defect.    
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Figure 5-3. Plaque size analysis of promoter swapped viruses.   
Confluent BSC-40 monolayers were infected with indicated viruses at 50 pfu/well and overlain with 
semisolid overlay. After 3 dpi monolayers were stained with crystal violet and scanned (A) and plaque 
area was calculated using imageJ software and plotted (n =15) (B). Significance from One way 
ANOVA: vF13-V5/A26-F vs other viruses P= ≤0.0001, v(pA26)F13-V5/(pF13)A26-F vs 
vF13V5/(pF13)A26-F and  v(pA26)F13-V5/A26-F P=≤0.0001. Representative data from two replicate 
experiments.   
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To confirm that the cause of plaque size reduction was due to altered expression kinetics, the 
expression profiles of A26 and F13 in all these 4 viruses were assessed by western blotting. A 
forward kinetic infection in BSC-40 cell monolayers was performed for each virus at an MOI 
of 5 PFU/cell. Infected lysates were processed and resolved via SDS-PAGE under reducing 
conditions and immunoblotted for V5 (F13), FLAG (A26) and the early viral protein C6 (Figure 
5-4).   
 
  
Figure 5-4. Analysis of the kinetics of expression of F13 and A26 in promoter swapped viruses.  
BSC-40 cell monolayers were synchronously infected at a moi of 5 pfu/cell, cells were prechilled to 4˚c 
for 1 hour before adding virus inoculum. Infected cells were incubated at 4˚c for 1 hour, after which 
monolayers were transferred to 37c initiate virus entry. Infected cells were collected at indicated time 
points and solubilized in lysis buffer, proteins were resolved via SDS-PAGE under reducing conditions 
and immunoblotted for FLAG, V5 and VACV protein C6. Representative data from two replicate 
experiments.   
  
The expression kinetic profiles of these V5 viruses recapitulated that of vF1F-F/A26-F and 
vF13-F/(pF13)A26-F. Within the wild-type control virus vF1F-V5/A26-F expression of A26 
was observed at 10-12 hpi, and F13 was first expressed at 6 hpi (Figure 5-4A). When expression 
of A26 was advanced (Figure 5-4B) initial expression was observed at 6 hpi, matching that of 
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F13. A similar pattern of A26 expression was observed in v(pA26)F13V5/(pF13)A26-F, where 
expression was first observed at 6 hpi. Interestingly, despite being expressed under the A26 
promoter sequence, the expression kinetic of F13 in v(pA26)F13V5/A26-F and v(pA26)F13-
V5/(pF13)A26-F remained unchanged in comparison to the wildtype control virus (Figure 5-
4C and Figure 5-4D).  Whilst the temporality of F13 expression between the (pA26)F13V5 
viruses was not significantly different, there was a visible reduction in the quantity of F13 
expressed. To quantify this reduction, the signal recorded for A26 (FLAG), F13 (V5) and C6 
at each time point for each virus was plotted (Figure 5-5). As expected the data showed a 
dramatic increase in A26 signal when expressed under the F13L promoter, whereas for F13 the 
data evidenced a ~2-fold reduction in the level of F13 signal when expressed under the A26 
promoter sequence. To be more precise about this quantitation, the levels of F13 signal for each 
virus were normalised to their corresponding levels of C6 (Figure 5-5B). This revealed a nearly 
4-fold reduction in relative F13 intensity when F13 was expressed from the A26L promoter.   
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Figure 5-5. Quantitation of F13, A26 and C6 in promoter swapped viruses.  
(A) Signal intensity from NIR western blot bands of viral proteins A26, F13 and C6 were quantitated 
using imagestudio software (Licor Biosciences) and plotted at indicated times. (B) Signal intensity data 
of F13 at each time point was normalized to C6 at each time-point and plotted to show relative F13 
expression over time for each indicated virus.  
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Collectively, these data recapitulated previous characterisation data obtained for recombinant 
virus where the kinetics of A26 expression was dramatically altered when expressed under the 
F13L promoter, but the temporality of F13 expression under the late A26 promoter remained 
largely unchanged. A potential explanation for this could be that transcription of F13L is only 
partly dependent on the cognate promoter sequence. Analysis of the poxviral transcriptome 
indicates that there is a significant level of run-through transcription from the neighbouring 
upstream gene F14 (Assarsson et al., 2008). This phenomenon is unlikely to be due to 
differential rates of mRNA decay, this is due the activity of virally encoded decapping enzymes 
D9 and D10 which act to actively degrade both host and viral mRNA (Liu et al., 2015; Parrish 
and Moss, 2006, 2007). Moreover, it is unlikely that there is a translational advantage attributed 
to F13 mRNA as both A26 and F13 contain the TAAAT motif that generates a polyA tract of 
the 5’ of newly synthesized mRNA (Dhungel et al., 2017). This polyadenylation, in addition to 
viral modification of host ribosomes ensures preferential translation of both intermediate and 
late transcripts (Jha et al., 2017).  
  
5.4. Advanced A26 expression does not affect viral replication  
To investigate the effect of the altered temporal kinetics of F13 and A26 on viral replication, 
the promoter swapped viruses were compared in a single-step growth curve. In a one-step 
growth curve cells are infected synchronously with a high MOI between 5-10 PFU/cell. When 
cells are infected in this way the viral replicative cycle is initiated synchronously and is 
independent from the virus’s ability to spread. The infected cell samples are then harvested at 
different timepoints pi, reflecting the different steps of viral replication; absorption, eclipse and 
release. These stages encompass the stages of the VACV replicative cycle, entry, DNA 
replication, virion assembly and release. If the number of viral particles released at 24h (the 
end-point of the VACV lifecycle) are similar, this implies that there is no impediment to viral 
replication or that toxicity associated with enhanced expression of A26 could be the cause of 
the observed plaque size reduction. The effects associated with altered A26 and F13 expression 
were so far associated with virus wrapping and spread rather than a defect viral DNA 
replication or aberrant cellular expression. Therefore, the viruses were not expected to be 
significantly different in a typical one-step growth curve. To address these concerns, cells were 
infected in triplicate at an MOI of 5 PFU/cell and incubated for 24 h. After this time, 
supernatants were harvested and clarified via centrifugation (Figure 5-6)   
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Figure 5-6. Cell associated virus and EEV release of V5 promoter swapped viruses at 24 hpi. BSC-40 
monolayers were infected with promoter swapped viruses (A,B,C,D) at an moi of 5 pfu/cell,  at indicated 
time points culture supernatants  (striped bars) or cell associated virus fractions (solid bars) were titrated 
in triplicate.   
  
The data indicates that there was no difference in cell associated virus (IMV and CEV) or  EEV 
release at 24 hours post infection across all viruses tested at a high MOI. This experiment 
addresses initial concern that increased A26 expression would be toxic to cells, limiting viral 
replication. No reduction in EEV release was observed in viruses where F13 is expressed at 
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intermediate time points, indicating that the reduced plaque size phenotype is not associated 
with A26 induced toxicity. 
  
5.5. Advanced A26 expression reduces EEV formation  
To determine if the plaque size reduction is due to a change in EEV release a multistep growth curve 
was performed. In this assay cells are infected at a low multiplicity of infection of 0.001 PFU/cell, as 
such the infection is not synchronous, and the amount of virus released reflects successive rounds of 
replication from infected cells. In this experiment the amount of EEV released into culture supernatants 
is dependent on the ability of each virus to spread. If enhanced A26 expression reduces EEV formation 
and release it would explain the observed reduction in plaque size. 
 
To investigate the effect of altered temporal kinetics of F13 and A26 on EEV production, the promoter 
swapped viruses were compared in a multistep growth curve (Figure 5-7).  Cells were infected at an 
MOI of 0.001 PFU/cell for 90 minutes. Following infection, monolayers were washed three times with 
DMEM and incubated for 24, 48 and 72hpi. At each timepoint culture supernatants were collected, 
clarified via centrifugation and titrated via plaque assay to quantitate EEV (Figure 5-7A). Cell fractions 
of each timepoint were collected, subjected to three freeze thaw cycles and cell associated virions were 
quantified by plaque assay (Figure 5-7B)   
 
Figure 5-7. Multistep growth curve of recombinant promoter swapped viruses.  
BSC-40 cell monolayers were infected with indicated viruses at an MOI of 0.01 pfu/cell for 90 minutes. 
Upon completion of infection monolayers were washed three times with DMEM and incubated for 
indicated times.  Aliquots of infected culture supernatants were collected and clarified via centrifugation 
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and titrated in triplicate for extracellular virus (A). Cell associated fractions were collected and subjected 
to three cycles of freeze thaw and titrated in triplicate for cell associated virus (B).  
Across the 72 h infection the levels of cell-associated virus for all 4 viruses were nearly 
identical. The levels of EEV in the supernatant, however, appeared to be reduced when A26 
was expressed from an intermediate promoter in vF13-F/(pF13)A26-F and 
v(pA26)F13V5/(pF13)A26-F (blue and red viruses, respectively). This decrease was observed 
at 24 hpi and 48 hpi. In the case of vF13-F/(pF13)A26-F this decrease was quantitated in half 
a log when compared to vF13-F/A26-F. In the case of the double-swapped virus v(pA26)F13-
V5/(pF13)A26-F, EEV production was reduced by 0.8 log at 24 and 48 hpi when compared to 
the wild-type virus vF13-F/A26-F. Surprisingly when F13 expression was delayed in 
v(pA26)F13-V5/A26-F there was no difference in EEV titre when compared to the wild-type 
control, even though this virus had shown a 4-fold decrease in F13 expression and reduced 
plaque size.  This could be due to the fact that there were more v(pA26)F13-V5/A26-F virions 
at the start of the experiment (Figure 5-7A) when compared to the other controls. 
  
To be more precise and to account for the small differences in titre observed for each virus at 
0 hpi, the EEV titre at 48 hpi was normalized to the average titre at 0 hpi and plotted (Figure 
5-8). Despite the subtle differences the total yield of EEV in the two mutant viruses (vF13-
F/(pF13)A26-F and v(pA26)F13-V5/(pF13)A26-F) was significantly decreased at 48 hpi. Even 
though the differences between the viruses tested were no greater than one log, the reduction 
of EEV release was sufficient to contribute to a reduced plaque size phenotype (Figure 5-4). 
This minor reduction is primarily attributed to the properties of the WR strain, where the 
majority of EEV that are produced become CEV and are retained on the cell surface and do not 
contribute to extracellular spread. As a result, within the WR strain (the background strain for 
the recombinant viruses produced in this work) plaque size is more representative of EEV 
production than EEV titre.  
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Figure 5-8. EEV yield of V5 promoter swapped viruses at 48 hpi.  
 Total EEV from supernatant harvested at 48 hpi was titrated and normalized to EEV titre at 0 hpi.  
Significance from unpaired t test.** p≥0.01.  
  
5.6. A26 associates with A27 in virions at intermediate times post infection 
Collectively, data demonstrated that when the temporal kinetics of expression of A26 was 
advanced, there was a significant  reduction in plaque size that correlated with a decrease in 
EEV titres and a prominent association with A27 in infected lysates. These data alluded to a 
potential mechanism by which intermediate A26 expression could act to negatively regulate 
IEV formation. If A26 is expressed from the F13L promoter, its intermediate expression would 
lead to the premature formation of A27/A26 complexes. This premature association would 
either prevent the function of A27 in the IEV morphogenesis pathway or associate with MV 
membranes via A27 to occlude EEV membranes. This would result in A26 being incorporated 
into virions at intermediate time points, thereby retaining virions in their IMV form and acting 
as a negative regulator of EEV formation. To test this hypothesis cells were infected with vF13-
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V5/A26-F (abbreviated WT) or the mutant virus vF13-V5/(pF13)A26-F where A26 expression 
is advanced (abbreviated Mut) at an MOI of 5 PFU/cell. Cell cultures were collected at 10 and 
24 hpi, and virions were extracted and enriched via ultracentrifugation on a 36 % sucrose 
cushion. The resulting virions were resolved via SDSPAGE under reducing or non-reducing 
conditions and immunoblotted for FLAG (A26), V5 (F13) and A27 (Figure 5-9)   
  
Analysis of the reduced blots (Figure 5-9A) revealed that virions produced upon WT virus 
infection had barely any detectable A26 at 10 hpi. In agreement with its late expression, A26 
was detectable in the virions collected at 24 hpi. Remarkably, in the case of the mutant virus 
where A26 expression was advanced, a substantial amount of A26 was detected on virions at 
10 hpi and this was comparable to the levels observed for the WT virus at 24 hpi.   
  
 
  
Figure 5-9: Enhanced A26/A27 incorporation on virions.   
BSC-40 cell monolayers were infected with vF13-V5/A26-F (WT) or vF13-V5/(pF13)A26-F (Mut) at 
an MOI of 5 pfu/cell, infected cultures were harvested at 10 and 24 hours post infection and virions 
were extracted and enriched via ultracentrifugation on a 36% sucrose cushion. Enriched virions were 
solubilized in 4xLDS buffer with (+2ME) or without (-2ME) reducing agent. Samples were resolved 
via SDS-PAGE immunoblotted. A) western blot of WT and Mut viruses at 10 and 24 hpi probed for 
FLAG, V5 and A27. B) NIR western blot of WT and Mut virions at 10 and 24 hpi under non-reducing 
conditions and probed for FLAG, V5 and A26.   
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 These data was reminiscent of previous observations in infected lysates, demonstrating that 
A26/A27 complex formation at 6 hpi with vF13-F/(pA26)A26-F mimics what occurs at 24 hpi 
with WT virus. After 24 hours the mutant virus virions had also substantially more A26 than 
the wild-type. When the levels of F13 were assessed, significant levels of F13 were observed 
at 10 hpi upon WT infection, indicating that at this time point a large proportion of virions 
undergo F13-mediated wrapping to become EEV. Concomitant to an elevated incorporation of 
A26, a decrease in virion-associated F13 was observed upon infection with the mutant virus 
vF13-V5/(pF13)A26-F. This demonstrated that A26 impaired F13 incorporation into virions 
and therefore their trafficking towards the EEV pathway. Importantly, when A27 was assessed, 
comparable levels were detected between the two viruses at 10 and 24 hpi, although these were 
elevated at 24 hpi due to a larger production of virions.   
  
Analysis of the blots under non-reducing conditions (Figure 5-9B) revealed only a very faint 
band corresponding to A26/A27 complexes at 10 hpi upon WT infection. This was in 
accordance with the minimal levels of A26 observed for this virus at this time point and 
confirmed that at 10 hpi the level of A26+ve IMV is residual. Interestingly, in these conditions 
a prominent band of A27 trimers was detected. Conversely, infection with the mutant virus 
presented a substantial increase in A26/A27 complexes that correlated with a decrease in A27 
trimers. This demonstrated that A26 syphoned A27 molecules into the large 90 kDa complex. 
Remarkably, A26/A27 complex formation at 10 hpi during infection with the mutant virus was 
equivalent to that observed at 24 hpi with the WT virus. These observations support the notion 
that A26 can associate with A27 multimers at various times pi and that this association 
coincides with an increased production of IMV. This indicates that A26 can strongly compete 
to bind A27 in a concentration dependant manner and that this association that was first 
observed in cellular lysates is reflective A26/A27 incorporation on virions. Moreover, subtle 
differences are observed in the amounts of F13 incorporated into virions. When the WT virus 
appeared to have higher levels of F13 when compared to the mutant at 10 hpi (Figure 5-10A), 
this band is of a similar level observed in both viruses at 24 hpi. This decrease appeared despite 
equivalent levels of A27 within these samples. 
 
 A biochemical explanation for this reduction could be that excess A26 restricts the trafficking 
of virions to the TGN where wrapping occurs. If less virions become wrapped, then there will 
be a decrease in the levels of CEV associated with the membranes of infected cells when 
compared to the wild-type control virus. Due to the design of this experiment, both IMV and 
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CEV that are associated with cellular membranes are enriched in the virion pellet after 
centrifugation. Subsequently the levels of F13 in each sample reflect the abundance of CEV 
retained on cellular membranes. The reduced level of F13 at 10h in the mutant virus when 
compared to the wildtype indicates that A27 complexes on MV preferentially associate with 
free A26 before they can be trafficked to the cell periphery for wrapping and deposition on the 
cellular membrane as CEV, resulting in a reduction in the levels of F13 observed at the 10 and 
24h timepoints. 
  
These data provide a mechanism by which intermediate A26 expression negatively regulates 
EEV. When A26 is expressed under an intermediate promoter it is incorporated on to virions 
via association with A27. In addition, reduced levels of F13 were detected at 10 hpi when 
compared to the wild-type. This reduction correlated with the observed decrease in EEV release 
and plaque size. Taken together, this demonstrated that A26 has the capacity to downregulate 
EEV production and that temporal control of its expression is a viral mechanism to regulate its 
function.   
  
5.7. Summary  
The results presented in this chapter provide a mechanism for the apparent negative regulation 
of EEV by intermediate A26 expression. Firstly, this chapter presented the production of a full 
suite of promoter swapped viruses: vF13-V5/A26-F, vF13V5/(pF13)A26-F, v(pA26)F13-
V5/A26-F and v(pA26)F13-V5/(pF13)A26-F. These viruses were generated by rescuing of the 
parental virus v∆F13 with F13-V5 alleles expressed under the F13L or A26L promoter 
sequences. Inclusion of the V5 tag appeared to be optimal, as no discernible plaque size 
reduction was observed when vF13-V5 was compared to WR. This optimization facilitated the 
production of recombinant viruses where expression of F13 was delayed under the A26 
promoter sequence where isolation of F13FLAG tagged viruses had previously failed.    
Construction of these viruses allowed the effect of delayed F13 expression to be observed. 
When the plaque size of these viruses was compared a unique pattern of plaque size reduction 
was observed. The wild-type control virus (vF13-V5/A26-F) demonstrated the largest plaque 
size and a significant decrease was observed when F13L was delayed  
(v(pA26)F13-V5/A26-F) and when A26 expression was enhanced vF13-V5/(pF13)A26-F. The 
extent of reduction between these two viruses was highly similar, both mutations appeared 
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produce independent phenotypes. This is exemplified by the further plaque size reduction when 
the promoter sequences of F13L and A26L are exchanged in v(pA26)F13V5/(pF13)A26-F.   
  
The associated expression kinetics of F13 and A26 of these viruses was also investigated. 
Expression of A26 under the intermediate F13 promoter in viruses; vF13-V5/(pF13)A26-F and 
v(pA26)F13-V5/(pF13)A26-F  was significantly enhanced, occurring at 6 hpi mimicking the 
kinetics of wild-type F13 expression. Interestingly, analysis of these viruses revealed that 
expression of F13 under the A26 promoter did not appear to alter its temporality, however a 
substantial reduction in F13L expression was observed when these blots were quantitated.  
  
The growth kinetics of these viruses was also explored, when the V5 promoter swapped viruses 
were first compared in a one-step growth curve. IMV titres at 24 hpi were identical across all 
viruses tested, demonstrating that intermediate expression of A26 did not result in aberrant viral 
replication. In addition viruses were compared in multistep growth curve a small reduction of 
EEV was observed at both 24 and 48hpi in vF13-V5/(pF13)A26-F and v(pA26)F13-
V5/(pF13)A26-F. The reduction in tire was most extensive in v(pA26)F13V5/(pF13)A26-F 
where it was reduced by 0.8 log when compared to WR.   
  
The final experiment of this thesis builds upon the notion that intermediate A26 expression 
leads to enhanced A26/A27 complex formation and therefore is indicative of IMV production. 
Isolation of virions from vF13-V5/A26-F and vF13-V5/(pF13)A26-F infections demonstrated 
that when A26 expression is enhanced the levels of A26/A27 complex on virions increases. 
Remarkably the levels of A26/A27 complex formation after 24hpi in the wildtype were 
matched by the mutant virus at 10 hpi. In contrast levels of A26/A27 in the wild-type virus at 
10 hpi were barely detectable. These data provide clear evidence that Intermediate A26 
expression can associate with A27 on virions, providing a biological mechanism underpinning 
the positive regulation of IMV at intermediate time points.   
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6 Discussion  
6.1 A strategy to determine phenotypic changes imposed by the architecture 
of the VACV genome  
This chapter explored the concept of delaying the expression kinetic of the F13L gene by the 
substitution of its natural promoter for that of the late A26L gene to test the feasibility of 
altering promoter sequences of key morphogenesis proteins. The F13L gene was selected for 
this first study because of its non-redundant function within the EEV morphogenesis pathway 
(Blasco and Moss, 1991). As a result, any alteration of F13 function and by extension EEV 
formation could be quantified by analysing plaque size, which within the WR background of 
VACV is sufficient to provide meaningful comparisons for EEV release (Borrego et al., 1999). 
The initial experimental strategy complemented the ∆F13 parental strain with functional F13L 
alleles under the control of the native F13L promoter or the heterologous A26L promoter. The 
strategy used to generate these viruses is centred upon the dominant positive selection pressure 
of introducing a functional F13L cassette into a ∆F13 virus. A similar strategy to introduce 
mutations into the virus by “piggybacking” the F13L gene has been proposed by others 
previously (Sanchez-Puig and Blasco, 2005). In addition, the F13L alleles were C-terminally 
fused to mCherry-FLAG tags. The initial rational for including the mCherry fluorophore was 
to generate a set of viruses (vF13mCF and v(pA26)F13mCF) that could then be modified to 
express fluorescent A26 alleles, effectively marking the EEV and IMV form. This was aimed 
at facilitating fluorescent microscopy studies. However, due to the unexpected deleterious 
effect of mCherry tagging the F13L gene, these approaches were not pursued.  
  
The fusion of the mCherry fluorophore to F13 was significantly detrimental to the ability of the 
virus to form EEV. The plaque size of vF13mCF was significantly reduced in comparison to 
the wild-type WR virus. These data recapitulated findings from others who identified that the 
inclusion of the mCherry fluorophore to the C terminus of F13L resulted in a failure of EEVs 
to be wrapped. During infection of F13mCherry viruses large membranous bubbles were 
observed enclosing multiple virions and cytoplasmic material (Carpentier et al., 2017).   This 
is reasonable due to the significant size of the mCherry tag which may sterically hinder the 
function of F13 and its association with other membrane proteins. This is could be attributed 
to the topology of F13 within the IEV membrane as both the N and C terminal domains of F13 
are orientated towards the cytoplasmic side of the IEV membrane facing the virion and are near 
170  
  
one another (Husain et al., 2003). The addition of such a large tag could sterically interfere with 
the associated functions of the N and C-terminus of F13. Contrary to the collective body of 
evidence implying that large fluorophores are detrimental to F13 function, C-terminal F13 GFP 
fusions have been purported to exhibit only minor defects in plaque size and spread within the 
WR background (Geada et al., 2001, Husain and Moss, 2001). However more significant 
defects in spread were observed in IHD-J F13-GFP viruses (Geada et al., 2001). The findings 
in this thesis data cannot exclude the possibility that GFP tagging is viable, however it is in 
keeping with data from others which suggests that the inclusion of large fluorophores is sub-
optimal to assess viral morphogenesis  Despite the inhibition of plaque size induced by 
mCherry tagging, a further plaque size reduction was observed when the expression of 
mCherry-tagged was delayed by the A26 promoter.   
  
Curiously, when the kinetics of F13mCherry expression were compared there was no 
appreciable difference between the two viruses, despite there being a consistent and statistically 
significant plaque size difference. A potential explanation could be that the addition of the A26 
promoter has a weaker effect in the F13L locus. This observation was further elaborated upon 
in chapter 5. Data obtained from the mCherry-tagged set of viruses indicate that for optimal 
F13 function, F13 expression must not occur synchronously with A26. As the expression 
kinetic of A26 was not altered in these viruses these data provide indirect evidence that the 
function of this gene is dependent on the temporal organisation of other genes within the 
morphogenesis pathway. This supports the notion that the transcriptional control of key genes 
is a potential regulatory mechanism that influences the differentiation of MV to IMV or EEV.   
  
In addition, these viruses offered a unique insight into both the viability of promoter swapping 
to generate novel phenotypes and the stability of these modifications with the VACV genome. 
Delaying F13-mCherry expression under the A26 promoter sequence in v(pA26)F13mCF 
facilitated the production of escape mutants, whereas in the “wild-type” control virus vF13mCF 
the F13mCherry allele remained stable. Two conclusions can be derived from the appearance 
of escape mutants in one virus but not the other; firstly, that alteration of promoter sequences 
introduces sufficient selective pressure to facilitate adaptations. Secondly, and perhaps more 
interestingly, these adaptations occurred within the coding sequence of the gene, not the 
promoter sequences. The compensatory mutation within vAP-1 occurred at the terminal codon 
of F13, leading to an I372N substitution that introduced STOP codon 17 aa residues 
downstream, effectively terminating mCherry translation. These observations imply that 
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compensatory mutations may preferentially occur within the coding regions of viral genes, 
rather than within promoter sequences. This may be because the promoter region is only 20 bp 
in total, therefore the probability mutations occurring within this region are unlikely.   
Indicating that VACV lack the ability to recognise aberrant intergenic sequences, or that the 
selective pressure required to instigate changes in intergenic regions requires additional 
mutations, therefore compensatory mutations are referred to distant sites within the genome. 
These findings were serendipitous as this adaptive mutation was only induced by the presence 
of the mCherry fluorescent protein in conjunction with the alteration of the F13L promoter 
sequence. Indicating the substantial negative selection of late, functionally defective 
F13mcherry alleles. These conclusions are reinforced by the fact that despite exhibiting a 
significant plaque size defect, the wild-type control virus vF13mCF was stable throughout the 
duration of this study.  
  
Taken together, these data reinforce the notion that promoter sequences may act as “islands of 
stability” which when modified (in the case of F13L), result in a change in phenotype (reduced 
plaque size). As such these data indicate that the VACV genome is sufficiently flexible to 
accommodate stable alterations in intergenic regulatory elements such as promoters, with 
profound effects on the resulting phenotype. Therefore, these findings can be applied to 
improve upon existing sequence analysis algorithms to predict and characterise novel pathogen 
populations.   
 
6.2. A26 is a negative regulator of VACV spread   
Following the initial findings from Chapter 3, it was clear that the F13mCherry fusion cassette 
was not an optimal approach due to the genomic instability of these viruses. Therefore, an 
alternative panel of viruses were constructed with F13L fused to a C-terminal 3XFLAG epitope 
tag. It was hypothesised that the use of a smaller, “minimal” epitope tag would be less 
detrimental to the function of F13 than a fluorophore. Recombinant VACV encoding an epitope 
tagged F13 gene have been reported previously (Husain et al., 2003). When the parental strain 
vΔF13 was complemented with F13-3XFLAG tagged alleles, plaque size was restored, 
however plaque size did not recover to wild-type levels. Others have demonstrated that F13 C-
terminally tagged with HA retains functionality with no visible defect in plaque size (Husain 
et al., 2003). The HA epitope tag is 9 aa in length, in contrast the size of 3xFLAG tag is 24 aa. 
This reiterates the sensitivity of the C-terminal region of F13 to appending tags as even minimal 
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epitope tags could interfere with membrane wrapping.  Nevertheless, when F13 expression was 
delayed under the A26 promoter (v(pA26)F13-F), a significant plaque size reduction was 
observed recapitulating the findings obtained from the F13mCF viruses. The new 3XFLAG 
tagged F13 viruses (vF13-F and v(pA26)F13-F) were stable, as no escape mutants were 
observed throughout the plaque purification of these viruses.  An alternative strategy would 
have been to incorporate an N-terminal 3XFLAG tag, however due to the topology and 
orientation of the N and C termini of F13 within the wrapping membranes it is unlikely that an 
N-terminal fusion would make a significant difference (Husain et al., 2002,). An additional 
experiment could have been designed to investigate the localisation of C-terminal FLAG 
tagged F13 via confocal microscopy and effect upon virus wrapping via electron microscopy. 
It has been shown that mCherry interferes with virus wrapping by occluding membranes due 
to steric hindrance (Carpentier et al.,). In retrospect it would have been interesting to see if a 
C-terminal 3XFLAG tag inhibits wrapping via a similar mechanism.  
 
Following the production of stable epitope tagged F13 viruses, the concept of altering the 
temporal regulation of A26 was explored. The role of A26 within the infectious cycle is to bind 
host GAG (Chiu et al., 2007) and act as the acid sensitive fusion regulator of the EFC complex 
required for endosomal fusion and entry (Chang et al., 2012). The effect of A26 on the EEV 
morphogenesis pathway was first alluded to by the observation that A26 is exclusive to IMV 
and absent on EEV (Ulaeto et al., 1996). It was then proposed that A26 could be a regulatory 
switch downregulating EEV production and initiating IMV accumulation. This possibility was 
explored later by Moss and colleagues when they discovered an association between A26 and 
A27, the virion component that mediates IEV trafficking. Howard et. al reported that a virus 
lacking A26L did not display enhanced plaque size or EEV production (Howard et al., 2008). 
They consequently concluded that A26 did not act as a negative regulator of EEV formation. 
The use of deletion mutants to investigate this aspect of IMV morphogenesis could not address 
this question because it does not account for the temporal segregation of F13 and A26. Under 
normal circumstances A26 is expressed late and is effectively segregated from the expression 
of intermediate genes in the EEV morphogenesis pathway. In that scenario, deletion of A26 
would have no impact on EEV levels. Indeed, as demonstrated in this thesis, A26 has the 
capacity to downregulate EEV production and plaque size, but this is prevented by its promoter 
region that drives A26 expression very late during infection.  
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In contrast, previous work by Yang et.al on transcriptomics have proposed that VACV 
transcription occurs in quick succession in the pre and post replicative phases. Moreover, after 
4 hours post infection 55% of transcripts were produced (Yang et al., 2010; Yang et al., 2011). 
Taking these data in context with the findings presented in this thesis, it indicates that despite 
the apparent delay between F13 (6 hpi) and A26 (16hpi) expression, the production of these 
transcripts would have occurred at 4 hours during the post replicative phase. However, the 
experiments performed by Yang et.al to determine the kinetics of VACV transcription were 
performed at a substantially higher MOI of 20 PFU/cell. By contrast, the experiments 
determining the expression kinetics of F13 and A26 were performed at an MOI of 5 PFU/cell. 
Therefore, it is plausible that a large majority of the post replicative transcripts appearing at 4 
hpi is largely due to the MOI of the starting infection, not as an intrinsic property of the viral 
transcriptional programme. This is also reinforced by the characterisation of late and 
intermediate promoter elements with differential promoter strength, resulting in a fine-tuning 
of protein expression during late and intermediate times post infection (Yang et al., 2013). 
Under the experimental conditions of this study both proteins exhibit clear 
compartmentalization in keeping with the hypothesis that both proteins are regulators of their 
respective forms; A26 for IMV and F13 for EEV and CEV.  
 
To determine the effect of intermediate A26 expression within the context of a normal F13 
expression kinetic, vF13-F was modified to express N-terminal 3xFLAG tagged A26 alleles 
expressed under the cognate A26L late promoter (vF13-F/A26-F) or the intermediate F13L 
promoter (vF13-F/(pF13)A26-F). Expressing A26 under the F13L promoter significantly 
advanced its expression kinetic. A26 expression in vF13-F/A26-F was barely detectable at 910 
hpi whereas in the promoter swapped virus, initial expression of A26 coincided with F13 at 5-
6 hpi. This shift in expression kinetic correlated with a reduction in plaque size. These data 
were the first indication that A26 could negatively regulate EEV and that a temporal 
relationship between the two proteins exists. Crucially, this phenotype was reverted when A26 
was reintroduced under its native late promoter sequence in vF13F/(pF13)A26-F R6 (vR6). 
This revertant virus restored both late A26 expression and plaque size, demonstrating causality 
between these two observations.   
  
Despite this correlation, F13 and A26 act independently within the IMV and EEV pathways. 
The A26 protein has not been shown (until now) to have any role within EEV morphogenesis.  
It was, however, observed that when A26 was ectopically overexpressed a reduction in EEV 
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occurred, but no data was offered to substantiate this claim (Howard et al., 2008). The IMV 
and EEV pathways are linked by the A27 protein. Before exiting the virus factory during the 
initial post replicative phase, MV membranes are modified with the 14 kDa A27 protein. Aside 
from its role within entry, A27 is critical for both EEV wrapping and cytoskeletal locomotion 
of MV to the cell periphery and the trans-Golgi network (Sanderson et al., 2000, Dallo et al., 
1987). The expression kinetic of A27 matches that of F13 (Ulaeto et al., 1996, Dallo et al., 
1987). Therefore, both proteins work in conjunction within the EEV pathway early in the post-
replicative phase at 6 hpi. Newly synthesized MV particles containing A27 are trafficked to the 
TGN where they are wrapped with membrane containing EEV proteins. This function of A27 
is temporally segregated from its interaction with A26, as A26 is expressed approximately 6 
hours later.   
  
To investigate the effect of the advanced A26 expression upon A27, cells were infected at a 
high multiplicity with the WT (vF13-F/A26-F), mutant (vF13-F/(pF13)A26-F and revertant 
(vR6) viruses in a forward kinetic manner and immunoblotted for FLAG under non-reducing 
conditions. Lysates were collected with the addition of N-ethylmaleimide (NEM) according to 
methods described previously (Howard et al., 2008). The addition of NEM maintains the 
stability of A26/A27 complexes by preventing disulphide interchange within the cellular 
lysates. Immunoblotting of these samples indicated that A26/A27 complex formation was 
significantly advanced. 90 kDa A26/A27 complexes were detected at 6-8 hpi in 
vF13F/(pF13)A26-F infected lysates. In contrast, equivalent levels of the A26/A27 complex in 
the WT and revertant viruses was only detected at 16 hpi. This demonstrates that A26 has the 
capacity to associate with A27 at different times during infection and that the only mechanism 
regulating this is its time of expression and hence its promoter element. More importantly, A26 
association with A27 correlated with reduced plaque size, proving that A26 molecules 
expressed under advanced kinetics are functional and have phenotypic impact.  
  
To further complement these data, the interaction between A26 and A27 was quantified using 
near infrared western blot. When lysates were probed using IR secondary antibodies for rabbit 
polyclonal FLAG and mouse monoclonal A27 antibodies under non-reducing conditions, co-
migratory complexes of A26/A27 were detected at 74 and 90 kDa from 6 hpi onwards in vF13-
F/(pF13)A26-F, in conjunction with elevated levels of monomeric A26 . Equivalent levels of 
A26/A27 complex in both wild-type and revertant viruses were detected at 24 hpi. These data 
indicate that biologically relevant concentrations of A26 (measured as sufficient to complex 
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with A27) appear at 24 hpi and these are met at 6 hpi in the mutant virus. Therefore, A26 under 
advanced expression mimics, but advances what is observed under natural expression. The 
levels of F13 within these lysates was equal across all viruses tested, indicating that the 
infections were equivalent.   
  
When the signal of the Uncomplexed A27 monomers, dimers and trimers were compared, they 
appeared to decrease in proportion to the levels of A26. This could be attributed to the fact that 
the stability of A26 is dependent upon its interaction with A27, as in the absence of A27 free 
A26 is degraded by the proteasome (Howard et al., 2008).  This data reveals that elevated levels 
of A26 occupy and deplete the levels of free uncomplexed A27. Therefore, during a typical 
viral infection A26 is limited, therefore there is a nascent pool of free A27 which is incorporated 
onto the MV particle to facilitate EEV production. When expression of A26 is initiated during 
late infection, it begins to deplete the available pool of A27 present on MV, bifurcating the 
morphogenesis pathway in favour of IMV formation.   
  
Despite the conclusions drawn from these data there are some limitations. This assay examined 
A26/A27 complex formation within cellular lysates and not on isolated virions, therefore the 
concept of A26 masking A27 is a hypothesis that needed to be validated with additional 
experiments. In addition, expression of intermediate A26 in the context of delayed F13 
expression was not shown as these viruses were unable to be produced.  This could have been 
due to the enhanced negative selection of intermediate A26 expression. Another inference that 
can be made from this observation is that in conditions of enhanced A26 expression and 
decreased F13 expression, the inhibitory effect of A26 on plaque size is enhanced shifting 
virion formation further toward IMV and effectively preventing wrapping of EEV and CEV.  
  
These recombinant viruses only assess the phenotype of intermediate A26 expression in the 
context of normal F13 expression. In spite of numerous attempts, v(pA26)F13-F viruses 
harbouring FLAG tagged A26 alleles could not be constructed. This is perhaps due to the 
deleterious phenotype associated with FLAG tagged F13 alleles in conjunction with the effect 
of delaying F13 expression. The combination of these factors possibly made the isolation of 
these recombinant viruses unlikely.   
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6.3. A mechanism for A26 regulation of EEV production  
The results within this chapter build upon the observation that intermediate expression of A26 
has a significant effect on plaque size and alters its association with the MV protein A27 at 
various times pi. Previous chapters have outlined the significance of intermediate A26 
expression in the context of normal F13 expression. However, investigating the influence of 
A26 upon IMV morphogenesis within the context of delayed F13 expression was not shown. 
To address this point, recombinant viruses expressing F13 fused to a single copy of V5, instead 
of the 3xFLAG used previously, were created. A successful rescue of the parental vΔF13 with 
F13-V5 alleles led to the production of both vF13-V5 and v(pA26)F13-V5 viruses. Contrary 
to what was observed with the 3xFLAG tag, inclusion of the V5 tag did not appear to be 
deleterious to the function of F13 as the plaque size of vF13V5 was indistinguishable to that of 
wildtype WR. This benefit undoubtedly facilitated the production of v(pA26)F13-V5/A26-F 
and  v(pA26)F13-V5/(pF13)A26-F. These observations reiterate the importance of the C-
terminal region of F13 and its sensitivity to epitope tagging.   
  
Construction of a full set of promoter swapped viruses; vF13-V5/A26-F, vF13V5/(pF13)A26-
F, v(pA26)F13-V5/A26-F and v(pA26)F13-V5/(pF13)A26-F provided further evidence that 
altering the temporal regulation of morphogenesis genes is sufficient to induce phenotypical 
change. When the ability of these viruses to form plaques was assessed, it revealed that each 
virus had a unique phenotype, the severity of which was related to the extent of temporal 
dysregulation. For example, delaying F13 expression in v(pA26)F13V5/A26-F  or advancing 
A26 expression in vF13-V5/(pF13)A26-F resulted in plaque size reductions that appeared to 
act independently. This can be explained as in the case of v(pA26)F13-V5/A26-F, a delay in 
F13 would directly impact EEV formation, causing a plaque size reduction. In the case of vF13-
V5/(pF13)A26-F, intermediate expression of A26 leads to premature association with A27, 
potentially biasing the viral progeny towards IMV formation and resulting in a decrease in EEV 
formation. The rational that these are two independent and distinct phenomena is reinforced by 
the fact that these phenotypes were additive in v(pA26)F13-V5/(pF13)A26-F leading to a 
further reduction of the size of the plaques. The combined effect of delayed F13 expression and 
intermediate A26 expression was shown to have the most extensive plaque size defect. These 
data underscore the notion that the temporal association and regulation of these genes is clearly 
important for optimal progression of the VACV morphogenesis cycle.   
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Following the quantification of plaque size in these viruses, the expression kinetics of F13 and 
A26 that underpinned these phenotypes were assessed. Analysis of vF13-V5/A26-F revealed 
the kinetics of F13 (expressed at 4 -6 hpi) and A26 (10-12 hpi) in wild-type conditions. When 
A26 expression was advanced under the F13L intermediate promoter sequence expression was 
observed at 4-6 hpi, recapitulating the phenotype observed in the F13-FLAG viruses. In 
contrast to these results, when F13 was expressed under the A26L promoter in v(pA26)F13-
V5/A26-F and v(pA26)F13-V5/(pF13)A26-F, the temporality of F13 did not substantially 
change despite the reduced  plaque size phenotype of these viruses. This observation could be 
explained by a unique feature of poxvirus transcription known as “run-through” transcription. 
Unlike early genes, intermediate and late genes have poorly defined termination sequences. 
The inability for late transcripts to terminate promptly is compounded by the fact that there is 
very little intergenic space between VACV ORFs. The combination of these two factors results 
in the continuation of late transcripts into the neighbouring downstream ORF. This generates 
multiple transcripts for the same ORF and are designated as “run-through” transcripts. Analysis 
of the VACV transcriptome revealed indicated that several ORFs have substantial run-through 
transcription originating from upstream intermediate and late genes (Assarsson et al., 2008).   
  
The biological relevance of run through transcription has been highlighted in several VACV 
genes including F1, J3 and J4 (Bajszar et al., 1983, Plucienniczak et al., 1985, Mehta et al., 
2018).  In the case of F13L, genes are located upstream (F14L) and downstream (F12L), the 
concept of run-through transcription applies to F13 as run-on transcription has been mapped to 
the F13 ORF from upstream genes (Yang et al., 2010).  In addition, the F13L promoter itself 
may play a role in regulating run-through transcription of the neighbouring upstream gene F14. 
Upon closer inspection of the F13L promoter sequence it was discovered that it contains the 
canonical early transcription termination motif T5TNT (Earl et al., 1990, Yuen and Moss, 
1987). This element is positioned immediately downstream of the F14L termination codon and 
accounts for 35 % of the F13L promoter sequence. Therefore, in this instance when F13L is 
expressed under is cognate promoter, run-through transcription from F14 may be prevented 
due to the presence of the T5TNT element. However, if the F13L promoter sequence is 
substituted with that of A26, the T5TNT element is also removed. It has been established that 
A26 expression is strictly late appearing at 10-12 hpi, therefore inclusion of this promoter 
should significantly delay F13L expression. This may not have happened as the strict late 
promoter of A26L is compensated by run-through transcription because of insufficient 
termination of the upstream F14L transcript. 
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 This hypothesis is strengthened as VACV intermediate promoters have been shown to have 
dual late activity, the expression of F13 under its native promoter at both intermediate and late 
times post infection can be attributed to  the dual late activity of intermediate promoter 
sequences (Yang et al., 2013). The structural features of the F13 promoter sequence; the T at 
+4 which follows the TAAA at the transcription start site, and the high T content between -12 
and -8 region of the promoter sequence correlate with strong late promoter activity (Yang et 
al., 2013). By comparison the A26 promoter sequence maintains the T at +4 of the TAAA 
initiation site but only has one T between the -12 and -8 regions. The differences in promoter 
structure are outlined in Table 6-1. 
 
Gene Promoter sequence 
F13L 
 
A26L 
  
 
Table 6-1. A comparison of the structural elements of F13 and A26 promoters conferring 
intermediate/late activity. Transcription initiation sites  
 When the F13 promoter is substituted for that of A26, the loss of the T rich 12- to -8 region in 
the A26 promoter may account for the slight decrease of F13 expression seen in the (pA26)F13 
viruses. However, this subtle difference does not explain why the weak activity of the A26 
promoter in its natural locus is not transferred when the promoter is used to drive F13 
expression. The similar levels of F13 expression can therefore be attributed to the loss of the 
T5TNT motif that would otherwise prevent run-through transcription from the F14. 
Alternatively, expression of F13 in viruses containing the A26 promoter may be explained by 
a cryptic regulatory sequence present upstream of the F13L promoter that exists or becomes 
prominent in the absence of the F13 natural promoter. Given the importance of F13 in VACV 
morphogenesis elucidation of the transcriptional control governing its expression deserves 
further experimentation.  
  
Whatever the exact compensatory mechanism(s) might be, they do not restore complete 
expression of F13. Upon closer inspection of the data it was shown that when F13 was 
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expressed under the A26L promoter element a reduction in F13 levels was observed. This 
reduction was independent of intermediate A26 expression and equal levels of C6 across each 
virus indicated that the infections were equivalent. Using C6 as an internal control for 
normalisation this reduction was estimated in 4 fold. This observation provides an explanation 
for the reduced plaque size phenotype seen in v(pA26)F13-V5/A26-F and v(pA26)F13-
V5/(pF13)A26-F, and highlights how essential F13 levels are for optimal VACV spread.   
  
Furthermore, when these viruses were compared in a one-step growth curve, each virus 
produced the same amount of cell associated virus; which includes IMV, IEV and CEV at 24 
hpi. Indicating that temporally advanced A26 expression of A26 does not affect viral 
replication. It was expected that an increase in IMVs titre would be observed in conditions were 
A26 was expressed under an intermediate promoter. This was not the case because any potential 
decrease in IMV may have been offset by the other cell associated virions IEV and CEV. It 
should be noted that other authors have proposed that over expression of A26 results in a 
reduction of EEV titre in addition to reduced levels of viral proteins, although no data was 
provided to substantiate this claim (Howard et al., 2008). In our system, advanced expression 
of A26 from the virus increased the amount of A26 available at times where it is not naturally 
present but did not affect the levels of any of the viral proteins tested (i.e. A27, C6, F13 or D8).   
  
Due to the observed plaque size reduction, the ability of the V5 promoter swapped viruses to 
generate EEV was compared using a multi-step growth curve. If intermediate A26 expression 
is the cause of the reduced plaque size phenotype, then a reduction of EEV titre should be 
observed. When the levels of extracellular virus were compared, it appeared that EEV titre was 
reduced when A26 was expressed under the intermediate promoter. This reduction was 
approximately 0.5 log for vF13-V5/(pF13)A26-F at 48 hpi, and approximately 0.8 log for 
v(pA26)F13-V5/(pF13)A26-F at the same time point. When these titres were normalised to the 
corresponding 0 h time point a significant decrease in EEV release was observed. These 
differences in titre were not huge and may seem subtle. However, it needs to be considered that 
they these viruses were produced in the WR strain, and therefore the amount of EEV produced 
accounts for 1 % of the total virus progeny (Payne, 1979, Payne and Kristensson, 1985). As a 
result, even subtle discrepancy’s in EEV titre can lead to significant plaque size changes. The 
reduced EEV titre correlates with the plaque size reduction phenotype observed in these 
viruses.   
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In retrospect it would have been interesting to construct these viruses in the IDH-J strain. This 
is a strain with a mutation in the A34R gene that reduces CEV accumulation and enhances EEV 
release (Blasco et al., 1993). Hence the proportion of EEVs produced in this virus is much 
higher, accounting for 35 % of the total virion progeny. Due to the significant differences 
between these two strains, comparing plaque size as a readout for EEV production has been 
shown to be more meaningful than measuring EEV titre in the WR backbone (Borrego et al., 
1999). This experiment did not assess the levels of CEV produced, which account for a 
significant proportion of EEV in WR infections (Blasco and Moss, 1992). If these CEV were 
accounted for, the differences between these viruses could be greater.  Determining differences 
in CEV can be accomplished in two ways; direct titration and visualisation of CEV on the 
surface of infected cells via microscopy. For direct titration CEVs can be dissociated from the 
infected cell membrane with trypsin after removing the culture supernatant.  Thus, CEVs can 
be titrated separately from EEV and IMV (Blasco and Moss, 1992). CEV can also be visualised 
by staining infected cells with an F-actin stain such as a fluorophore conjugated phalloidin. 
During VACV infection, CEV are propelled from the cell surface via the polymerization of 
actin filaments, thus the presence of actin tails is indictive of the quantity of CEV produced by 
the infected cells (Blasco and Moss, 1992). In addition, these actin filaments can be stained for 
a viral envelop protein such as F13 to colocalise an enveloped virion to the tip of the actin tail 
(Doceul et al., 2010). Unfortunately, these experiments were unable to be performed due to 
time constraints.  
  
The data presented in this chapter has shown that if A26 expression advanced under the F13 
promoter a reduction in plaque size and EEV release was observed. This was correlated by an 
increased association with the A27 protein at intermediate time points, a key component of the 
MV membrane which is implicated in EEV wrapping (Dallo et al., 1987, Rodriguez and Smith, 
1990). Inclusion of the A26 protein on IMV membranes was hypothesised to inhibit the 
function of A27 and subsequent formation of EEV. If A26 is produced synchronously with F13 
and A27, then A26 would prematurely associate with A27 on the surface of MV, preventing 
that virion from being recruited into the EEV pathway and retaining it as an IMV. To determine 
if this was the case, virions were isolated from cells infected with vF13-V5/A26-F (WT) or 
vF13-V5/(pF13)A26-F (mutant) at 10 and 24 hpi and assayed for the presence of F13 
(indicating EEV abundance), A27 (present on IMV and EEV) and A26 (exclusive to IMV). 
Remarkably, when these virions were compared under reducing conditions the levels of A26 
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in the mutant virus at 10 hpi match that produced by the wild-type at 24h. This pattern was 
mirrored when the levels of A26/A27 complex formation were assessed under no-reduced 
conditions: 90 kDa A26/A27 complex formation in the mutant virus 10 hpi matched that of the 
wildtype at 24 hpi. This provides direct evidence that incorporation of A26 at intermediate time 
points positively regulates IMV formation. It should be noted that the levels of A27 at 10 hpi 
and 24 hpi in both viruses were indistinguishable.   
When the levels of F13 are compared between the two viruses under reducing conditions there 
appeared to be a greater amount of F13 present in the wildtype virus at 10 hpi when compared 
to the mutant virus. This confirms that A26 and F13 are mutually exclusive (Ulaeto et al., 1996) 
and demonstrates that incorporation of A26 into virions prevents their F13 dependent wrapping. 
The levels of F13 in the mutant virus appeared to be lower than that of the wild-type at 24h. 
This was because these blots were produced using virions enriched from the cell-associated 
fraction, the culture supernatants containing EEVs were discarded. Therefore, the F13 signal 
in the blot represents the levels of CEV within the sample which are the dominant form 
extracellular virus form in WR infection and therefore act as a marker of F13-dependant 
wrapping (Blasco and Moss, 1992). Additional experiments determining the levels of CEV via 
titration or microscopy as described above could support this hypothesis.  A decrease in the 
levels of F13 when A26 is expressed at intermediate times, indicates that interaction of A26 
with A27 is sufficient to restrict virions as IMV, diverting them away from the EV pathway 
(Figure 6-1).  
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Figure 6-1. Proposed mechanism of A26 regulation of VACV spread.   
A. During a wild-type VACV infection A27 expression is temporally segregated from A26, therefore 
A27 incoporation on MVs occurs in the first instance and results in their recruitment into the EEV 
pathway. MVs are trafficked to the TGN where they acquire membrane containing F13 and are released 
as EEV or (in the case of WR) retained as CEV. B. Intermediate expression of A26 occurs 
synchronously with A27, as temporal segregation of these proteins no longer exists A26 can readily 
associates with A27 on MVs, preventing their recruitment to the EEV pathway, resulting in a decreased 
in EEV and CEV production and a reduction in viral spread.   
 
The exact mechanism by which intermediate A26 expression could impair EEV is unclear. 
Premature association of A26 with A27 could impair the microtubular transport of MV to the 
trans-Golgi network, spatially separating IMV from the sites of wrapping. An alternative and 
more plausible hypothesis is that incorporation of A26 physically prevents wrapping, and that 
its association with A27 via its disulphide bond is sufficient to abrogate the wrapping function 
of A27. This could be possible as the wrapping function of A27 is dependent upon the first 29 
aa residues of the N-terminus of the protein (Vazquez and Esteban, 1999). The C-terminus of 
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A26 shares 45% sequence homology with A27 (Howard et al., 2008). Due to its topology 
within the MV membrane both the N and C terminus of A27 are exposed on the external MV 
membrane and are in close proximity. Therefore, binding of A26 to A27 via the cysteine 
residues on the C terminus of the A27 protein could be sufficient to occlude the Nterminal 
region of A27 and prevent it from interacting with wrapping membranes (Howard et al., 2008). 
A summary of the potential mechanism of A26 negative regulation of EEV is shown in Figure 
6-1.  
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6.4 Conclusion  
In conclusion the data presented in this thesis support the notion that promoter sequences of 
A26 and F13 can be manipulated to introduce phenotypical change. Manipulation of intergenic 
promotor sequences was sufficient to alter the phenotype of the virus and influence the IMV 
and EEV morphogenesis pathway. This finding underscores the inherent flexibility of the 
poxvirus genome, where exchange of wildtype promoter sequences between key 
morphogenesis genes was stable throughout the course of this study. These findings will assist 
in the streamlining and development of sequence analysis platforms to discern novel pathogen 
populations. In addition, the unique phenotypes observed in these viruses provide crucial 
insight into the importance of their relative abundance and resulting effect on EEV/IMV 
production. Moreover, this method of generating novel phenotypes has significant advantages 
over traditional reverse genetic approaches as it can reveal functions of proteins that would 
have otherwise remain uncovered. These data provide clear evidence that intermediate A26 has 
the potential to downregulate EEV production and VACV spread and that this is prevented by 
its late expression. It is therefore proposed that the differential expression of F13 and A26 
represent a virally-encoded regulatory switch that dictate EEV and IMV production.  These 
findings also bring to attention to the underlying evolutionary significance to A26+ve IMV 
accumulation. It has been recently discovered that ΔA26 MV have enhanced entry and 
replication in innate immune cells such as bone marrow derived macrophages compared to 
A26+ve IMV (Kasani et al., 2017). The enhanced replication ΔA26 in BDMCs is presumably 
due to differences in the way that the virus is sensed within the cell due to an alternative 
mechanism of entry. These findings imply that innate immune cells have been primed to sense 
A26+ve IMV as this form is the most likely to be encountered by a naive host in the 
environment. The mechanistic insights into the morphogenesis of IMV and EEV presented in 
this thesis offer further opportunity to investigate the evolutionary history and innate immune 
sensing of VACV virion forms.  
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